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Abstract 
Cryptococcus neoformans is an opportunistic fungal pathogen and a leading cause of 
fungal infection related fatalities in immunocompromised hosts. Compared to well-studied 
Cryptococcus neoformans virulence factors like the polysaccharide capsule and melanin 
synthesis, very little is known about phospholipase B1 (Plb1). Plb1 is a phospholipid 
modifying enzyme that is implicated in multiple stages of cryptococcal pathogenesis.  
Herein I demonstrate that a Plb1 deficient strain of C. neoformans has a profound defect in 
intracellular growth within macrophages.  In addition I show that the Δplb1 strain 
undergoes a novel morphological change during in vitro and in vivo infection, resulting in 
a sub-population of very large ‘titan cells’ that may arise as a result of the mutant’s 
inability to cope within the macrophage. I go on to test whether these phenotypes are due 
to a reduction in eicosanoid production caused by Plb1 deficiency. Finally I present an 
additional project where I  optimise a C. neoformans intracellular proliferation assay for 
high throughput analysis via flow cytometry. This work provides a new insight into the 
function of this unappreciated virulence factor and helps to lay the foundation for new 
treatment strategies to combat cryptococcosis.  
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CHAPTER 1 – INTRODUCTION 
 
Parts of this chapter have been adapted from already published work (Robert Evans 
and Robin May 2013. The Mycota XII, pages 97 - 106; ISBN: 978-3-642-39431-7) 
1. Cryptococcus neoformans and the Cryptococcus genus.  
1.1 Cryptococcus neoformans 
Cryptococcus neoformans is an encapsulated, pathogenic fungus that can cause disease in 
humans and other animals. The first recorded case of human C. neoformans infection was 
in a subcutaneous skin lesion (Mitchell and Perfect, 1995), but infection more commonly 
occurs in the lungs following inhalation. Although infection begins in the lungs, C. 
neoformans can disseminate to the central nervous system (CNS) where it can cause fungal 
meningitis. Dissemination occurs almost exclusively in individuals with pre-existing 
immune deficiencies. In the decades following the discovery of C. neoformans, cases of 
cryptococcal meningitis were rare because immune deficiency syndromes were 
uncommon. Medical advances in the 21st century such as organ transplantation and cancer 
treatment (that require or result in immune deficiency) led to increased cryptococcosis 
rates; however it was not until the spread of HIV in the 1980s that C. neoformans truly 
emerged as a major global pathogen (Antinori, 2013).  
Cryptococcosis currently afflicts around a million people around the world annually - 
mainly within HIV infected populations. In sub-Saharan Africa, where the HIV epidemic 
has hit hardest, complications caused by cryptococcosis account for up to 44% of HIV 
related deaths (Park et al., 2009). Ominously, the rise of cryptococcosis within immune 
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suppressed populations may foreshadow a wider emergence of disease amongst healthy 
populations. Of particular note is an ongoing outbreak of cryptococcosis amongst 
immunocompetent residents of Pacific Northwest Canada and the USA. This outbreak has 
been caused by a particularly virulent lineage of Cryptococcus gattii - a Cryptococcus 
species closely related to C. neoformans. The outbreak began in the Vancouver Island area 
of British Columbia, Canada, in 1999. As of 2009 there were 263 human cases of C. gattii 
infection (Hoang et al., 2011). The outbreak has since spread from Vancouver Island and 
infections related to the outbreak have been reported across North West Canada as well as 
many North Western US states (Bartlett et al., 2008; Byrnes et al., 2009; Byrnes,Edmond 
J., I.,II et al., 2010; Harris et al., 2012; Hoang et al., 2011; MacDougall et al., 2007).  
1.2 Pathogenic species within the Cryptococcus genus. 
Cryptococcus neoformans and C. gattii produce a number of virulence factors that help 
them infect the host; these include a polysaccharide capsule (Bose et al., 2003) (quite 
unique among fungi), melanin (Casadevall et al., 2000), phospholipase B (Chen et al., 
1997a; Wright et al., 2002) and urease (Olszewski et al., 2004; Osterholzer et al., 2009c; 
Singh et al., 2013).The genus Cryptococcus denotes a group of at least 40 basidiomycete 
fungal species, almost all cases of human infection however are caused by a small group of 
species within the genus. Until recently it was thought that there were two disease causing 
species -   C. neoformans and C. gatti. These two species have been further classified 
according to variations in capsule polysaccharide (Ikeda et al., 1982). Variants are split 
into five serotypes - serotype A, otherwise known as C. neoformans var. grubii or 
VNI/VNII/VNB; serotype D, otherwise known as C. neoformans var. neoformans or 
genotype VNIV; serotypes B and C, which collectively made up the C. gattii species 
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(Kwon-Chung et al., 2002; Kwon-Chung and Varma, 2006). Serotypes B and C have been 
further divided into five genotypes (VGI, VGII, VGIII, VGIV and VGIV/VGIIIc). Finally 
there is serotype AD which is a hybrid of serotypes A and D (Lengeler et al., 2001), in 
addition to the AD hybrid, there are also reported occurrences of C. neoformans / C. gattii 
hybrids in the literature (Aminnejad et al., 2012; Bovers et al., 2006; Bovers et al., 2008). 
Recently, phylogenetic re-analysis of C. neoformans and C. gattii genotyping has provided 
a convincing argument that each genotype is a species in its own right (Hagen et al., 2015). 
The proposed new species names are given in Table 1. 
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Existing species 
name  
Serotype Genotype(s) Species name as 
proposed by Hagen 
et al. 2015 (Hagen et 
al., 2015) 
Cryptococcus 
neoformans var. grubii 
A VNI / VNII / VNB Cryptococcus 
neoformans 
Cryptococcus 
neoformans var. 
neoformans 
D VNIV Cryptococcus 
deneoformans 
Cryptococcus inter-
variety hybrid 
AD VNIII Cryptococcus 
neoformans x 
Cryptococcus 
deneoformans hybrid 
Cryptococcus gattii B and C VGI Cryptococcus gattii 
VGII Cryptococcus 
deuterogattii 
VGIII Cryptococcus 
bacillisporus 
VGIV Cryptococcus 
tetragattii 
VGIV/VGIIIc Cryptococcus 
decagattii 
 
IMPORTANT NOTE 
The species names above represent the vegetative budding forms of Cryptococcus that replicate 
asexually. Cryptococcus species can also reproduce sexually via a teleomorph form (Kwon-Chung, 
1976a; Kwon-Chung, 1976b) and, as is typically the case for fungal taxonomy, the teleomorph is 
given a different species name. Thus C. neoformans and C. gattii have the telomorph forms 
Filobasidiella neoformans and Filobasidiella bacillispora respectively. It is still not clear how 
these teleomorph names will be changed to fit with the new seven species naming system. 
 
Table 1 – Overview of C. neoformans and C. gattii species nomenclature. 
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For the remainder of this thesis (unless otherwise stated) C. neoformans VNI/VNII/VNB 
and C. deneoformans VNIV will be referred to collectively as ‘Cryptococcus neoformans’ 
whereas C. gattii VGI, C. deuterogattii VGII, C. bacillisporus VGIII , C. tetragattii VGIV 
and C. decagattii VGIV/VGIIIc will be referred to collectively as ‘Cryptococcus gattii’. 
This is due to the similarity in biology between members within each group in terms of 
pathogenesis and host macrophage interactions - if a distinction between species within 
each group is made the new species name and the genotype will be given e.g. 
Cryptococcus neoformans VNI/VII (Hagen et al., 2015). 
2. The epidemiology and aetiology of cryptococcosis  
2.1 Aetiology 
C. neoformans and C. gattii are primarily environmental organisms, in the literature their 
environmental niches are often said to be bird guano and rotting wood respectively 
however additional niches such as the soil are also populated by these fungi (Del Poeta and 
Casadevall, 2012; Kronstad et al., 2011). The host range for each organism is wide; it 
includes many different types of birds (e.g. pigeons, parrots and cockatoos), mammals (e.g. 
koalas, ferrets, dogs, cats, horses, dolphins, bats, humans and bandicoots) and plants (e.g. 
Eucalyptus, pine, mopane tree) (Cogliati, 2013). Interestingly as well as being an 
environmental niche for cryptococcal survival, plants may also be a host for Cryptococcus 
infection (Warpeha et al., 2013) 
There is little evidence to suggest that either Cryptococcus species can be spread between 
animal hosts, thus all cases of infection are presumed to be due to infection from 
environmental sources. Geographical modelling of the Vancouver Island C. gattii outbreak 
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supports the role of environmental exposure – in a 2010 paper Mak et al. modelled the 
greater Vancouver Island area to predict environmental habitats most amenable to C. gattii 
colonisation. The habitats that were identified clustered around the South Eastern tip of 
Vancouver Island and an area on mainland British Columbia across the Strait of Georgia. 
These areas demarcated almost exactly the geographical spread of the human and 
veterinary cases reported during the outbreak (Mak et al., 2010).  
It is still unclear whether the spore form or the (desiccated) yeast form of Cryptococcus is 
the causative agent of infection. Both spores and desiccated yeast cells have been shown to 
induce infection experimentally but the relative contribution of each vector to disease 
aetiology is unclear (Giles et al., 2009). Cryptococcus species can sporulate in two ways - 
sexually when Cryptococcus ‘a’ and ‘α’ mating type strains reproduce (Kwon-Chung, 
1976a; Kwon-Chung, 1976b) and asexually via a process known as monokaryotic fruiting 
– however only mating type α strains can sporulate via monokaryotic fruiting (Wickes et 
al., 1996).  
Cryptococcus spores possess a number of attributes that make them the likelier candidate 
for an infectious vector. Firstly, Cryptococcus spores are smaller than desiccated yeast 
cells with a diameter of 1 – 3 µm compared to 3 µm – 8 µm for yeast cells (Botts et al., 
2009). At this size, all spores and yeast cells in the lower size range should be able to be 
inhaled into the alveolar space, but the smaller size range of Cryptococcus spores may give 
them an advantage. Secondly Cryptococcus spores are surrounded by a thick outer coating 
that makes them more resistant to environmental stresses compared to yeast cells (Botts et 
al., 2009). Persistence in the environment is important because cryptococcosis results 
almost exclusively from environmental exposure. Finally the process of sporulation leads 
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to the development of vertical hyphae tipped with basidia, in which the spores grow and 
are eventually released (Botts and Hull, 2010). These aerial structures should allow spores 
to become airborne much easier than yeast cells and subsequently more readily inhaled 
(Velagapudi et al., 2009). For these reasons it is therefore likely that Cryptococcus spores 
are the main causative agent of infection. 
2.2 The global distribution of C. neoformans and C. gattii species 
All seven pathogenic Cryptococcus neoformans and Cryptococcus gattii species (Hagen et 
al., 2015) can be found across Europe, Asia, North and South America and Oceania 
(Figure 1). Of these seven Cryptococcus species, Cryptococcus neoformans VNI is the 
most prevalent worldwide. Globally C. neoformans isolates are about eight times more 
prevalent that C. gattii - Oceania (Australia, New Zealand and Papua New Guinea) is the 
only continent where Cryptococcus gattii is more prevalent than Cryptococcus 
neoformans.  C. neoformans VNI is also the most clinically important Cryptococcus 
species as it causes the majority of cryptococcosis cases worldwide (Cogliati, 2013). 
Although C. neoformans VNI predominates, a highly virulent Cryptococcus neoformans 
strain called VNB (Beale et al., 2015) also exists. C. neoformans VNB is found endemic in 
a few southern African countries – primarily Botswana; this country is believed to be the 
geographical point of origin of VNB (Cogliati, 2013; Litvintseva et al., 2006).  
Among the C. gattii species, C. deuterogattii VGII is the most clinically important. C. 
deuterogattii VGII was responsible for the 1999 to present day Vancouver Island outbreak 
previously discussed (Harris et al., 2012; Hoang et al., 2011). Before the Vancouver Island 
outbreak, it was thought that Cryptococcus gattii species were confined to tropical locales 
such as Oceania and South America. Analysis of VGII isolates collected during this 
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outbreak revealed two disease causing strains; these two strains were subsequently called 
VGIIa and VGIIb. VGIIa was found to have caused more infections than VGIIb, the VGIIa 
strain was also found to be more virulent than VGIIb in mice (Bartlett et al., 2012).  It is 
likely that the VGII outbreak strains originated from Australia or South America and 
spread to the Pacific Northwest area (Cogliati, 2013). 
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Figure 1: 
Map of the world showing the most common Cryptococcus genotype found in each 
country surveyed. Each colour (see ‘KEY’) represents the most common Cryptococcus 
genotype found in that country according to analysis by Cogliati et al. (Cogliati, 2013).  
Greyed out countries were not included in the analysis by Congliati et al.  Two locations of 
interest have been highlighted – Vancouver Island where a recent C. gattii outbreak 
occurred and Botswana where the geographically isolated VNB genotype is found most 
often (some elements of this figure have been taken from http://commons.wikimedia.org). 
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2.3 Risk factors for Cryptococcus neoformans infection 
Most of the world’s population are exposed to Cryptococcus neoformans at a young age 
but do not develop cryptococcosis (Abadi and Pirofski, 1999; Goldman et al., 2001; Houpt 
et al., 1994a). This is because Cryptococcus neoformans is primarily an opportunistic 
pathogen, and, as such, it only causes serious infection in conjunction with pre-existing 
immune deficiencies. Following inhalation, C. neoformans first grows within the alveolar 
spaces of the lung. C. neoformans eventually disseminates from the lungs into the blood 
stream, unless it is contained and cleared from the lungs by an effective immune response. 
From the bloodstream C. neoformans disseminates to many organs of the body, the CNS is 
the most common site. This could be due to the fungus’s propensity to grow in 
cerebrospinal fluid (CSF) (Casadevall et al., 2000). Growth of C. neoformans in the CNS 
leads to cryptococcal meningitis (meningoencephalitis) – a complication of infection that 
can be deadly. 
HIV and AIDS 
The major risk factor for C. neoformans infection, and the subsequent development of 
cryptococcal meningitis, is HIV infection. Uncontrolled HIV infection can dramatically 
decrease an individual’s CD4+ T cell count, resulting in the development of AIDS 
(Acquired Immune Deficiency Syndrome). This immunocompromised state leaves 
individuals highly susceptible to opportunistic pathogens such as C. neoformans (Grant et 
al., 1997). 
Cryptococcal meningitis is classified as an AIDS defining illness; in a clinical setting it is 
often used as an initial diagnosis of HIV positive status. Before the HIV epidemic C. 
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neoformans infection was rare; however as HIV spread, reported cases of cryptococcal 
meningitis increased dramatically. In the USA during the 1980s (1981 – 1990) when HIV 
spread globally, cryptococcal meningitis cases rose 1500 % over the previous decade 
(1965 - 1977) (Antinori, 2013).  In developed countries the use of Highly Active Anti-
Retroviral therapy (HAART) has brought the HIV epidemic under control; it has done this 
by preventing the spread of the virus, and also by improving the life expectancy of those 
infected. Concordant with the introduction of HAART, the prevalence of cryptococcal 
meningitis in the developed world has also decreased (Dromer et al., 2004; Kaplan et al., 
2000; Mirza et al., 2003). Unfortunately, due to its expense, HAART has only recently 
begun to become available in developing countries. 
The impact of cryptococcal meningitis as a co-morbidity of HIV AIDS is still large in the 
developing world. WHO figures state that in 2013, 35 million individuals worldwide were 
living with HIV AIDS – in the same year 1.5 million infected individuals died of an AIDS 
related illness (World Health Organisation, 2015). Around 70 to 90 % of HIV AIDS 
sufferers develop a neuropathological condition with cryptococcal meningitis being the 3rd 
leading cause (Del Valle and Pina-Oviedo, 2006). The majority of cryptococcal meningitis 
cases today occur in Sub-Saharan Africa where the rate of HIV infection is highest. 
Estimates of infection and mortality rates for cryptococcal meningitis in Sub Saharan 
Africa vary; this is probably due to poor disease reporting mechanisms in these countries.  
In the year 2006, an estimated 720,000 (median) cases of cryptococcal meningitis occurred 
in Sub-Saharan Africa - this figure represents 75 % of the estimated 957,900 (median) 
cases worldwide that same year. In the same study, the mortality rate following infection 
was estimated to be 70% i.e. 504,000 deaths out of 720,000 infected (Park et al., 2009). 
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Some estimates put the mortality rate lower than Park et al. -  for instance, a Ugandan 
study by Kambugu et al. has estimated a mortality rate of 20 – 42 % for cryptococcal 
meningitis (Kambugu et al., 2008) whilst in South Africa Bicanic et al. estimated a similar 
mortality rate of 17 – 37 % (Bicanic et al., 2007), although  mortality rates of 88% - 100 % 
have also been reported (Mayanja-Kizza et al., 1998; Mwaba et al., 2001). Overall the 
cryptococcal burden in Sub-Saharan Africa is hard to judge – this is not likely to change 
unless diagnosis and medical case reporting is improved in affected countries.  
Although the statistics vary, it is likely that unless the HIV epidemic can be controlled 
cryptococcal meningitis will continue to be a leading cause of AIDS related death in 
developing countries (Park et al., 2009).  The use of HAART in developing countries is 
slowly becoming more common - especially in Sub-Saharan Africa where large efforts are 
being made to control the epidemic (Fox and Rosen, 2010). A study from Jarvis et al. 
worryingly shows however that although the use of HAART in a Cape Town hospital 
increased substantially over a 5 year period (660 patients on HAART in 2003 vs. 13,985 in 
2008), the rate of cryptococcal meningitis did not decrease (Jarvis et al., 2009).. Taken 
together this suggests that although HAART has helped control cryptococcal meningitis in 
the developed world, further medical advances in developing countries - such as effective 
diagnosis and treatment - may be needed to obtain a similar effect.     
Solid organ transplant 
Figures show that around 100,000 solid organ transplants are performed worldwide per 
year (2007 figure) (Chinen and Buckley, 2010). Solid organ transplant is a risk factor for 
C. neoformans infection due to the long courses of immune suppressive drugs such as 
cyclosporine and corticosteroid that are prescribed to prevent organ rejection (Patel and 
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Paya, 1997). On average 3 % of solid organ transplant recipients will develop an 
opportunistic fungal infection within the first year of transplant.  C. neoformans causes 7-
8% of these fungal infections (Shoham and Marr, 2012); this makes it the third leading 
cause of infection behind Candida and Aspergillus species. The median time from 
transplantation to the development of Cryptococcus infection is 2 – 5 years and the 
mortality rate 1-year post infection is 27 %.  Most Cryptococcus infections in these 
patients are similar to those observed in the HIV/AIDS risk group i.e. the fungus 
disseminates from the lungs to the CNS resulting in cryptococcal meningitis (Shoham and 
Marr, 2012). 
The relatively long gap in time between transplant and infection (2-5 years) suggests that 
Cryptococcus infection usually develops following environmental exposure post 
transplant. This said infection can sometimes develop much sooner after the transplant. 
Faster developing infections may be due to the reactivation of a latent Cryptococcus 
infection that the patient already has (this will be discussed in the next section) or (in rare 
cases), the transplanted organ might have harboured a reservoir of Cryptococcus that 
subsequently infects the recipient (Baddley et al., 2011). 
Cancer 
Until the HIV epidemic of the 1980s, most cases of cryptococcosis were seen in patients 
with cancer. The malignancies linked to Cryptococcus infection are unsurprisingly those 
that involve immune cells (or tissues where immune cells develop) such as leukaemia, 
lymphoma and myeloma. As these cancers progress the immune system becomes depleted 
of properly functioning white blood cells creating an immune deficient state. The severity 
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of C. neoformans infection in cancer patients is extenuated by the under-lying malignancy 
which is often at a very late stage when opportunistic infection occurs (Perfect, 2012a).   
Other conditions 
In addition to the major risk factors described above, there are a number of less common 
risk factors that may increase an individual’s susceptibility to C. neoformans infection. 
These include sarcoidosis (Baughman and Lower, 2005), cirrhosis (Singh et al., 2004) and 
methamphetamine use (Patel et al., 2013; Talloczy et al., 2008).  
Cryptococcosis in immune competent hosts 
There are occasionally case reports of cryptococcal meningitis caused by C. neoformans in 
immunocompetent individuals (Chen et al., 2008b; Zhu et al., 2010). This is especially the 
case in China where it has been estimated that 17 % of individuals presenting with 
Cryptococcosis have no underlying immune deficiency (Yuchong et al., 2012).Two 
theories try to explain these cases. The first posits that these infections have been caused 
by C. neoformans strains that have mutated to become more virulent and able to infect 
healthy individuals. The second that the individuals infected have an undiagnosed genetic 
immune deficiency that pre-disposes them to C. neoformans infection. Recent data suggest 
that the latter theory i.e. host susceptibility is most likely. In this respect a 2011 study by 
Ou et al. found that susceptibility to C. neoformans in a cohort of non HIV infected 
patients with cryptococcosis correlated to a number of genetic alleles related to mannose 
binding lectin protein (Ou et al., 2011). 
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3. Treatment of C. neoformans infection  
3.1 Treatment of cryptococcal meningitis 
The treatment of cryptococcosis is complicated by the fact that infection usually occurs 
alongside serious medical conditions such as HIV AIDS or cancer. Additionally, the 
majority of cryptococcal infections occur in poor countries where effective diagnostics and 
treatments are not always readily available. Even with access to treatment, cryptococcal 
meningitis has an unacceptably high mortality rate (Ma and May, 2009).  
Aggressive treatment is vital to control cryptococcal meningitis (the most serious 
manifestation of cryptococcal disease), a three stage therapeutic strategy is used to combat 
infection – initially antifungal drugs are given intravenously at high doses for about 2 
weeks, this clears the CSF of infection and stabilises the patient’s meningitis. During the 
second stage antifungal drug treatment is maintained for a further 8 weeks at a reduced 
dosage to continue fungal clearance. The third stage involves long-term low dose 
antifungal drug treatment to prevent relapses of infection. Relapse of infection is a big risk 
for patients, especially if their underlying immune deficiency still persists (Perfect and 
Bicanic, 2015).  
The best available treatment for cryptococcal meningitis is a combination of intravenous 
amphotericin B (0.7 – 1.0 mg/kg/day) and flucytosine (100 mg/kg/day) for 2 weeks 
followed by a long course of oral fluconazole (400 mg/day) to maintain fungal clearance 
(Jackson and Hosseinipour, 2010). Unfortunately, when given in high doses both 
amphotericin B and flucytosine are harmful – amphotericin B damages kidney functions 
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while flucytosine can elicit toxic reactions within the body.  Liposomal amphotericin B (an 
improved preparation of amphotericin B) has greatly reduced kidney toxicity, but it is 
expensive and thus not available in many developing countries (Jarvis et al., 2014). It is 
now recommended to create a tailored drug regimen for each patient – the relative dosages 
of each drug should be manipulated to achieve maximum efficacy while constantly 
monitoring kidney health and flucytosine levels in the blood to avoid unwanted side effects 
(Jackson and Hosseinipour, 2010; Perfect et al., 2010).  
Intravenous Amphotericin B and flucytosine combination therapy can be effective at 
curing cryptococcal meningitis if used correctly. However, in the developing world where 
the majority of C. neoformans infections are found these drugs are not always available 
due to cost. In the developing world the less effective but cheaper azole family of drugs are 
sometimes all that are available. In this setting the azole drug fluconazole commonly used, 
not only due to its low cost but also as it is one of the most soluble azoles which it an 
advantage when treating neurological infections. Fluconazole is often given orally at a 
dose around 400 mg per day (Jackson and Hosseinipour, 2010). The efficacy of 
fluconazole when administered in this way is poor and has lead to the development of 
fluconazole resistant C. neoformans strains (Bicanic et al., 2006; Sionov et al., 2013; Smith 
et al., 2015a).  
Due to the inefficacy of standard fluconazole treatment there has been a big push in 
clinical cryptococcal research to find a better alternate for the developing world.  
Fluconazole appears to have lower toxicity at higher doses compared to amphotericin B or 
flucytosine. Administering fluconazole at much higher doses – up to 2g/day – has been 
trialled and has shown better efficacy over lower, standard dosages (Milefchik et al., 
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2008). Other trials have experimented with using different doses (Bicanic et al., 2008) or 
shorter courses (Bicanic et al., 2007) of amphotericin B (to reduce the cost required per 
patient) in combination with fluconazole with some promising results.  
3.2 Treatment of pulmonary and cutaneous infection 
The pulmonary stage or cutaneous stages of cryptococcosis is treated less aggressively than 
disseminated disease – oral fluconazole, itraconazole, voriconazole or posaconazole are 
recommended. In severe cases pulmonary infection can be treated with intravenous 
flucytosine and amphotericin B similar to disseminated disease. When infection cannot be 
cleared pharmacologically, surgical resection can be used to remove infected tissue 
(Perfect et al., 2010). 
3.3 Treatment complications - Cryptococcal IRIS  
In the case of HIV associated cryptococcal infection, the introduction of HAART has 
reduced the requirement for lifelong antifungal drug therapy. However, HAART treatment 
produces complications of its own for cryptococcosis patients. As HAART reduces HIV 
viral load the patients’ CD4+ T cell count increases, for individuals with opportunistic co 
infections such as C. neoformans or Mycobacterium tuberculosis, their rejuvenated 
immune systems sometimes become dysregulated. As a result of this dysregulation an 
excessive immune response is generated against pathogen derived antigen circulating in 
the body leading to dangerous levels of inflammation – this condition is called Immune 
Reconstitution Inflammatory Syndrome (IRIS) (Murdoch et al., 2007). IRIS has been 
estimated to affect around 30 % of Cryptococcus infected individuals who are also 
receiving HAART (Shelburne et al., 2005).      
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4.  The Pathogenesis of Cryptococcus neoformans infection  
Cryptococcosis initiates in the lungs following inhalation of either spores or desiccated 
yeast cells (Giles et al., 2009). C. neoformans first colonises the alveolar space of the lungs 
where it interacts with cells of the host immune system – most notably with macrophages 
(Alanio et al., 2011; Charlier et al., 2009; Feldmesser et al., 2000; Ma , 2009) (Figure 2). 
Most of the world’s population are exposed to C. neoformans from a young age (Deshaw 
and Pirofski, 1995b; Houpt et al., 1994b), however life threatening disseminative infection 
usually only occurs when individuals have an existing immune deficiency. Without an 
effective immune response to control it, C. neoformans grows rapidly within the lungs both 
extracellularly and within infected macrophages (Feldmesser et al., 2000; Ma , 2009). 
Pulmonary cryptococcal infection leads to pneumonia like symptoms; without containment 
the fungus can disseminate from the lungs, into the blood and subsequently to the CNS 
(Sabiiti and May, 2012). Cryptococcal meningitis occurs as a result of fungal growth in the 
brain and spinal column; symptoms include - headaches, fever, deafness, blindness, 
dementia and coma (Ma and May, 2009). Cryptococcal meningitis is a common co-
morbidity of HIV AIDS (Chuck and Sande, 1989; Lin et al., 2015; Park et al., 2009); this 
indicates the requirement of a T-cell mediated adaptive immune response to control and 
clear infection before it can disseminate (Jarvis et al., 2013; Lindell et al., 2006; Uicker et 
al., 2006; Wozniak et al., 2011). 
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4.1 Pulmonary infection 
Initial pulmonary infection is an important stage of C. neoformans pathogenesis. If C. 
neoformans is not contained within the lungs by the immune system then life threatening 
cryptococcal meningitis can develop (Sabiiti and May, 2012). During pulmonary infection 
C. neoformans grows within the alveolar space (Garcia-Rodas and Zaragoza, 2012) where 
it encounters the innate arm of the host immune system. The cellular component of the 
innate immune response to pulmonary infection includes macrophages, neutrophils and 
dendritic cells (Wozniak et al., 2006).  During early stages of pulmonary infection the 
innate immune response is the body’s only protection against C. neoformans until an 
adaptive immune response can be generated – typically 14 days after the initial 
inflammatory signals generated by the innate immune system (Cauley and Murphy, 
1979). 
By inoculating mice with fluorescently tagged C. neoformans strains Wozniak et al. have 
found that within 2 hours of infection all three innate phagocytic cell types (macrophages, 
neutrophils and dendritic cells) can phagocytose C. neoformans cells (Wozniak et al., 
2006). The early interaction between C. neoformans and innate immune cells (with the 
exception of macrophages) is generally protective for the host (Osterholzer et al., 2009b). 
Dendritic cells (Hole et al., 2012) and neutrophils (Miller and Kohl, 1983; Miller and 
Mitchell, 1991) are more fungicidal towards C. neoformans than macrophages, this is 
because macrophages require activation by the adaptive immune system in order to be 
fully effective at killing C. neoformans (Kawakami et al., 1995; Voelz et al., 2009) while 
dendritic cells and neutrophils are intrinsically fungicidal (Hole et al., 2012; Lehrer and 
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Ladra, 1977). If macrophages are not appropriately activated C. neoformans can become 
an intracellular parasite (Feldmesser et al., 2000). 
4.2 Neutrophils 
Neutrophils are able to kill both internalised and extracellular cryptococci (Qureshi et al., 
2010; Qureshi et al., 2011). The neutrophil cytoplasm contains a number of cytotoxic 
granules that are loaded with anti-microbial agents such as myeloperoxidase, serine 
proteases and cathepsins (Mambula et al., 2000; Segal, 2005). After phagocytosis of C. 
neoformans cells, these cytoplasmic granules fuse with the phagosome and disgorge their 
contents – at the same time neutrophils generate an intense oxidative burst mediated by the 
enzyme NADPH oxidase. These two mechanisms combine to kill phagocytosed C. 
neoformans cells (Diamond et al., 1972). Extracellular killing by neutrophils also involves 
cytoplasmic granules; however in this situation, the contents of the granules are released 
into the extracellular space rather than into the phagosome (Qureshi et al., 2010). A second 
killing mechanism called NETosis is also used by neutrophils. During NETosis apoptotic 
neutrophils release their nuclear contents into the extracellular environment producing 
cytotoxic effects (Remijsen et al., 2011). Evidence suggests however that the C. 
neoformans capsule is able to inhibit NET formation by neutrophils (Rocha et al., 2015).     
Neutrophils are more fungicidal towards C. neoformans than macrophages (Miller and 
Kohl, 1983; Miller and Mitchell, 1991); crucially the anti-fungal activity of neutrophils is 
intrinsic (Alcouloumre et al., 1993; Ganz et al., 1985; Lehrer and Ladra, 1977), whereas 
macrophages require classical activation by CD4+ T cells to effectively kill C. neoformans  
(Kawakami et al., 1995; Voelz et al., 2009). Notably however, the Cryptococcus 
polysaccharide capsule offers protection from the antimicrobial activities of neutrophils 
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(Del Poeta, 2004; Rocha et al., 2015). Environmental cryptococci do not possess large 
capsules as capsule induction is triggered by growth conditions within the host, suggesting 
that neutrophils may play an important role in the early defence against C. neoformans 
before capsule growth is induced. It is clear however that careful regulation of the 
neutrophil response by macrophages and dendritic cells is required to balance their anti-
cryptococcal activity with detrimental damage to the lungs (Osterholzer et al., 2009b). 
4.3 Macrophages 
Resident macrophages within the alveolar space can kill phagocytosed C. neoformans cells 
(Kawakami et al., 1995) by producing free radical oxygen species within the phagosome 
and lowering phagosomal pH leading to activation of phagosomal digestive enzymes 
(Amer and Swanson, 2002; Russell et al., 2009). The efficacy of this killing mechanism is 
dependent on the macrophage’s activation state (Kawakami et al., 1995; Voelz et al., 
2009).  
During infection, macrophages become either ‘classically’ (M1) or ‘alternatively’ (M2) 
activated depending on the cytokine milieu at the site of infection (Classen et al., 2009). 
Although ‘classical’ and ‘alternative’ activation is often used to describe macrophage 
activation it is becoming increasing clear that the polarisation is not binary – depending on 
stimulation macrophages can have attributes of both classical and alternative activation at 
any given time. The use of ‘classical’ and ‘alternative’ herein implies to an overall shift 
towards either extreme on a scale of activation (Martinez and Gordon, 2014). 
Classical macrophage activation is protective against C. neoformans pulmonary infection 
whereas alternatively activated macrophages cannot control intracellular infection 
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(Kawakami et al., 1995; Voelz et al., 2009). Classically activated macrophages kill 
phagocytosed C. neoformans cells (Kawakami et al., 1995; Voelz et al., 2009); classical 
activation induces the macrophage oxidative burst, required during phagosome maturation, 
it also increases the amount of pro-inflammatory cytokines such as IL-1, IL-6 and IL-23 
that are produced by macrophages during inflammation. The classical activation of 
macrophages is induced largely by two cytokines – IFN-γ and TNF-α. IFN-γ is produced 
mainly by Th1 CD4+ T helper cells following activation of adaptive immunity (Schoenborn 
and Wilson, 2007) whereas TNF-α is produced by macrophages following toll like receptor 
recognition of pathogen associated molecular patterns (PAMPs) (Parameswaran and Patial, 
2010). Alternative macrophage activation is induced by the cytokine IL-4 which is a 
product of Th2 CD4+ T helper cells, basophils and mast cells. Alternatively activated 
macrophages produce lower levels of pro-inflammatory cytokines and are also poor 
activators of intracellular killing mechanisms (Classen et al., 2009).  
The alveolar spaces of the lungs are protected by alveolar macrophages. Each tissue has a 
tissue specific subset of macrophages that are specially adapted to protect it. Macrophages 
originate in the bone marrow as monocytes and circulate in the vascular and lymphatic 
systems, monocytes differentiate into macrophages after they have migrated into a specific 
tissue. Macrophage specialisation is achieved via tissue specific signalling factors that alter 
the differentiation phenotype of monocytes upon migration (Hussell and Bell, 2014). 
Resident alveolar macrophages (CD11c+, CD11b-) initially interact with C. neoformans, 
however evidence from infections of mice indicates that a phenotypically distinct subset of 
macrophages termed ‘exudate macrophages’ (CD11c+, CD11b+, Lyc-6Chigh) migrate into 
the alveolar space once inflammation begins (Osterholzer et al., 2011). Osterholzer et al. 
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identified these exudate macrophages in 2011 (Osterholzer et al., 2011) however it is likely 
that they were first identified in 2009 (Osterholzer et al., 2009b) (Pulmonary CD11c+, 
CD11b+ leukocyte numbers increased significantly in C. neoformans infected mice by day 
7 post infection), however they were misidentified as dendritic cells (dendritic cells are 
also CD11c+ and CD11b+). In a second 2009 study Osterholzer et al. reported that the 
source of these ‘dendritic cells’ were Lyc-6Chigh monocytes which had migrated to the 
lungs before differentiating (Osterholzer et al., 2009a). Only in 2011 did Osterholzer et al. 
find that the migratory CD11c+ CD11b+ cell population was composed of macrophages as 
well as dendritic cells. By 14 days post infection Osterholzer et al. found that the exudate 
macrophage population in the lungs was ~ 2.5 times larger than the original alveolar 
macrophage population. Exudate macrophages were found to have higher expression levels 
of phagocytic receptors such as CD107b and CD204, costimulatory molecules such as 
CD40 and CD86 and the antigen presentation complex MHC II compared to resident 
alveolar macrophages. Furthermore non-resident exudate macrophages were found to be 
significantly more fungicidal towards C. neoformans than resident alveolar macrophages 
(Osterholzer et al., 2011). The accumulation of exudate macrophages at the site of 
infection was found to require expression of CCR2 by monocytes – a chemokine receptor 
with the ligand known as macrophage chemotactic protein 1 (MCP-1) or C-C motif ligand 
2 (CCL2). Previous studies have found that pulmonary levels of CCL2 increase during 
cryptococcal infection, that CCL2 is required for monocyte and CD4+ T cell migration to 
the lungs (Huffnagle et al., 1995c; Huffnagle et al., 1997) and that CCL2 levels influence 
the generation of adaptive immunity (Traynor et al., 2000). Alveolar macrophages as well 
as lung epithelial cells are known to produce CCL2 (Brieland et al., 1992; Deshmane et al., 
2009; Standiford et al., 1991; Yoshimura et al., 1989). Alveolar macrophages therefore 
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presumably still have an important role during early cryptococcal pulmonary infection by 
triggering dendritic cell and exudate macrophage accumulation. 
The inflammatory response of macrophages to early cryptococcal infection in the lung is 
vital to generate and coordinate a protective inflammatory response (Wozniak et al., 2006). 
Paradoxically however some studies have found that the presence of macrophages in the 
lung can actually aid the fungus. A recent study by Sabiiti et al. selected a group of C. 
neoformans strains isolated from HIV+ patients and exposed them to macrophages in vitro 
(Sabiiti et al., 2014). The phagocytic efficiency and intracellular proliferation of each strain 
was assessed and then correlated to the clinical outcome for each patient. Sabiiti et al. 
found a positive correlation between improved efficiency of phagocytosis of each strains in 
vitro and fungal burden in vivo within the CNS. A similar study by Alanio et al. reported a 
similar correlation (Alanio et al., 2011). These studies indicate that parasitism of host 
macrophages (under certain conditions) is beneficial to C. neoformans. If macrophages are 
unable to kill phagocytosed cryptococci, the macrophages can act as a protective niche for 
fungal growth (Diamond and Bennett, 1973; Feldmesser et al., 2000; Garcia-Rodas and 
Zaragoza, 2012; Goldman et al., 2000a; Levitz et al., 1999a) and also potentially also as 
vehicles for dissemination (Charlier et al., 2009).   
A study by Shao et al. illustrates the protective versus deleterious paradox that the 
macrophage poses during cryptococcal infection (Shao et al., 2005). Shao et al. assessed 
the effect of macrophage depletion on pulmonary cryptococcosis in two animal models; 
mice – which are susceptible to pulmonary C. neoformans infection, and rats – which are 
more resistant to infection than mice. Shao et al. found that depletion of macrophages in 
rats increased fungal burden in the lungs. In contrast, depleting mice of macrophages 
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decreased fungal burden in the lungs. This study shows how in susceptible hosts, 
macrophages can aid cryptococcal pathogenesis by providing a protective niche for growth 
(Diamond and Bennett, 1973; Feldmesser et al., 2000; Garcia-Rodas and Zaragoza, 2012; 
Goldman et al., 2000a; Levitz et al., 1999a; Shao et al., 2005). In resistant hosts however 
appropriately activated macrophages are able to kill intracellular C. neoformans cells 
(Kawakami et al., 1995; Voelz et al., 2009).       
The requirement for adaptive immunity to activate macrophages before they are able to 
control C. neoformans infection is likely why individuals with AIDS (which causes a CD4+ 
T cell deficiency) are susceptible to disease (Park et al., 2009). Adaptive immunity takes 
longer to activate than innate immunity – about 14 days. To activate adaptive immunity 
professional antigen presenting cells, mainly dendritic cells, carry antigen from the site of 
infection to lymph nodes where naive T and B cells are found (Savina and Amigorena, 
2007).    
4.4 Eosinophils 
Eosinophils are another class of innate immune cell that are associated with 
Cryptococcosis infection, especially during pulmonary infection. Eosinophilia at the site of 
an infection is normally associated with parasitic infections however it also occurs during 
fungal infection and has been reported during pulmonary Cryptococcus infection of mice 
and rats (Huffnagle et al., 1994; Huffnagle et al., 1995a). The recruitment of eosinophils 
during cryptococcal infection has been shown to be CD4+ T cell and IL-5 dependant 
(Huffnagle et al., 1994). There is some evidence for eosinophilia during human 
Cryptococcus infection but it is not as well documented as in rodents (Watanabe et al., 
1995). This may be because in human C. neoformans infection often occurs alongside 
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CD4+ T cell depletion due to HIV infection and this phenotype that is not commonly 
replicated in mouse or rat models of infection. 
4.5 Adaptive immune response 
Cytokine production by CD4+ T cells - as well as antibody production by B cells - can 
augment the ability of innate immune macrophages and neutrophils to clear C. neoformans 
infection (Voelz and May, 2010). Furthermore CD4+ T cells also exhibit direct anti 
microbial activity against C. neoformans by releasing granulysin (Zheng et al., 2007). The 
generation of a Th1 adaptive immune response – characterised by the production of IFN-γ 
and IL-12 by CD4+ T cells – is protective against cryptococcal pulmonary infection, 
whereas a Th2 adaptive immune response – characterised by the production of IL-4 and 
IL-10 by CD4+ T cells – is non protective (Chen et al., 2008a).  
As has previously been discussed, a Th1 adaptive immune response leads to ‘classical’ 
activation of macrophages. ‘Classically’ activated macrophages are more fungicidal 
towards C. neoformans compared to Th2 ‘alternatively’ activated macrophages (Voelz et 
al., 2009). In a 2009 study, Voelz et al. elucidated the basis for this observation (Voelz et 
al., 2009). In vitro treatment of macrophages with Th1 associated cytokines (IFN-γ and 
TNF-α) increased macrophage phagocytosis of C. neoformans and C. gattii cells whereas 
Th2 associated cytokines (IL-4 and IL-13) did not – this is in agreement with a previous 
study from Kawakami et al. (Kawakami et al., 1995). Interestingly Voelz et al. found that 
Th1 cytokine treatment of macrophages did not alter their ability to control intracellular 
proliferation of the fungus as one might expect, however Th2 cytokine treatment made 
macrophages less effective at controlling infection (Voelz et al., 2009).      
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It is known that C. neoformans actively promotes the development of Th2 biased immunity 
during infection (Voelz and May, 2010). One of the ways that C. neoformans promotes 
Th2 immunity is by manipulating dendritic cell function via expression of the 
Cryptococcus virulence factor urease (Osterholzer et al., 2009c). Mice infected with a 
urease deficient C. neoformans mutant were found to have stronger Th1  immune 
responses compared to those infected with the wild type strain, this resulted in better 
fungal clearance.  Urease expression by C. neoformans during pulmonary infection was 
found to increase the number of phenotypically immature dendritic cells at the site of 
infection. Furthermore greater numbers of immature dendritic cells were found in lymph 
nodes associated with the mouse lung. Antigen presentation by immature dendritic cells 
poorly induces Th1 induction and promotes Th2 immunity during C. neoformans infection 
(Chen et al., 2008a; Osterholzer et al., 2009c).  As well as urease, additional virulence 
factors have been found to affect dendritic cell function. In this respect it has been 
observed that dendritic cells exposed to encapsulated C. neoformans strains develop 
different gene expression patterns to cryptococci exposed to un-encapsulated strains (Lupo 
et al., 2008).  Additionally it has recently been shown that prostaglandin E2 (PGE2) 
signalling in the lung during C. neoformans infection promotes alternative macrophage 
activation (Shen and Liu, 2015) – host immune cells such as macrophages (Park et al., 
2006) and also C. neoformans itself (Noverr et al., 2003a) produce PGE2 but Shen et al. do 
not address the source in their study. 
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Figure 2 –  
The pathogenesis of Cryptococcosis. A. Cryptococcus neoformans infection begins when 
desiccated yeast cells, or infectious spores, are inhaled into the respiratory tract. B. Inhaled 
Cryptococcus cells reach the alveolar spaces of the respiratory tract where they germinate 
and grow. C. As part of the host innate immune response against C. neoformans, 
professional phagocytes such as macrophages and neutrophils migrate to the site of 
infection in the alveolar space. These cells phagocytose extracellular C. neoformans cells. 
Following phagocytosis there are three possible outcomes for C. neoformans and the 
macrophage. D. The macrophage is improperly activation and as a result cannot control the 
intracellular growth of C. neoformans, growth within the macrophage phagosome, escape 
from the macrophage and subsequent dissemination to the central nervous system is 
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possible. E. The macrophage is properly activated; it can kill the intracellular C. 
neoformans cells. F. The macrophage cannot kill phagocytosed C. neoformans cells but 
instead is able to contain them within a granuloma. For C. neoformans infection, fatal 
disseminative disease (D) occurs almost exclusively in individuals with pre-existing 
immune deficiencies whereas total clearance (E) and latent disease (F) can manifest in 
individuals who are immune competent (some elements of this figure have been taken 
from http://commons.wikimedia.org).   
  
30 
 
 
4.6 Disease latency 
Latent infection develops when a balance is reached between the host’s immune defence 
and the pathogen’s virulence. There is evidence to suggest that pulmonary C. neoformans 
infection can enter a latent stage (Garcia-Hermoso et al., 1999). Latent C. neoformans 
infection is characterised by the formation of granuloma like structures in the lungs. 
Cryptococcus cells remain viable within these structures, additionally if the host immune 
response weakens sufficiently (e.g. an individual with latent infection develops an immune 
deficiency) then the fungus can emerge from the granuloma and re-establish infection 
potentially leading to disseminative disease (Garcia-Hermoso et al., 1999; Goldman et al., 
2000b). 
Cryptococcal granulomas develop in the alveolar space and are composed of aggregates of 
infected macrophages. Macrophages within these cryptococcal granulomas have ‘giant 
cell’ and ‘multinuclear’ morphologies that are also seen in Tuberculosis granulomas. C. 
neoformans is contained intracellularly inside macrophages within the granuloma - this is 
different to Tuberculosis granulomas where mycobacterium cells reside in a necrotic 
pocket formed at the centre of the granuloma (Shibuya et al., 2005).       
Epidemiologically, it is hard to estimate the global prevalence of latent C. neoformans 
infection. For healthy populations the majority of Cryptococcus infections are 
asymptomatic and go unreported, thus the presence of latent infection is never suspected. 
Studies that have measured the level of anti-cryptococcal immunoglobulin titres within 
immune competent populations conclude that cryptococcal infection is inevitable by 
adulthood (Deshaw and Pirofski, 1995a; Goldman et al., 2001; Houpt et al., 1994b) and 
most individuals are first exposed to the fungus during childhood  (Abadi and Pirofski, 
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1999; Goldman et al., 2000b; Houpt et al., 1994a). These conclusions seem reasonable 
considering the ubiquity of C. neoformans within the natural environment, thus it is likely 
that an individual encounters C. neoformans many times during a single lifetime - it is not 
known however how often these encounters lead to the development of latent infection.  
Studies suggest that latent pulmonary cryptococcal infection may re-emerge if the host 
develops an immune deficiency. In this respect it has been found in vivo that latent 
Cryptococcus infection of rats can be induced to reactivate following immune suppressive 
glucocorticoid treatment (Goldman et al., 2000b). Additional evidence for latent infection 
can be found in a clinical study from Garcia-Hermoso et al. In this study Garcia-Hermoso 
et al. determined the genetic origin of clinical C. neoformans isolates taken from a cohort 
of cryptococcosis sufferers in France. Their analysis found that a number of 
immunocompromised African immigrants in the study (who had lived in France for many 
years before developing immune deficiency) were infected with C. neoformans strains 
originating in Africa. Garcia-Hermoso et al. concluded that these patients may have 
developed a latent form of cryptococcosis before moving to France and that the infection 
re-emerged when immune deficiency later developed (Garcia-Hermoso et al., 1999).   
4.7 Extrapulmonary infection 
If pulmonary Cryptococcus infection cannot be controlled there is a good chance that the 
fungus will disseminate from the lungs to other organs in the body via the blood stream. 
Dissemination from the lungs to the CNS is a crucial escalation point for Cryptococcus 
infection; this is because growth of C. neoformans in the brain and CSF causes 
cryptococcal meningitis - the most fatal complication of C. neoformans infection (Sabiiti 
and May, 2012). C. neoformans infection begins in the lungs. In order to reach the CNS, 
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the fungus must disseminate from the lungs into the blood stream and then subsequently 
across the blood brain barrier (BBB) into the CNS. The BBB is a highly specialised barrier 
that separates the CNS from the rest of the body. The brain is especially sensitive to tissue 
damage due to its slow rate of regeneration; to prevent damage blood brain barriers 
restricts movement of potentially harmful cells, proteins and large molecules from the 
blood into the CNS (Ballabh et al., 2004) . 
4.8 Exit from the lungs  
For C. neoformans to disseminate to the CNS it must first exit the lung by crossing the 
epithelial and endothelial cells layers that separate the alveolar space from the blood 
stream. It has been observed that C. neoformans can bind to alveolar epithelial cells and 
subsequently invade into the intracellular space. The initial adhesion of C. neoformans to 
epithelial cells appears to be mediated via the binding of glucuronoxylomannan (GXM) – 
one of the two major constituent polysaccharides in the cryptococcal capsule (Bose et al., 
2003). Although GXM was found to mediate initial adhesion to lung epithelial cells, 
intracellular invasion required active processes by the fungus (Barbosa et al., 2006). The 
virulence factor phospholipase B1 (Plb1) has been identified as a potential mediator of the 
lung epithelium invasion. In a study by Santangelo et al. it was found that in a mouse 
model of infection, Plb1 was required for dissemination from the lungs into the 
bloodstream but not from the bloodstream to the brain (Santangelo et al., 2004). Using a 
Plb1 deficient C. neoformans mutant strain (Δplb1) Santangelo et al. observed a lower rate 
of fungal dissemination for Δplb1 compared to the wild type strain when mice were 
infected intratracheally. Interestingly when Santangelo et al. took Δplb1 infected 
macrophages from the lungs of mice and injected them directly into the blood stream of 
33 
 
 
uninfected mice they found that Δplb1 no longer showed a difference in CNS 
dissemination. Taken together the data from this study suggests that Plb1 is required for 
dissemination from the lungs into the blood stream but is expendable for subsequent 
invasion of the blood brain barrier (Santangelo et al., 2004). Plb1 is a lipid modifying 
enzyme that is capable of hydrolysing phospholipids (key constituents of cell plasma 
membranes); this function may explain its role in dissemination as this activity could 
potentially disrupt the integrity of lung epithelium. Interestingly, one of the preferred 
substrates of Plb1 is dipalmitoyl phosphatidylcholine (DPPC) which is one of the most 
abundant lipids found in lung surfactant, this could indicate an additional target for Plb1 
during pulmonary infection (Wright et al., 2007). 
4.9 Penetration of the blood brain barrier      
The blood brain barrier is composed of the endothelial cells; these cells line all of the 
capillaries which supply the CNS with blood. The endothelial cells that make up the blood 
brain barrier have a greater number of tight junctions between adjacent cells and less 
pinocytotic activity than normal endothelium – these properties make the BBB less 
permissive to transcellular and paracellular movement (Ballabh et al., 2004).            
It is known that C. neoformans is able to cross the BBB; however, the mechanism it uses to 
do this is still unclear. There are currently three theories for how C. neoformans crosses the 
BBB (Figure 3). The first theory dictates that Cryptococcus yeast cells that are circulating 
in the blood during fungemia interact with endothelial cells in brain capillaries, and cross 
the BBB transcellularly (through endothelial cells) (Chang et al., 2004). Secondly 
cryptococci may pass paracellularly (between adjacent endothelial cells) following 
disruption of the BBB (Chen et al., 2003; Olszewski et al., 2004). The third theory is called 
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the ‘Trojan Horse’ hypothesis, this theory posits that macrophages infected with C. 
neoformans cross the BBB and release their fungal cargo into the CNS. Evidence to 
support all three theories of dissemination can be found in the literature suggesting that the 
mechanisms may not be mutually exclusive and in fact may co-exist. In this respect a study 
that examined disseminative cryptococcosis in an in vivo mouse model found that 
cryptococcal cells could be found within the brain both extracellulary or associated with 
monocytes and endothelial cells (Chrétien et al., 2002). 
In order for C. neoformans to transcytose across the BBB, it must first bind to an 
endothelial cell. After binding to the endothelium, the fungus facilitates its entry by 
rearranging the cytoskeleton of the endothelial cell (Chen et al., 2003). In order to interact 
for a sufficient time with host endothelial cells for transcytosis to occur C. neoformans 
must stop itself in the blood flow. Intravital imaging of C. neoformans in mouse brain 
capillaries has found that arrest of movement in the capillary lumen appears to be purely 
via mechanic trapping when the size of Cryptococcus cells exceeds that of the capillary. 
Once stopped C. neoformans binds to the endothelium and crosses the blood brain barrier. 
While stopping in the blood vessel was found to be passive, crossing of the endothelial 
layer was found to be an active process requiring viable cryptococcal cells (Shi et al., 
2010a). The active mediation of uptake by C. neoformans is indicated by additional studies 
which show that the cryptococcal virulence factors urease (Shi et al., 2010b; Singh et al., 
2013) and Plb1 (Maruvada et al., 2012) play a role in fungal uptake by endothelial cells. A 
further, well defined, active invasion mechanism has also been identified whereby C. 
neoformans incorporates hyaluronic acid into its capsule (Jong et al., 2007; Liu et al., 
2013)  that is likely derived from metabolism of host inisitol by C. neoformans. Hyaluronic 
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acid in the C. neoformans capsule is able to bind to CD44 expressed on endothelial cells, 
facilitating transcytosis of Cryptococcus cells through the endothelium (Jong et al., 2008). 
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Figure 3 - Possible routes of dissemination across the blood brain barrier (BBB) for C. 
neoformans. There are three routes that C. neoformans is thought to use to cross the blood 
brain barrier (BBB): A - fungal cells may pass directly through endothelial cells lining 
capilliaries in the brain, cells are taken up at the apical side and exit on the basal side – this 
is termed the transcellular route; B - fungal cells pass betweeen endothelial cells following 
disruption of cell to cell contacts, this disruption could be due to factors produced by the 
fungi or inflammation – this is called the paracellular route; C- macrophages that are 
infected with C. neoformans cells could pass from the circulation through the blood brain 
barrier via diapedesis, the fungi within the macrophage then escape into the extracellular 
space- this is called ‘Trojan Horse’ dissemination. 
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4.10 ‘Trojan Horse’ dissemination 
The ‘Trojan Horse’ theory of dissemination posits that C. neoformans infected 
macrophages migrate from the lungs to the CNS where upon they release their infective 
cargo. It is possible that C. neoformans could disseminate into the blood unaided and then 
are engulfed by macrophages and transported to the brain. In this respect it has been shown 
that Cryptococcus infected macrophages injected directly into the blood lead to increased 
fungal burden in the brain (Charlier et al., 2009). 
Once an infected macrophage has migrated to the CNS, Cryptococcus cells within must 
escape in order to grow freely within the brain tissue. One of the most interesting aspects 
of cryptococcal pathogenesis is the fungus’s cellular escape mechanism called 
‘vomocytosis’ (also known as non-lytic expulsion). Vomocytosis is a mechanism first 
observed in 2006 by two groups independently (Alvarez and Casadevall, 2006; Ma et al., 
2006). This mechanism allows C. neoformans to escape from infected macrophages 
without causing host cell lysis. Exiting without host cell lysis is likely to be beneficial to C. 
neoformans as it would result in lower levels of inflammation. Vomocytosis was first 
discovered and is largely studied in vitro however there is good evidence to show that the 
process also occurs in vivo (Nicola et al., 2011). Vomocytosis is also reported to occur in 
other fungi such as Candida albicans (Bain et al., 2012) and Candida krusei (Garcia-Rodas 
et al., 2011). 
4.11 Growth within the CNS 
Following dissemination, Cryptococcus neoformans proliferates within the CNS. 
Cryptococcal meningitis is associated with high levels of fungal burden in the CNS – 
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primarily in the CSF where the fungus readily grows. Due to the rapid growth of C. 
neoformans within CSF, dissemination of only a few cryptococci into the CNS can 
precipitate cryptococcal meningitis. A 1994 study by Hill et al. illustrates this phenomenon 
- following intravenous infection of mice with C. neoformans Hill et al. estimated that as 
few as 10 cells or 0.1 % of their original inoculum (104 cells) disseminated to the brain.  
By day 7 post infection Hill et al. found that the Cryptococcal burden in the CNS was 106 
cells, surpassing the total original inoculum by a factor of 100 (Hill and Aguirre, 1994).  
One of the reasons why C. neoformans grows so well in the CNS could be because C. 
neoformans metabolises neurotransmitters such as dopamine to produce melanin which is a 
known cryptococcal virulence factor (Casadevall et al., 2000).     
The growth of C. neoformans within the CNS triggers an immune response that is partly 
effective at decreasing the proliferation of the fungus. Protective immunity against CNS 
infection is dependent on CD4+ T cells (Buchanan and Doyle, 2000; Hill and Aguirre, 
1994; Uicker et al., 2006) however the accumulation of CD8+ T cells, macrophages and 
neutrophils during CNS infection has also been observed (Buchanan and Doyle, 2000). 
Furthermore, the efficacy of this immune response is dependent on IFN- γ and TNF-α; this 
suggests that, as with pulmonary infection, Th1 cell mediated immunity is required for 
immunity following dissemination to the CNS (Buchanan and Doyle, 2000; Hill and 
Aguirre, 1994; Uicker et al., 2006) 
To summarise this section, protective immunity against pulmonary C. neoformans 
infection requires a robust innate immune response in the form of neutrophils, 
macrophages and dendritic cells (Wozniak et al., 2006). When Cryptococcus infection is 
recognised, host cells are able to phagocytose and kill the fungus; furthermore, recognition 
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of C. neoformans leads to immune cell activation and the release of pro-inflammatory 
cytokines that shape the future adaptive immune response. The adaptive immune response 
is important because unless macrophages are ‘classically’ activated by a Th1 adaptive 
immune response, C. neoformans is able to survive within them intracellularly (Diamond 
and Bennett, 1973; Feldmesser et al., 2000; Garcia-Rodas and Zaragoza, 2012; Goldman et 
al., 2000a; Levitz et al., 1999a).   Dendritic cells that become activated by the presence of 
fungal cells in the lungs are required to trigger the development this adaptive immune 
response (Wozniak et al., 2006). Antigen presentation by dendritic cells in the lymph nodes 
can activate CD4+ T helper cells, these cells then migrate to the site of infection where they 
promote either a protective Th1 immune response or a non protective Th2 immune 
response (Voelz and May, 2010). The response that these CD4+ T cells induce depends on 
conditions at the time of their activation e.g. the phenotype of antigen presenting cells and 
composition of the cytokine milieu at the site of infection. 
There are broadly three potential outcomes to C. neoformans infection. The first outcome 
is seen in healthy hosts - Cryptococcus spores or yeast cells in the alveolar space are 
phagocytosed by host innate immune cells. A robust Th1 adaptive immune response leads 
to ‘classical’ macrophage activation. ‘Classically’ activated macrophages are able to kill 
the fungus resulting in total clearance of infection (Kawakami et al., 1995; Voelz et al., 
2009). The second outcome is usually seen in hosts who have a pre-existing immune 
deficiency. Host macrophages phagocytose cryptococci; however in the absence of a 
protective Th1 response – and perhaps in the presence of a non protective Th2 response – 
macrophages are unable to control their intracellular burden (Feldmesser et al., 2000; 
Voelz et al., 2009). Cryptococci subsequently replicate inside of macrophages (Feldmesser 
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et al., 2000). Uncontrolled pulmonary infection then leads to dissemination to the CNS 
(Sabiiti and May, 2012). The third outcome - disease latency - is the least studied of the 
three outcomes. In this scenario a healthy host experiences pulmonary infection however 
their immune system is unable to completely clear the fungus from the lungs. Cryptococci 
remain in the lungs in a latent state contained within granulomatous structures formed by 
infected macrophages (Shibuya et al., 2005). Cryptococcal infection may reactivate from 
this latent state at a future date if the host develops an immune deficiency (Garcia-
Hermoso et al., 1999). 
5. Cryptococcus virulence factors during infection 
The interaction between C. neoformans and host macrophages during pulmonary C. 
neoformans infection is an important stage of pathogenesis for both the pathogen and the 
host. Macrophages can phagocytose and kill C. neoformans however they do not become 
fully effective at controlling infection until they are ‘classically’ activated by Th1 CD4+ T 
cells (Kawakami et al., 1995; Voelz et al., 2009), whereas ‘Alternatively’ activated 
macrophages are susceptible to intracellular parasitism by C. neoformans (Voelz et al., 
2009). The fungus is able to survive within the macrophage’s phagosome and proliferate 
(Feldmesser et al., 2000; Garcia-Rodas and Zaragoza, 2012); additionally C. neoformans 
may use the macrophage as a vehicle for dissemination from the lungs to the CNS 
(Charlier et al., 2009).  
The outcome of cryptococcosis is determined by the host’s ability to defend against 
infection and also the ability of a particular C. neoformans strain to cause infection 
(Perfect, 2012b). Host factors (such as the strength and polarisation of the immune 
response) do significantly influence the outcome of C. neoformans infection; however, 
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virulence factors produced by the fungus also play a role. During infection C. neoformans 
utilises a number of virulence factors to help it survive within the host, these include the 
cryptococcal polysaccharide capsule (Bose et al., 2003), melanin production (Casadevall et 
al., 2000), the ability to grow at mammalian body temperature (Perfect, 2006), Titan cell 
morphology changes (Crabtree et al., 2012; Zaragoza et al., 2010) and secreted enzymes 
such as Plb1 (Cox et al., 2001; Djordjevic, 2010). 
5.1 The Cryptococcus polysaccharide capsule  
A characteristic feature of C. neoformans is the polysaccharide capsule that surrounds its 
cell wall. The capsule is composed of two key polysaccharide components: 
glucuronoxylomannan (GXM) and glucuronoxylomannogalactan (GXMGal) (Bose et al., 
2003; Heiss et al., 2009) (Figure 5), with a ratio of approximately 9:1 by mass in favour of 
GXM (Idnurm et al., 2005). Capsule growth can be stimulated in vitro by high CO2, 
neutral pH, low levels of available iron, high mannitol levels or low nutrient conditions. 
These conditions are similar in many ways to those found during host infection (Granger et 
al., 1985; Guimaraes et al., 2010; Vartivarian et al., 1993; Zaragoza et al., 2003a; Zaragoza 
and Casadevall, 2004) and concurrently, capsule growth has also been observed to occur in 
vivo (Rivera et al., 1998).  Synthesis of the capsule is controlled by at least four genes, 
designated CAP64, CAP59, CAP10 and CAP60 (Buchanan and Murphy, 1998; Ma and 
May, 2009). In a series of studies Chang et al. found that deletion of each CAP gene 
produced an acapsular mutant (Chang and Kwon-Chung, 1994; Chang et al., 1996; Chang 
and Kwon-Chung, 1998; Chang and Kwon-Chung, 1999). Acapsular C. neoformans 
mutants have been found to be avirulent during infection indicating that the capsule is 
required for host infection (Chang and Kwon-Chung, 1994; Fromtling et al., 1982). The 
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capsule has a number of properties that contribute to virulence during infection but the 
most important seems to be its anti-phagocytic properties as acapsular strains can be 
phagocytosed more readily than capsular strains by macrophages (Cross and Bancroft, 
1995; Kozel and Gotschlich, 1982).  
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Figure 4 – India ink stain of C. neoformans var. grubii strain H99, India ink staining 
reveals the characteristic polysaccharide capsule surrounding Cryptococcus cells as a white 
halo. 
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5.2 Anti-phagocytic properties of the Cryptococcus capsule 
Macrophages must detect the presence of foreign organisms before they can phagocytose 
them. To detect foreign organisms, macrophages express a number of phagocytic receptors 
on their cell surface; these receptors detect ligands that are found on foreign cells but not 
host cells. Phagocytic receptors are categorised according to the nature of their ligands. 
Non opsonic phagocytic receptors or ‘pathogen recognition receptors’ (PRRs) bind to 
‘pathogen associated molecular patterns’ or PAMPs - such as polysaccharide residues or 
lipid species found on the surface of foreign cells. Meanwhile opsonic receptors bind to 
opsonising proteins, such as antibodies or complement proteins that coat foreign cells 
following activation of the humoral immune system. One of the main ways that the capsule 
protects C. neoformans against phagocytosis is by providing a shroud around the cell that 
interferes with macrophage detection.  This shrouding effect blocks uptake via both 
opsonic and non-opsonic phagocytic receptors although it appears to have a greater 
inhibitory effect on non-opsonic uptake, since non-opsonised C. neoformans cells are 
almost completely protected from phagocytosis (Mukherjee et al., 1996). 
Phagocytosis of yeast-like fungi that do not produce a polysaccharide capsule, such as 
Candida albicans and Saccharomyces cerevisiae has been found to occur via non-opsonic 
phagocytic receptors such as Dectin-1 and Mannose receptor (MR) (Brown and Gordon, 
2001; Gantner et al., 2005; Giaimis et al., 1993; Porcaro et al., 2003). Both of these 
phagocytic receptors bind to cell wall constituents found in the cell wall of fungi ; Dectin-1 
binds to β-1, 3 and β-1, 6 linked glucan residues (Brown and Gordon, 2003) while MR 
binds to mannoproteins (Mansour et al., 2006). Macrophages can easily phagocytose 
acapsular C. neoformans mutants via Dectin-1 or MR ligation but they struggle to 
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phagocytose encapsulated cells (Cross and Bancroft, 1995). In wild type capsular strains, 
the ligands for each receptor are obscured by the overlying capsule, thus it is thought that 
non-opsonic phagocytic receptors such as Dectin-1 and MR may contribute to the 
phagocytosis of recently inhaled cryptococcal cells (which have a minimal capsule), but 
once conditions within the host stimulate capsule growth non-opsonic uptake becomes 
redundant.  
Opsonisation is more effective at facilitating the detection and phagocytosis of C. 
neoformans because opsonins bind to capsular components and thus are more accessible to 
macrophage phagocytic receptors than the non-opsonic receptor ligands. Two main classes 
of opsonic phagocytic receptors are expressed by macrophages: complement receptors, 
which recognise activated complement proteins deposited on the surface of foreign cells 
during infection, and Fc receptors, which recognise the Fc regions of immunoglobulin 
(antibody) molecules bound to specific antigens. 
The complement cascade is an important component of the innate immune system. 
Complement proteins are found circulating in blood serum and also in tissues. Upon 
detection of infection, the complement cascade is activated. Activation of the complement 
cascade results in the sequential cleavage of complement proteins – the end products of the 
cascade opsonise foreign cells and trigger further inflammation; in some cases they can 
also induce apoptosis of foreign cells such as bacteria (Sarma and Ward, 2011).  
Complement can be activated via three pathways – the classical pathway, the alternative 
pathway (these are different from macrophage classical and alternative activation 
pathways) and also the lectin pathway. Classical complement activation requires the 
presence of immunoglobulin – either IgM or IgG - bound to the surface of the foreign cell. 
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Alternative activation and lectin activation are triggered by PAMPs on the surface of 
foreign cells and as such do not require antigen specific immunoglobulin to be bound to 
the cell prior to activation.  Regardless of activated route the end result of each cascade is 
the generation of complement protein fragments which are deposited on foreign cell 
surfaces. The fragments produced are C3b, C3a, C5a and C5bC6C7C8(C9)n - also known 
as the ‘membrane attack complex’ (MAC). C3b is opsonising protein that can be 
recognised by phagocytes, C3a and C5a are pro-inflammatory agents that can stimulate 
chemotaxis and activation of immune cells at the site of infection and the MAC is able to 
form pores in foreign cell membranes potentially leading to cell death (Sarma and Ward, 
2011). Antibody produced during cryptococcal infection is thought to be ineffective at 
activating classical complement cascades (Houpt et al., 1994a) and thus the alternative 
complement and lectin cascades are likely more important during C. neoformans infection. 
As previously mentioned, C. neoformans is phagocytosed poorly by macrophages unless 
cryptococci are opsonised (Mukherjee et al., 1996). In terms of phagocytosis of C. 
neoformans therefore, C3b is the most important product of the complement cascade as it 
is an opsonising protein. Furthermore it has been shown that C3 deficiency leads to 
increased susceptibility to C. neoformans infection (Diamond et al., 1973).   Macrophages 
are able to recognise C3b via the phagocytic receptor ‘complement receptor 3’ (CR3) 
however there is evidence that the capsule can obscure C3b on C. neoformans cells. 
Cryptococcus cells that have thicker capsules (Zaragoza et al., 2003b) or a capsule that is 
less dense (Gates and Kozel, 2006) have increased protection against complement 
mediated phagocytosis by macrophages. By increasing the thickness of the capsule or by 
decreasing its density C. neoformans is able to reduce the efficacy of C3b opsonisation. 
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This is thought to be because a thicker, more permeable capsule is able to hide C3b below 
its surface thus obscuring C3b from recognition by CR3.  
Host production of antibodies against newly encountered antigens requires activation of 
the adaptive immune response - secondary exposure to an antigen however evokes a 
quicker response due to the persistence of immunological memory. Antibody opsonisation 
improves the phagocytic uptake of foreign cells in two ways. Firstly they amplify 
complement opsonisation by activating the classical complement pathway (Sarma and 
Ward, 2011), secondly antibodies directly promote phagocytosis via ligation of 
macrophage Fc receptors which bind to the non variable region of antigen bound 
antibodies (Nimmerjahn and Ravetch, 2007).  
In healthy individuals, anti-capsular GXM antibody titres are often used as markers of 
acquired immunity to C. neoformans (Deshaw and Pirofski, 1995a; Goldman et al., 2001; 
Houpt et al., 1994a). The protective role of anti GXM antibodies during infection however 
is debateable. For example a 1994 study by Houpt et al. found that the sera of healthy 
subjects contained IgG and IgM antibodies reactive against cryptococcal GXM, but that 
these antibodies were ineffective at activating the classical complement cascade (Houpt et 
al., 1994a). Interestingly antibodies which cannot bind to Fc receptors such as IgM have 
been found to be opsonic against C. neoformans. It is thought that the binding of these 
antibodies to the fungus results in alteration of the capsule (Taborda and Casadevall, 
2002). 
Another potential source of opsonins during pulmonary Cryptococcus infection is 
surfactant proteins. Surfactant proteins are a key component of lung surfactant – a 
protective mixture of lipids and proteins that lines the lungs. During pulmonary infection, 
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surfactant proteins bind to pathogens, clump them together and induce uptake by 
professional phagocytes. Studies that examine the interaction between C. neoformans and 
surfactant proteins have found that the binding of surfactant protein SP-D can enhance the 
uptake of C. neoformans by macrophages, however it was observed that the presence of 
capsule does effectively block this binding. In addition to this it was found that following 
phagocytosis SP-D protects C. neoformans from fungicidal conditions within the 
macrophage (Geunes-Boyer et al., 2009), this finding is in agreement with additional 
studies that have found that the presence of surfactant proteins facilitates Cryptococcus 
infection (Geunes-Boyer et al., 2012; Holmer et al., 2014). 
5.3 Other capsule virulence mechanisms 
During infection C. neoformans sheds capsule polysaccharide into the surrounding 
environment (Eng et al., 1986; Zaragoza et al., 2009). Shed capsule is called 
exopolysaccharide. Exopolysaccharide can be detected during infection in the extracellular 
space within infected tissues (Eng et al., 1986) but also intracellularly within macrophages 
(Tucker and Casadevall, 2002). Comparison of polysaccharide residues obtained from 
capsule associated and exopolysaccharide pools reveal structural differences, this suggests 
that exopolysaccharide may be produced specifically for secretion as opposed to simply 
diffusing out from the capsule (Frases et al., 2008). 
During macrophage infection exopolysaccharide accumulates within the macrophage 
(Tucker and Casadevall, 2002), due both to accumulation from phagocytosed 
Cryptococcus cells and also from the direct engulfment of exopolysaccharide (Chang et al., 
2006; Monari et al., 2003). This means that both infected and uninfected macrophages can 
become loaded with exopolysaccharide during C. neoformans infection. GXM has a 
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number of effects on macrophages and other host immune cells. Interactions with GXM 
can modulate macrophage expression of co-stimulatory molecules required for activation 
and also cytokine production (Monari et al., 2005a). Additionally GXM has been found to 
upregulate macrophage expression of FAS ligand (FasL) (Monari et al., 2005b; Villena et 
al., 2008) – a ligand via which macrophages can induce apoptosis of T cells (Monari et al., 
2005b) as well as other macrophages (Villena et al., 2008) during C. neoformans infection. 
5.4 Capsule independent antiphagocytic factors 
C. neoformans also has capsule independent antiphagocytic mechanisms. A study by Liu et 
al. has identified a GATA family transcription factor called Gat201 that appears to control 
such a mechanism (Liu et al., 2008). Knockout of the GAT201 gene affected the 
transcription of ~1,100 genes in C. neoformans although only 62 of these genes are thought 
to be regulated by direct binding of Gat201.  Phenotypic analysis of the GAT201 knockout 
strain showed reduced capsule size and increased uptake by macrophages. The 
susceptibility to phagocytosis observed was greater than that of acapsular mutants alone 
suggesting that capsule independent antiphagocytic mechanisms are also controlled by 
Gat201 potentially  via two downstream genes – BLP1 and GAT204 (Chun et al., 2011). 
Another capsule independent antiphagocytic mechanism is the secreted protein App1. This 
protein is expressed by C. neoformans during infection. App1 reduces complement 
dependent phagocytosis by blocking macrophage CR3 receptors (Luberto et al., 2003).  
5.5 Melanin production  
Melanin is a dark coloured pigment that is produced by C. neoformans under certain 
growth conditions. Cryptococcus synthesis of melanin requires an external substrate 
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meaning that melanisation only occurs under growth conditions where a suitable phenolic 
or indolic precursor substrate is available (Casadevall et al., 2000). The synthesis of 
melanin by C. neoformans is catalysed by the cryptococcal enzyme laccase (Williamson et 
al., 1998). 
Melanisation is another mechanism used by C. neoformans to promote virulence. Clinical 
C. neoformans isolates that produce high levels of melanin have been found to be more 
virulent than lower melanin producing strains (Huffnagle et al., 1995b) as well as melanin 
deficient mutants (Kwon-Chung and Rhodes, 1986; Kwon-Chung et al., 1982; Salas et al., 
1996). Production of melanin has been shown to occur in vivo by a number of studies 
(Nosanchuk et al., 1998; Nosanchuk et al., 1999; Rosas et al., 2000). As previously 
mentioned, to produce melanin C. neoformans requires an external substrate. Interestingly 
the CNS contains a number of catecholamine molecules such as dopamine, and 
epinephrine which are produced by the host as neurotransmitters but are also ideal 
compounds for C. neoformans to produce melanin (melanisation of C. neoformans is often 
induced experimentally using growth media supplemented with L-dopa (a catecholamine 
precursor), this may partly explain why C. neoformans has a preference for growth in the 
CNS following dissemination (Casadevall et al., 2000).  
Melanin is known to have a number of different functions during host infection. Firstly it 
appears to be an immune modulator – it was observed that mice infected with high melanin 
producing strains produced lower levels of TNF- α during pulmonary infection and had 
lower levels of lymphocyte proliferation (Huffnagle et al., 1995b). Additionally one of 
melanin’s properties is that it is an antioxidant and as such it has been observed that 
melanised C. neoformans are more resistant to free radical oxygen and nitrosative species 
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produced by immune cells such as macrophages and neutrophils during inflammation 
(Wang et al., 1995). Finally, because melanin is a negatively charged molecule, melanised 
cells are more repulsive towards other cells which usually have an inherent negative 
charge, thus melanisation may interfere with phagocytic cells while they are attempting to 
engulf C. neoformans (Casadevall et al., 2000). 
It has been already been discussed that in a recent study by Sabiiti et al.  it was found that 
C. neoformans isolates with higher laccase activity were more virulent clinically (Sabiiti et 
al., 2014). Although a correlation between laccase activity and clinical outcome was 
identified there was no correlation between melanisation and clinical outcome with the 
same strains. This suggests that laccase has virulence attributes that are independent of 
melanin production. In this respect laccase has also been linked to the production of 
immune modulatory eicosanoids by C. neoformans (Erb-Downward et al., 2008) and may 
also have a secondary role during CNS infection as the catecholamine molecules that 
laccase turns into melanin are also potentially toxic to the fungus (Casadevall et al., 2000). 
5.6 Growth at mammalian body temperatures  
C. neoformans is primarily an environmental organism and as such it grows well at 
ambient temperatures e.g. around 25oC or room temperature. This said the range of 
temperatures that C. neoformans can grow at is relatively broad, this is important as the 
ability to grow at 37oC makes C. neoformans a viable pathogen of humans and other 
mammals. Mammals are endothermic or ‘warm blooded’ animals; this means that they 
expend energy in order to warm themselves and maintain a constant body temperature. 
Ectothermic or ‘cold blooded’ animals on the other hand have an internal body temperature 
that is the same as their environment. Ectothermic animals are susceptible to colonisation 
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by environmental microorganisms such as fungi because their body temperature provides 
optimal growing conditions. By maintaining a body temperature above the ambient 
temperature of the environment, mammals preclude colonisation by many environmental 
microorganisms that could otherwise be potential pathogens.  
A good demonstration of this paradigm is seen with Chytridiomycosis – a disease of 
amphibians caused by the fungus Batrachochytrium dendrobatidis that has in recent years 
caused the extinction of a number of frog species and threatens many more. Amphibians 
are ectothermic or ‘cold blooded’ and as a result their body temperature is roughly the 
same as the ambient temperature of their immediate environment. This makes frogs 
susceptible to infection by B. dendrobatidis which also grows well at ambient temperatures 
e.g. 17oC to 25oC. Interestingly it has been found that infected frogs can be cured of 
Chytridiomycosis by raising their body temperature with a heat lamp to 30oC - a 
temperature outside B. dendrobatidis’ acceptable growth range (Chatfield and Richards-
Zawacki, 2011).  
It is noteworthy that out of the 50 plus Cryptococcus species in the Cryptococcus genus, C. 
neoformans and C. gattii are the only Cryptococcus species that regularly cause infection 
in humans – concurrently these two species are the only Cryptococcus species that are able 
to grow at human body temperature of 37oC. Additionally, rabbits have been observed to 
be more resistant to C. neoformans infection than many mammals. One of the reasons for 
this resistance could be because rabbits have a slightly higher body temperature, ~ 39oC 
(Perfect, 2006). These points highlight the importance of optimal and maximum 
temperatures of growth for a pathogen such as C. neoformans during infection.  
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A number of genes that help C. neoformans grow at mammalian body temperature have 
been identified. Many of these genes are involved in either metabolism or protein synthesis 
which presumably reflects the kinds of denaturing stress that above optimal temperatures 
can have on cells (Perfect, 2006). For instance, cryptococcal growth at high temperatures 
induces up regulation of the TPS and TPS2 genes. Increased expression of these two genes 
leads to higher levels cellular levels of the polysaccharide trehalose which protects cellular 
proteins from denaturation (Petzold et al., 2006). Another Cryptococcus gene involved in 
temperature dependant growth is CPA1 - this gene is required for growth by C. neoformans 
at the very top of its temperature range (39oC) however at 37oC the gene is dispensable, 
this indicates that there is a stratification in genes required for temperature growth (Wang 
et al., 2001).  
5.7 Titan cell morphology 
Several studies have reported the presence of abnormally large Cryptococcus cells in the 
lungs during in vivo infection (Cruickshank et al., 1973; Feldmesser et al., 2001; Love et 
al., 1985; Zaragoza et al., 2010), these ‘giant’ or ‘Titan’ cells appear to be resistant to 
phagocytosis (Okagaki et al., 2010). The diameter of Titan Cells differs between studies, 
with ranges from around 25 µm to 100 µm, making their volume up to 900 times greater 
than that of normal cryptococci (Zaragoza et al., 2010). The underlying mechanism or 
stimuli behind Titan Cell development is not known although the presence of 
macrophages, or at least spent media used to grow macrophages, can induce the 
morphology suggesting that interactions with the macrophage play at least some role in the 
process (Okagaki et al., 2010).  
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Titan Cells appear to be more resistant to phagocytosis than normally sized cells. The most 
obvious defence a Titan Cell has against a macrophage is its physical size.  However recent 
work has suggested that the presence of Titan Cells during infection may also protect 
neighbouring wild type cells from phagocytosis, suggesting the presence of a secreted 
inhibitory factor (Okagaki et al., 2010; Okagaki and Nielsen, 2012). The presence of Titan 
cells during infection also appears to shift the host immune response from Th1 towards 
Th2, again the mechanism behind this observation is unknown but it could also be due to a 
secreted factor produced by Titan cells (Crabtree et al., 2012; Garcia-Barbazan et al., 
2015).  
5.8 Phospholipase B1 
Phospholipase B1 (Plb1) is a phospholipid modifying enzyme with multiple enzymatic 
activities (Chen et al., 1997b). In cryptococcal cells a significant proportion of Plb1 
enzymatic activity is cell wall associated, although secretion of Plb1 from Cryptococcus is 
known to occur in vitro (Wright et al., 2002). Plb1 is secreted following cleavage of a GPI 
anchor motif that anchors the enzyme to the cell wall (Djordjevic et al., 2005b; Siafakas et 
al., 2007) and export of Plb1 to the cell wall is facilitated by Sec14-1 – part of C. 
neoformans’ protein export system (Chayakulkeeree et al., 2011). Plb1 has optimal activity 
in acidic conditions at around pH 4.0 to 5.0 (conditions similar to that of the phagosome) 
and is active at 37oC (Chen et al., 2000).   
In line with this putative role in pathogenesis, deletion of PLB1 strongly attenuates 
virulence in C. neoformans (Chayakulkeeree et al., 2011; Cox et al., 2001; Noverr et al., 
2003a; Santangelo et al., 2004). Mice infected with a PLB1 deletion C. neoformans strain 
(Δplb1) show reduced fungal burden in the lungs (Chayakulkeeree et al., 2011).  In 
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addition, during murine infection Plb1 appears to be required for cryptococcal 
dissemination from the lungs into the blood stream (Santangelo et al., 2004), and 
additionally may be involved in translocation of cryptococcal cells across the blood brain 
barrier into the brain (Maruvada et al., 2012). Plb1 will be discussed with greater detail in 
the introduction to Chapter 2.  
5.9 Evolution of C. neoformans virulence 
Cryptococcus neoformans is primarily an environmental fungus that grows in the soil and 
rotting wood; it does not need to infect a host to complete its life cycle and has not evolved 
to do so. It is thought that the virulence factors that allow C. neoformans to infect the host 
evolved due to completely different evolutionary pressures. A widely accepted theory to 
explain this ‘accidental virulence’ (Casadevall and Pirofski, 2007) is that C. neoformans’ 
virulence mechanisms were actually evolved as a result of a predator/prey relationship 
between the C. neoformans and soil amoeba. Within the soil there are species of amoeba 
that are quite similar to macrophages in that they ingest prey cells via phagocytosis and 
digest cells within a structure similar to the phagosome. Many of the mechanisms that 
allow C. neoformans to survive within macrophages also help the fungus avoid predation 
by amoeba such as Acanthamoeba castellani (Steenbergen et al., 2001).  
Experimentally it has been shown that Acanthamoeba castellani is able to phagocytose and 
eat C. neoformans cells, additionally many aspects of the Cryptococcus / macrophage 
relationship – e.g. intracellular proliferation, exopolysaccharide accumulation and 
vomocytosis have been shown to also occur when C. neoformans is eaten by A. castellani 
(Chrisman et al., 2010; Steenbergen et al., 2001). Furthermore, virulence factors required 
by C. neoformans to cause macrophage infection such as Plb1 and the presence of the 
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polysaccharide capsule also help the fungus survive within Acanthamoeba castellani after 
it is eaten (Steenbergen et al., 2001; Steenbergen and Casadevall, 2003). 
Conventionally evolved pathogens (i.e. pathogens that have specially evolved to cause 
infection such as the fungal pathogen Pneumocystis jirovecii) possess virulence factors that 
have evolved under selective pressure in their respective hosts. Evolutionary pressure 
means that these virulence factors usually benefit the pathogen and as a result are often 
detrimental to the host. Due to the fact that C. neoformans has not evolved as part of a 
host/pathogen relationship its virulence factors are often paradoxical in function.   
An example of C. neoformans’ paradoxical virulence during infection is its phagocytosis 
by host macrophages. During infection C. neoformans attempts to prevent phagocytosis by 
host macrophages, even though parasitism of macrophages can be beneficial to the fungus. 
In this respect it has already been discussed that unactivated macrophages during the early 
stages of infection are possibly detrimental to the host  (Shao et al., 2005) due to the fact 
that C. neoformans cells are able to survive and grow within the phagosome (Feldmesser et 
al., 2000). If C. neoformans were a conventional pathogen one would posit that the fungus 
would have evolved a mechanism to actively induce uptake by macrophages rather than 
avoid it. Even though C. neoformans cells benefit from macrophage phagocytosis they 
actively attempt to avoid it by producing antiphagocytic defences such as the 
polysaccharide capsule  (Mukherjee et al., 1996) and proteins such as APP1 (Luberto et al., 
2003). In the context of a conventionally evolved host/pathogen relationship these two 
mechanisms are at odds, however when seen against the evolutionary context of a 
predator/prey relationship it begins to make more sense. As an environmental fungus, 
Cryptococcus has evolved mechanisms to avoid being eaten by soil dwelling amoeba 
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because being predated produces evolutionary pressure. Inevitably however in a 
predator/prey relationship the amoeba can also evolve to become more efficient at eating 
Cryptococcus, therefore as well as actively trying to avoid being eaten by the amoeba, C. 
neoformans also evolves mechanisms to survive within amoeba in the event that the initial 
anti phagocytic defences fail. Thus in the context of host infection it is not C. neoformans’ 
‘intention’ to infect macrophages but if it is phagocytosed it can employ survival 
mechanisms to cope with its situation. 
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Figure 5 
A. Schematic showing the general structure of a Cryptococcus cells with the capsule and 
cell wall layer marked in addition to a budding daughter cell and a ‘bud scar’ – the 
impression left by a recently departed daughter cell. B.  A zoomed in schematic showing 
the cryptococcal capsule and cell wall with the major constituents of each structure marked 
showing their relative position. 
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6. Cryptococcus neoformans / macrophage interactions 
6.1 Survival within the phagosome 
During macrophage infection C. neoformans is contained within the phagosome. In order 
to survive and proliferate within the phagosome C. neoformans must endure and/or subvert 
the fungicidal conditions generated during phagosomal maturation. Phagosomes that 
contain C. neoformans do mature (at least to some degree) meaning that the fungus must 
resist the deadly conditions within the phagosome. Increasingly, however, there is also 
evidence to suggest C. neoformans is able to attenuate the full extent of phagosome 
maturation.  
C. neoformans uses a number of strategies to survive within the phagosome. The 
production of melanin by C. neoformans has been shown to protect the fungus against free 
radical oxygen species produced during the macrophage oxidative burst (Wang et al., 
1995). In addition to melanin, capsule enlargement during macrophage infection may also 
be protective against oxygen free radicals as it creates a barrier between the cell body and 
phagosomal contents. Additionally GXM within the Cryptococcus capsule may act as an 
antioxidant (Feldmesser et al., 2000; Garcia-Rodas and Zaragoza, 2012; Monari et al., 
2006; Vecchiarelli et al., 1996). 
Although C. neoformans is resistant to fungicidal conditions within the phagosome it does 
also appear to manipulate phagosome maturation, in doing so it is likely that C. 
neoformans blunts the full killing effects of phagosome maturation.  In this respect C. 
neoformans is able to increase the permeability of the phagosome membrane (Tucker and 
Casadevall, 2002); increased permeability would allow leakage of phagosome components 
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resulting in lower concentrations of digestive enzymes but also lower acidification due to 
proton leakage.  
During phagosome maturation the activity of the V-ATPase proton pump increases the 
acidity of the phagosome; low acidic pH is damaging in itself to living organisms however 
the low pH also helps activate digestive enzymes contained within the phagosome. It is 
generally thought that C. neoformans does not hinder the acidification of the phagosome 
(Levitz et al., 1999a); however a recent study by Smith et al. has found evidence to the 
contrary – in this study Smith et al. found that acidification of the phagosome, as measured 
using LysoTracker Red pH dye, did not occur in ~ 90% of phagosomes containing live C. 
neoformans cells, when heat or UV killed Cryptococcus cells were used however 
acidification occurred in almost 100% of phagosomes.  Due to the fact that C. neoformans 
does not inhibit V-ATPase activity the aforementioned increase in phagosomal 
permeability could be an explanation for the lack of acidification. Increased phagosome 
permeability (Tucker and Casadevall, 2002) would likely result in a leakage of H+ protons 
from the phagosome and as a result a higher phagosomal pH.  Paradoxically although C. 
neoformans may reduce phagosomal acidification during macrophage infection as it has 
been found that the phagosomal acidification may actually be beneficial to C. neoformans, 
since neutralising phagosomal pH can block intracellular replication (Levitz et al., 1999a). 
This discrepancy is probably another carry over from the predator/prey vs. host/pathogen 
evolution paradigm that was discussed in the previous section.  
6.2 Replication within the phagosome 
A number of studies have examined the correlation between Cryptococcus replication and 
overall virulence. For C. gattii a positive correlation can be observed between a strain’s 
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ability to replicate within the macrophage and in vivo virulence (Ma et al., 2009). For C. 
neoformans the same correlation cannot be seen (Sabiiti et al., 2014). This difference may 
be due to the differences in pathogenesis between the two species. For C. gattii, 
disseminative infection is not as common as for C. neoformans – C. gattii stays within the 
lungs and death usually occurs from overwhelming pulmonary infection. With this in 
mind, intracellular proliferation of C. gattii within alveolar macrophages likely has a much 
greater impact on pathogenesis than C. neoformans. This is because the additional factor of 
C. neoformans’ need to disseminate to the brain also determines to its virulence.  Although 
intracellular proliferation might not have as direct an impact on C. neoformans virulence as 
it does with C. gattii, replication within macrophages is still an important survival 
mechanism prior to dissemination.  
6.3 Escape from the macrophage 
Proliferation within macrophages is beneficial to C. neoformans however escape from the 
macrophage and dissemination from the lungs determines the outcome of infection. As 
previously mentioned C. neoformans possesses a specialised macrophage escape 
mechanism termed vomocytosis (Ma et al., 2006), or non-lytic expulsion (Alvarez and 
Casadevall, 2006; Nicola et al., 2011). This mechanism may help C. neoformans 
disseminate to the CNS within infected macrophages via the ‘Trojan Horse’ route of 
dissemination. 
Vomocytosis is a relatively rare macrophage interaction, it occurs in about 10% - 20% of 
macrophages in vitro (Ma et al., 2006). Vomocytosis rates in vivo are thought to be higher, 
although the methodology to measure vomocytosis in vivo is potentially not as definitive as 
in vitro methods (Nicola et al., 2011). Prior to vomocytosis the macrophage phagosome 
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has been found to permeablise (Johnston and May, 2010). During vomocytosis a 
Cryptococcus containing phagosome moves to the edge of the macrophage, the phagosome 
then fuses with the macrophage plasma membrane and the Cryptococcus cell is expelled.  
Vomocytosis is sometimes termed non-lytic expulsion due to the observation that both the 
macrophage and Cryptococcus appear to remain viable following expulsion. This said 
there is some evidence to suggest that the process of vomocytosis may affect the 
macrophage – in this respect it has been reported that following vomocytosis many 
macrophages develop enlarged vesicles within the cytoplasm. The contents and purpose of 
these vesicles is unknown and as such it is not known whether they represent cellular stress 
or are themselves detrimental to macrophage physiology (Alvarez and Casadevall, 2007).  
Additionally the macrophage appears to detect and subsequently try to block vomocytosis 
from occurring (Johnston and May, 2010).    
The cellular events driving vomocytosis are not fully understood. Interestingly, host cells 
appear to attempt to block vomocytosis by initiating repeated actin polymerisation / 
depolymerisation cycles (actin flashing) around the phagosome following permeabilisation 
(Johnston and May, 2010). Vomocytosis only occurs from phagosomes containing live 
yeast indicating that vomocytosis is at least in part yeast mediated (Ma et al., 2006; Smith 
et al., 2015b), additionally the secreted virulence factor Plb1 has been shown to be 
involved in the process (Chayakulkeeree et al., 2011). 
A distinct but related cellular event to vomocytosis occurs during cryptococcal infection of 
macrophages, this event is called ‘lateral transfer’ (Alvarez and Casadevall, 2007; Ma et 
al., 2007). During lateral transfer a Cryptococcus cell is able to pass between two adjacent 
macrophages seemingly without leaving the intracellular compartment. Lateral transfer 
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occurs when two macrophages move together so that there is contact between plasma 
membranes – it is still not clear whether the coming together of two macrophages is an 
active process driven by the fungus or the host cell or whether lateral transfer only occurs 
when two macrophages stochastically touch. As with vomocytosis, lateral transfer was first 
described in vitro although it is also thought to occur in vivo. Its role during cryptococcal 
pathogenesis is also unclear. Speculatively it could be a way for macrophages unable to 
cope with intracellular infection to pass off their burden to surrounding cells that may be 
able to help. Alternatively, it is possible that Cryptococcus triggers the event for the 
opposite reason i.e. to escape from a macrophage that is beginning to kill it into one that 
might be more amenable to intracellular parasitism.  
To summarise this section, the role of the macrophage during antifungal immune responses 
is of central importance (Figure 6). Not only is the macrophage responsible for detecting 
infection and shaping subsequent immune responses, it is also required to directly kill and 
clear fungal cells. The behaviour of the macrophage during C. neoformans infection is of 
even greater importance than most fungal infections because while the macrophage seeks 
to clear infection, the fungus itself relies on the macrophage as safe niche for intracellular 
proliferation and possibly as a vehicle for CNS dissemination. During macrophage 
infection C. neoformans employs a number of virulence factors that allow it survive and 
replicate within the macrophage and also to escape once intracellular parasitism no longer 
beneficial. Many of the virulence factors produced by C. neoformans seem perfectly 
adapted to survival in the host. This is at odds with the fact that C. neoformans evolved as 
an environmental pathogen, thus it is likely that many of these virulence mechanisms were 
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evolved by C. neoformans as a result of interactions between the fungus and soil dwelling 
phagocytic amoeba.  
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Figure 6.  
The possible outcomes following C. neoformans infection of macrophages. A. Opsonised 
C. neoformans (in this case opsonised with antibody) binds to phagocytic receptors on the 
cell surface of the macrophage. B. Ligation of phagocytic receptors induces cytoskeletal 
rearrangements within the macrophage resulting in invagination of the membrane and the 
formation of phagocytic pseudopodia around the bound cell. C. C. neoformans is contained 
inside the macrophage within a membrane bound compartment called the phagosome. D. 
Overtime the phagosome matures, maturation begins with the recruitment of V-ATPase, 
NADPH oxidase and NOS to the phagosome membrane resulting in the lowering of pH 
and the production of reactive oxygen species within the phagosome. E. Phagosomal 
maturation culminates when lysosomes fuse with the phagosome, this releases digestive 
proteolytic enzymes into the phagosome (which is now termed the phagolysosome). There 
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are three possible outcomes for C. neoformans following formation of the phagolysosome 
i) fungicidal conditions within the phagosome destroy the fungus which is then digested. ii) 
C. neoformans resists the conditions within the phagolysosome and begins to replicate. iii) 
C. neoformans escapes from the macrophage via a process called vomocytosis - N.B. 
outcome iii) can happen after replication e.g. outcome ii). 
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7.  Project summary 
The following sections will detail the experimental work that I have undertaken during my 
PhD study. Each chapter discusses a different aspect of project, each chapter has been 
written as if it were a standalone publication e.g. introduction, materials and methods and 
discussion (albeit more in-depth). The chapters are as follows. 
CHAPTER 2 - THE ROLE OF CRYPTOCOCCAL PHOSPHOLIPASE B1 DURING 
MACROPHAGE INFECTION 
An abridged version of this chapter has already been published (Evans et al., 2015). This 
chapter deals with the main focus of my PhD research. In this chapter I explore how 
expression of the C. neoformans virulence factor Phospholipase B1 (Plb1) influences the 
outcome of macrophage infection. To do this I use a C. neoformans mutant strain deficient 
in Plb1 called Δplb1 and characterise some of the phenotypes that arise during in vitro 
infection of J774 murine macrophages. 
In this study I demonstrate that Δplb1 deficiency results in lower replication of C. 
neoformans within macrophages, as well as increased susceptibility to macrophage killing 
and phagocytosis. I also a describe a novel morphological phenotype for Δplb1 that 
develops during macrophage infection – this morphology appears to be closely related to 
Titan Cell morphologies but, in contrast to classical Titan morphology, occurs 
intracellularly. These findings suggest that Plb1 might have a previously unknown function 
in the control of the Titan Cell morphology. 
CHAPTER 3 – THE ROLE OF EICOSANOIDS DURING CRYPTOCOCCAL 
INFECTION OF MACROPHAGES 
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This chapter continues from my published research (Evans et al., 2015), the research in this 
chapter is based upon a hypothesis that eicosanoids produced by C. neoformans influence 
the outcome of macrophage infection – potentially by mimicking and interfering with host 
eicosanoid signalling pathways. 
This chapter details work I have conducted to this point to address this hypothesis. First I 
examine whether co-infected macrophages that contain Δplb1 Plb1 deficient cells and wild 
type Plb1 producing H99 cells show any difference in phenotype to singly infection Δplb1 
cells, in order to test whether a secreted factor produced by the wild type cells can rescue 
Plb1 deficient cryptococci within the same cell. Next I attempt to reverse some of the 
phenotypic observations I have previously published (Evans et al., 2015) by adding 
exogenous eicosanoids or eicosanoids precursors to infected macrophages in culture. 
CHAPTER 4 – DEVELOPMENT OF A HIGH THROUGHPUT FLOW 
CYTOMETRY METHOD FOR THE DETERMINATION OF CRYPTOCOCCUS 
INTRACELLULAR PROLIFERATION 
This chapter represents research I have performed as part of a side project to develop a 
high throughput flow cytometry based protocol to accurately measure the intracellular 
proliferation of C. neoformans within in vitro cultured macrophages. The benefits of this 
protocol over other available protocols is that it does not require the use of antibody 
labelling or genetic modification of C. neoformans, instead it makes use of readily 
available cell staining reagents (Calcofluor white and propidium iodide 
) thus the protocol is quick and easy to perform. It is hoped that this protocol will open up 
the study of C. neoformans intracellular proliferation such that large gene knockout 
libraries and clinical isolate collections can be quickly and accurately examined. 
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This chapter details how the methodology was developed and also includes a proof of 
principle experiment using a selection of clinical isolates and comparing the flow 
cytometry results to the standard haemocytometer based method of counting. 
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CHAPTER 2 – THE ROLE OF 
CRYPTOCOCCAL PHOSPHOLIPASE B1 
DURING MACROPHAGE INFECTION 
 
Parts of this chapter have been adapted from work already published work. (Evans et al., Infection 
and Immunity 2015 Apr;83(4):1296-304. doi: 10.1128/IAI.03104-1).  
The Titan cell data (Figure 7) was a result of collaboration with Kirsten Nielsen and Zhongming 
Li, Department of Microbiology, University of Minnesota, MN 55455, USA. 
1. Introduction 
During infection, C. neoformans produces a number of secreted enzymes that can influence 
pathogenesis; phospholipase B1 (Plb1) is one such enzyme (Cox et al., 2001). Plb1 is a 
lipid modifying enzyme that has multiple enzymatic activities; it is secreted by C. 
neoformans during growth and is known to be expressed during infection (Himmelreich et 
al., 2003; Santangelo et al., 2005). Plb1 is member of a family of phospholipase enzymes - 
phospholipase enzymes are found in some form in most eukaryotic cells; their function is 
to modify phospholipid molecules and their constituents. Generally, phospholipases cleave 
lipids but some variants of the enzyme (such as Plb1) have a number of complex 
enzymatic activities that allow them to both cleave and also form new phospholipid 
molecules (Djordjevic, 2010). 
1.1 Phospholipase enzyme classification. 
Phospholipids are an important group of lipids within living cells. All phospholipids share 
a similar structure – a glycerol backbone attached by ester linkages at one end to two fatty 
acid chains, and at the other, to a phosphate head group. The types of fatty acids and 
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phosphate head groups attached to the glycerol backbone determine each class of 
phospholipid. Phospholipids are major constituents of lipid bi-layers found in cell 
membranes; they are able to form these bi-layers due to their dual hydrophobic and 
hydrophilic properties in aqueous solution. In addition to forming cell membranes, 
phospholipids and their constituents have roles in cell signalling processes, cell growth and 
cellular metabolism (van Meer et al., 2008).  
Phospholipases are grouped into a number of classes – A, B, C and D. Each class of 
phospholipase cleaves phospholipid molecules at a different location to produce different 
products. Phospholipase A1 or A2 activities hydrolyse the ester linkage between the fatty 
acid tail and the glycerol back bone of the phospholipid to produce a free fatty acid and a 
lysophospholipid (Figure 1). Phospholipase A1 enzymes cleave at the Sn1 position while 
phospholipase A2 enzymes cleave at the Sn1 position – phospholipase enzymes that cleave 
at either the Sn1 or Sn2 position are classed as phospholipase B enzymes. Phospholipase C 
enzymes cleave the phosphate head group from phospholipids producing diacylglycerol 
and a free phosphate head group while phospholipase D cleaves within the phosphate head 
group producing phosphatidic acid and a free head group in the form of an alcohol (Shea et 
al., 2006). 
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Figure 1 – A Diagram showing the cleavage sites for the enzymes Phospholipase A1 
(PLA1), Phospholipase A2 (PLA2), Phospholipase C (PLC) and Phospholipase D (PLD) 
within the chemical structure of a phospholipid.   
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1.2 Cryptococcal phospholipase B1 (Plb1). 
Plb1 is encoded by the gene PLB1. This gene is encoded on C. neoformans’s third largest 
chromosome as a single copy. The PLB1 gene is 2218 base pairs long and contains six 
introns (Cox et al., 2001). Once expressed Plb1 is 637 amino acids in length; native Plb1 is 
about 75 kDa in size however the protein has a number of N-linked glycosylation sites that 
increase the size of the protein to 120 kDa (Chen et al., 2000; Turner et al., 2006). Plb1 has 
17 predicted N-linked (Asn-X-Ser/Thr) (Chen et al., 2000) and 3 predicted O-linked (Ser-
Thr) glycosylation sites (Latouche et al., 2002) in its amino acid sequence however it is 
possible that not all of these sites are utilised. Full Plb1 glycosylation is required for 
enzymatic activity (Chen et al., 2000) and also for secretion (Turner et al., 2006). Other 
key features of Plb1 include a 19 amino acid N-terminal leader peptide secretion motif that 
targets Plb1 for secretion from Cryptococcus and a 22 amino acid C-terminal 
glycosylphosphatidylinositol (GPI) anchor motif that anchors the Plb1 to the cryptococcal 
membrane prior to secretion (Djordjevic et al., 2005a). Deletion of these motifs leads to 
Plb1 hyposecretion and Plb1 hypersecretion respectively; these phenotypes indicate the 
role of each motif in regulating Plb1 secretion (Djordjevic et al., 2005b). Additionally Plb1 
possesses lipase (GLSGGS) and phospholipase (AGGGXRAML) motifs (Latouche et al., 
2002). 
1.3 Plb1 enzymatic activities. 
Plb1 is generally referred to in the literature by its generic name ‘Phospholipase B1’ 
(denoting its A1 and A2 activities); this name can be misleading because Plb1 has 
additional enzymatic activities not addressed by standard phospholipase nomenclature. In 
addition to phospholipase B (PLB) activity, Plb1 also has lysophospholipase (LPL) and 
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lysophospholipase transacetylase (LPTA) activities (Figure 2). These additional enzymatic 
activities allow Plb1 to degrade and also remodel phospholipids. LPL activity allows Plb1 
to hydrolyse lysophospholipid species produced by prior PLB activity to form a 
phosphoglycerol species and a free fatty acid. This is achieved by hydrolysing the 
remaining fatty acid chain from the lysophospholipid. LPTA activity meanwhile takes the 
lysophospholipid produced by prior PLB activity and reattaches a free fatty acid at either 
the Sn1 or Sn2 position forming a complete phospholipid (Djordjevic, 2010). 
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Figure 2 -  
Schematic diagram showing the different enzymatic actions of Plb1. Phospholipid 
molecules are broken down by the enzyme’s phospholipase B (PLB) activity producing a 
free fatty acid and a lysophospholipid. The lysophospholipids produced by PLB activity 
can be further degraded by the enzyme’s lysophospholipase (LPL) activity to give a 
glycerophospholipid and a second free fatty acid. Finally, Plb1’s lysophospholipase 
transactylase (LPTA) activity can produce new phospholipid molecules by combining 
intermediate lysophospholipid species and free fatty acids.  
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Initially it was believed that C. neoformans produced three separate enzymes with PLB, 
LPL or LPTA activities (Santangelo et al., 1999). It was soon discovered however that a 
single enzyme, Plb1, possessed all three activities (Chen et al., 2000). Interestingly all 
three Plb1 enzymatic activities are facilitated by a single active site. Knockout of three key 
amino acids – Arg108, Ser146 and Asp392 - within this active site has been shown to 
abrogate all three enzymatic activities simultaneously (Jones et al., 2007). All three Plb1 
activities have optimal activity at acidic pHs – PLB activity has an optimal pH of 4.0 while 
LPL and LPTA activities have an optimal pH range of 4.0 – 5.0 (Chen et al., 2000).  As 
each enzymatic activity has a different set of optimal conditions, the relative dominance of 
each activity changes depending on the physiological location of Plb1 within the 
Cryptococcus cell. In this respect it has been shown that PLB activity dominates when 
Plb1 is secreted while LPL and LPTA activities dominate cytosolically and when the 
enzyme is cell wall/membrane associated (Ganendren et al., 2004).  
The substrate specificity of Plb1 is broad; its preferred substrates are 
Dipalmitoylphosphatidylcholine (DPPC) and 1, 2-Dioleoyl-sn-glycero-3-phosphocholine 
(DOPC) however it can also hydrolyse many other phospholipid species found in cell 
membranes such as Phosphatidylinositol (PI), Phosphoglyceride (PG) and 
Phosphatidylserine (PS). It has been found that Plb1’s PLB activity cannot hydrolyse 
Phosphatidic acid (PA), Sphingomyelin (SPH), Trioleoylglycerol or Palmitoylcarnitine 
(Chen et al., 2000). Analysis of Plb1’s LPL activity has found that 1-Palmitoyl lyso-PC 
and 1-Oleoyl lyso-PC are the preferred substrates and that Lyso-PI, 1-Palmitoyl lyso-PE 
while 1-Palmitoyl lyso-PS can also be hydrolysed. 
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1.4 Phospholipase B1 enzymes from other species of fungi. 
Many species of fungi – both pathogenic and non-pathogenic – produce enzymes similar to 
Plb1. Non pathogenic fungi that produce similar enzymes include Saccharomyces 
cerevisiae (Lee et al., 1994), Penicillium notatum (Sugatani et al., 1978) and 
Schizosaccharomyces pombe (Oishi et al., 1996). Pathogenic species that produce enzymes 
similar to Plb1 include Candida albicans (Leidich et al., 1998; Sugiyama et al., 1999), 
Aspergillus fumigatus (Shen et al., 2004) and Cryptococcus gattii (Latouche et al., 2002; 
Wright et al., 2004). Phospholipase B enzymes from non-pathogenic fungi and pathogenic 
fungi differ in a number of ways. Phospholipase B enzymes from pathogenic fungi have 
between 10 and 100 times greater PLB activity than non pathogenic species, additionally 
the substrate preferences of the pathogenic phospholipase B enzymes include lipids such as 
DPPC which are found in host lung surfactant. This suggests that these pathogenic 
phospholipase B enzymes are capable of attacking host lipids in the periphery. Non-
pathogenic phospholipase B enzymes meanwhile prefer lipids more commonly found on 
the inner leaflet of cell membranes suggesting a role in fungal homeostasis (Djordjevic, 
2010).  
As mentioned,  C. neoformans and the more virulent Cryptococcus species Cryptococcus 
gattii both produce very similar Phospholipase B1 enzymes (91.7% peptide sequence 
homology) (Latouche et al., 2002). Interestingly the ratio of PLB to LPL activity for C. 
gattii derived phospholipase B1 is higher than that seen with C. neoformans derived 
phospholipase B1. Additionally, the substrate specificity of C. gattii phospholipase B1 is 
much narrower than C. neoformans phospholipase B1. For C. gattii phospholipase B1, the 
only substrates hydrolysed in significant amounts by the enzyme’s PLB and LPL activities 
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are DPPC and 1-palmitoyl lyso-PC respectively. The higher PLB: LPL ratio observed for 
C. gattii phospholipase B1 and its preference for lipids found in lung surfactant may, at 
least in part, explain why C. gattii infection typically involves more pulmonary activity 
and less disseminative disease than C. neoformans infection (Wright et al., 2004). 
1.5 Plb1 secretion. 
Following translation, Plb1 moves into the endoplasmic reticulum where it is glycosylated. 
Plb1 is then exported from the endoplasmic reticulum to the cryptococcal cell surface 
where it is secreted (Djordjevic, 2010). Transport of Plb1 to the cryptococcal cell surface is 
dependent on the protein Sec14. C. neoformans has two Sec14 homologs – Sec14-1 and 
Sec14-2. Sec14-1 (and to a lesser extent Sec14-2) facilitates the export of Plb1 to the 
cryptococcal cell wall before secretion. A C. neoformans mutant deficient in Sec14-1 
(Δsec14-1) still expresses Plb1 however cell wall associated, and secreted, activity of Plb1 
is almost completely abrogated (Chayakulkeeree et al., 2011). At the Cryptococcus cell 
surface, Plb1 localises to the cell membrane and also to the fungal cell wall. Plb1’s C- 
terminal GPI anchor motif allows it to anchor to the Cryptococcus cell membrane where it 
appears to concentrate in lipid rafts (Siafakas et al., 2006). In the cell wall meanwhile Plb1 
is thought to crosslink with β-1, 6-glucan moieties (Djordjevic, 2010). Secretion of Plb1 
occurs when the GPI anchor is cleaved by proteases, phospholipases (C and D) or 
glucanases. It has been observed that the majority (>85%) of phospholipase B activity in C. 
neoformans is associated with the cellular fraction of C. neoformans - as opposed to 
supernatant (Santangelo et al., 1999). Interestingly however experiments with the Δsec14-1 
mutants indicate that many of the virulence mechanisms facilitated by Plb1 are dependent 
on secreted enzymatic activity (Chayakulkeeree et al., 2011). 
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1.6 Evidence that Plb1 is a virulence factor during host infection. 
Plb1 was first identified as a cryptococcal virulence factor by Chen et al. in 1997. Chen et 
al. assessed the relative phospholipase activity of fifty C. neoformans isolates from both 
environmental and clinical sources. Once they had identified strains with high, medium 
and low phospholipase activities they infected a representation selection of isolates into 
BALB/c mice and identified a correlation between high phospholipase activity and 
increased fungal virulence (Chen et al., 1997a). In 2001 a PLB1 deletion mutant (Δplb1) 
was produced by Cox et al. in the C. neoformans H99 genetic background. Cox et al. 
found that that mice infected with this mutant had a significantly increased time of survival 
compared to those with wild type infection, while in a rabbit meningitis model Δplb1 had 
poorer survival in CSF (Cox et al., 2001). A subsequent study using a similar mouse 
pulmonary infection model found that the poor virulence of Δplb1 is linked to both reduced 
fungal burden in the lungs and also reduced dissemination to the CNS (Chayakulkeeree et 
al., 2011).  
Reduced fungal burden in the lungs during host infection may occur because Δplb1 cannot 
grow properly within host macrophages. In this respect it has been reported that the Δplb1 
mutant has a number of growth and survival deficiencies in a variety of experimental 
macrophage infection models (Cox et al., 2001; Noverr et al., 2003a; Wright et al., 2007). 
It has also been observed that Δplb1 mutant cells have reduced cell wall and cell membrane 
stability leading to increased susceptibility to the membrane stressor SDS (Chayakulkeeree 
et al., 2011; Siafakas et al., 2007). This decreased stress resistance may explain why Δplb1 
does not grow well within the macrophage phagosome. In addition to decreased stress 
resistance it has been observed that Plb1 helps C. neoformans to acquire, metabolise and 
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detoxify host lipids during macrophage infection. In this respect Wright et al. have shown 
that C. neoformans cells can scavenge host derived fatty acids such as arachidonic acid via 
a Plb1 dependant process, during in vitro infection of THP1 macrophages. In this same 
study it was found that C. neoformans could metabolise host associated lipids such as 
DPPC and DOPC as an alternative energy source if glucose was omitted from growth 
media – importantly this metabolism was also Plb1 dependant. Finally, Δplb1 C. 
neoformans cells were found to be unable to detoxify the lipid LysoPC (a lipid species 
derived from DPPC metabolism that can be toxic to eukaryotic cells) under glucose poor 
conditions. Interestingly both wild type and Δplb1 cells could cope with LysoPC when 
glucose was added to the growth media. Wright et al. concluded that Plb1 LPTA activity 
provides a glucose independent way to detoxify LysoPC to PC under low energy poor 
conditions, however in the presence of glucose Plb1 is made redundant by the ATP 
dependant Coenzyme A pathway that can also detoxify LysoPC (Djordjevic, 2010; Wright 
et al., 2007).  
As well as promoting fungal lung burden, it has been observed that Plb1 also helps to 
facilitate the dissemination of C. neoformans from the lungs to the CNS (Chayakulkeeree 
et al., 2011; Cox et al., 2001; Santangelo et al., 2004). In this respect it has been observed 
that during in vivo mouse infection, Plb1 is required for dissemination from the lungs into 
the bloodstream but not for dissemination from the blood into the CNS (Santangelo et al., 
2004). To disseminate from the lungs C. neoformans presumably needs to interact with 
lung epithelial cells in order to either to trigger translocation or to damage the epithelial 
layer sufficiently to breach it. As previously discussed one of the preferred substrates of 
Plb1 is Dipalmitoylphosphatidylcholine (DPPC), a key constituent of lung surfactant that 
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coats and protects that lung epithelium (Chen et al., 2000). Additionally it has also been 
observed that the Δplb1 strain adheres to lung epithelial cells poorly in vitro suggesting 
that Plb1 may help C. neoformans bind to lung epithelium prior to dissemination 
(Ganendren et al., 2006).    
In vivo data suggests that Plb1 facilitates dissemination from the lungs into the 
bloodstream but not from the blood stream into the CNS (Santangelo et al., 2004); this said 
in vitro data has been published that implicates Plb1 in various aspects of CNS 
dissemination. For instance it has been reported that C. neoformans facilitates translocation 
across human endothelial cell monolayers via the activation of Rac1 (Maruvada et al., 
2012). Additionally it has been found that Δplb1 cells have a lower rate of vomocytosis 
from macrophages (Chayakulkeeree et al., 2011) in vitro which could hinder dissemination 
to the CNS via the ‘Trojan Horse’ mechanism.    
In addition to Plb1 which has PLB, LPL and LPTA enzymatic activities, C. neoformans 
and C. gattii also produce lysophospholipase enzymes that have just LPL and LPTA 
activities. It has been suggested that these lysophospholipase enzymes may contribute a 
significant proportion of the LPL and LPTA activities observed during fungal growth. 
Analysis of the purified C. gattii enzyme indicates that the optimum pH range of LPL and 
LPTA activities is pH 7.0, much higher than the corresponding acidic optimal pH for LPL 
and LPTA activities from Plb1 (Coe et al., 2003).      
To summarise, Plb1 is a virulence factor required by C. neoformans during host infection. 
It has been observed that the Plb1 deficient C. neoformans mutant strain Δplb1 has 
attenuated virulence during in vivo infection (Cox et al., 2001). During infection this strain 
displays lower fungal burden in the lungs (Chayakulkeeree et al., 2011), and reduced 
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dissemination to the CNS (Chayakulkeeree et al., 2011; Cox et al., 2001; Santangelo et al., 
2004). A number of studies have also reported that Δplb1 may be attenuated within 
macrophages, therefore it is possible that Plb1 mediated virulence during in vivo infection 
may be due to Plb1 influencing the outcome of macrophage intracellular parasitism (Cox et 
al., 2001; Noverr et al., 2003a; Wright et al., 2007).   
The main aim of my PhD research was to explore how expression of Plb1 contributes to 
the outcome of the interaction between C. neoformans and the macrophage. To do this I 
used the previously constructed Δplb1 strain (Cox et al., 2001) which is deficient in Plb1 
and examined how deficiency of this protein changed the well characterised interaction 
between C. neoformans and in vitro murine macrophage J774 cell line.  In this chapter I 
will detail my findings. Herein I report that Plb1 is critical for both proliferation and 
survival within J774 macrophages. In addition, I show that the Δplb1 strain responds to 
macrophage infection by significantly increasing both capsular thickness and overall cell 
size within the phagosome and in the murine lung. This novel morphology is reminiscent 
of, and closely related to, the previously published titan cell morphology (Crabtree et al., 
2012; Okagaki et al., 2010; Zaragoza et al., 2010). This interesting finds and suggests that 
control of cryptococcal Titan cell morphology during by Plb1 may play a vital role in the 
outcome of host macrophage infection.   
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2. Materials and methods 
2.1 Ethics statement 
A total of fourteen mice were handled in strict accordance with good animal practice, as 
defined by the relevant national and/or local animal welfare bodies. All animal work was 
approved by the University of Minnesota Institutional Animal Care and Use Committee 
(IACUC) under protocol no. 1308A30852. 
2.2 Strains, media and cell lines 
Strains used in this work are listed in the Appendix (Appendix Table 1, page 188). Strains 
were stored long-term in MicroBank vials at -80oC.  Strains were rescued onto YPD agar 
(YPD 50 g/L Sigma Aldrich, 2 % Agar – Melford) for 48 hours at 25oC and then stored 
until needed at 4oC. Before experimentation, liquid cultures were grown from these stock 
plates in 2 ml YPD growth medium (50 g/L) for 24 hours at 25oC under constant rotation. 
The J774 murine macrophage cell line was used for all in vitro infection assays. Cells were 
passaged in DMEM culture media with serum (Dulbecco’s Modified Eagle medium, low 
glucose, Sigma Aldrich, 10 % FBS - Invitrogen, 1% 10,000 units Penicillin / 10 mg 
streptomycin – Sigma Aldrich, 1 % 200 mM L – glutamine – Sigma Aldrich). Assays were 
performed with J774 cells between passages 4 and 15. Assays were performed in serum-
free DMEM (DMEM high glucose, 1% P/S, 1% L-glutamine) unless otherwise stated. 
2.3 Intracellular proliferation assay 
The Intracellular proliferation assay was performed as previously described (Ma et al., 
2009). Briefly, 24 hours before infection, 1x105 J774 macrophages were seeded into 24 
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well plastic plates (Greiner Bio One Cell Star) in 1 ml culture media with serum and 
incubated for 24 hours at 37oC 5% CO2. Before infection, J774 cells were activated with 
150 ng/ml phorbol 12-myristate 13-acetate in DMSO (PMA) Sigma), in 1 ml serum free 
culture medium for 45 minutes. This media was then replaced with serum-free media 
alone. Simultaneously, overnight C. neoformans cultures grown at 25oC in YPD were 
washed three times in sterile 1x PBS, counted and adjusted to 1 x107 cells per ml in PBS 
before opsonisation for 1 hour with 10 μg/ml anti capsular 18B7 antibody (a kind gift from 
Arturo Casadevall, Albert Einstein College of Medicine, New York USA). The activated 
J774 cells were then infected with 100 μl opsonised C. neoformans to give an MOI of 10 
(e.g. 1x105 J774 / 1x106 C. neoformans) in un-supplemented serum-free DMEM (e.g. no 
PMA) and incubated for 2 hours at 37oC 5% CO2. After two hours (time point 0) infected 
wells were washed at least 3 times with warm 1x PBS until all non-phagocytosed C. 
neoformans cells were removed from the wells.  
For calculation of the intracellular proliferation rate the number of internal cryptococci was 
counted at time points 0, 18 and 24 (t.p. 0 + 18 hr, + 24 hr respectively).  At each time 
point each well to be counted was washed three times with 1x PBS to remove any 
extracellular yeast. The macrophages in the well were then lysed in 200 μl deionised water 
(dH2O) for 30 minutes. To remove lysed macrophages and cryptococci a pipette tip was 
used to scrape the surface of the well, the 200 μl of lysate was then removed to a clean 
Eppendorf and a further 200 μl dH2O added to the well to wash any remaining cells, this 
200 μl was also added to the Eppendorf to give a final sample volume of 400 μl.  
C. neoformans cells in the lysate were quantified at each time point with a cell counting 
chamber and the intracellular proliferation rate (IPR) calculated by dividing the count at 
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which intracellular burden peaked by the count at time point 0. Viability testing of the 
recovered cells was achieved by diluting the lysate to give a concentration of 200 yeast 
cells per 100 μl, and then plated onto YPD agar at 25oC for 48 hours prior to counting 
colony forming units. 
2.4 Phagocytosis assay 
24 hours before assaying, J774 macrophages were seeded onto 13 mm glass cover slips 
(nitric acid treated) inside 2 cm2 24 well plates at a concentration of 1x105 cells per ml in 
1ml DMEM culture media with serum and incubated at 37oC and 5% CO2. Activation and 
infection of the macrophages with opsonised C. neoformans cells followed the same 
protocol as described above for the intracellular proliferation assay. After a 2-hour 
incubation the cells were washed 3 times with 1x PBS to remove un-phagocytosed cells 
and then fixed for 10 minutes with 250 μl 4% paraformaldehyde in PBS at 37oC. 
Following fixation, coverslips were washed with 1x PBS and sterile deionised water and 
mounted on glass slides using Mowiol mountant (100 mM Tris-HCl, pH 8.5, 9% Mowiol, 
25% glycerol). Mounted coverslips were analysed on a Nikon Ti – S inverted microscope 
fitted with a plan APO 60x1.40 DIC oil immersion objective.  
2.5 Cell size assay 
J774 cells were plated into 24 well plates, activated and infected with opsonised C. 
neoformans strains as described above for the IPR assay. Two hours post infection each 
well was washed at least 3 times with warm 1x PBS until all non-phagocytosed C. 
neoformans cells were removed from the wells, 1 ml serum free DMEM media was then 
added to each well. 
88 
 
 
The 24-well plate was placed into an environmentally controlled stage (Okolabs) set to 
37oC, 5 % CO2.  The cells were imaged using a Nikon TE2000 microscope fitted with a 
Digital Sight DS-Qi1MC camera and a Plan APO Ph1 20 x dry objective. Images were 
recorded every 4 minutes for 20 hours. Image acquisition and analysis was performed 
using the Nikon NIS Elements software package (Nikon). 
Cell size was measured using the ellipse area tool, measuring from the centre of each 
Cryptococcus cell to edge, to obtain the diameter of each cell. 
2.6 In vivo titan cell and phagocytosis assay 
**The Titan cell experiments (Figure 8) were kindly performed by Kirsten Nielsen and 
Zhongming Li, Department of Microbiology, University of Minnesota, MN 55455, USA. ** 
Cryptococcus neoformans cells were grown in YPD broth overnight. Cells were pelleted 
and resuspended in sterile phosphate-buffered saline (PBS) at a concentration of 1×107 
cells/ml based on haemocytometer count. Groups of 6- to 8-week-old female A/J mice 
(Jackson Laboratory, Bar Harbor, ME) were anesthetized by intraperitoneal pentobarbital 
injection. Four to five mice per treatment were infected intranasally with 5×105 cells in 50 
µl PBS. At 3 days post-infection, mice were sacrificed by CO2 inhalation. Lungs were 
lavaged with 1.5 ml sterile PBS three times using an 18.5-gauge needle placed in the 
trachea. Cells in the lavage fluid were pelleted and fixed in 3.7% formaldehyde at room 
temperature for 30 min. Cells were washed once with PBS, and >500 cells per animal were 
analyzed for size by microscopy (AxioImager, Carl Zeiss, Inc.). Cell body sizes were 
measured with cells classified as small cells (<15µm in cell body diameter) or titan cells 
(>15 µm in cell body diameter).  
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2.7 Titan cell flow cytometry 
H99 was cultured in YPD broth overnight. Cells were pelleted, washed three times in PBS 
and fixed in 3% paraformaldehyde at room temperature for 10 min. Bronchoalveolar 
lavage (BAL) samples were washed once in 0.05% sodium dodecyl sulfate (SDS) to lyse 
mammalian cells and then washed three times in sterile water. Cells were pelleted and 
fixed in 3% paraformaldehyde at room temperature for 10 min. Following fixation, 
samples were washed with PBS, stained with 0.5 µg/ml Hoechst (Sigma, St. Louis, MO) at 
room temperature for 10 min, washed again with PBS and then resuspended in PBS. 
Approximately 10,000 cells were examined for cell size by forward scatter (FSC) and for 
DNA content by Hoechst staining using an LSRII flow cytometer with FACSDiva 
software (BD Biosciences, San Jose, CA). Graphs were generated using Flowjo software 
(Tree Star, Inc., Ashland, OR). T-test was used to analyze the differences in titan cell 
formation and phagocytosis, and P-values of < 0.05 were considered significant. 
2.8 Cell stress 
Overnight C. neoformans cultures in 2 ml YPD were grown at 25oC. Cultures were diluted 
1:1000 into 500 μl buffered YPD (pH 7.0, 15mM HEPES) in plastic bottomed 48 well 
plates (Greiner) with the following concentrations of SDS: 0, 0.01, 0.05, 0.1, 0.25, 0.5 
mM, H2O2:0, 0.125, 0.25, 0.5, 1, 3, 6, 14 mM or NaCl: 0, 125, 250, 500, 1000 mM. The 
plate was then sealed with a breathable membrane (Breath Easy®, Sigma Aldrich) and 
growth curve assays performed for 24 hours at 30oC in a Fluostar Omega plate reader 
using a custom script that took 600 nm absorbance readings from the bottom of the plate 
every 30 minutes. Between reads the plate was shaken at 200 RPM with a linear shaking 
pattern.  
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2.9 Statistics 
Figure 3:  
Figure 3A, infection rate data was analysed using Chi-square on the raw count (.e.g. total 
uninfected macrophages vs. total infected macrophages), three pair wise tests were made 
comparing H99 to Δplb1, Δplb1 to Δplb1:PLB1 and Δplb1 to Δplb1:PLB1. Bonferroni 
correction was used to correct for multiple comparions. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001 and **** p ≤ 0.0001. The corrected  value was 0.017. 
Figure 3B, Phagocytic uptake data determined to be normally distributed using the 
Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not normally 
distributed) (See appendix Table 2, page 188). Unpaired two tailed T tests were performed, 
comparing each strain to the H99 wild type. Bonferroni correction was used to correct for 
multiple comparions. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. The 
corrected  value was 0.025 
Figure 4:  
4A - Intracellular proliferation rate (IPR) data was determined to be normally distributed 
using the Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not 
normally distributed) (See appendix Table 3, page 189). Unpaired two tailed T tests were 
performed, comparing each strain to the H99 wild type. Bonferroni correction was used to 
correct for multiple comparisons. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 
0.0001. The corrected  value was 0.0125.  
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4B - CFU viability data was determined to be normally distributed using the Shaprio-Wilk 
normality test (p-value < 0.05 reject null hypothesis that data is not normally distributed) 
(See appendix Table 4, page 187). A two way ANOVA with Tukey post test was used to 
compare 0hr, 18hr and 24hr time points for each strain. P values under 0.05 were taken to 
be statistically significant * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. 
4 C-E - Phagocytic uptake data (4C i, 4D i and 4E i) was determined to be normally 
distributed using the Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that 
data is not normally distributed) (See appendix table 2, page 188). Unpaired two tailed T 
tests were performed, comparing each strain to the H99 wild type. Bonferroni correction 
was used to correct for multiple comparions. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and 
**** p ≤ 0.0001. The corrected  value was 0.025. Intracellular proliferation rate (IPR) 
data (Figures 4C ii, 4D ii and 4E ii), was determined to be normally distributed using the 
Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not normally 
distributed) (See appendix table 3, page 189). Unpaired two tailed T tests were performed, 
comparing each strain to the H99 wild type. Bonferroni correction was used to correct for 
multiple comparisons. * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p ≤ 0.0001. The 
corrected  value was 0.025. 
Figure 6:  
6 A-D - Cell size measurement data (A-D) was found to be not normally distributed using 
the Shapiro-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not 
normally distributed) (See appendix tables 5 to 12, page 190 to 192). Comparison between 
time points was made using a Mann Whitney U test (e.g. StrainX 0 hour vs. StrainX 18 
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hour). A p-value below 0.05 was taken as significant.  * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 
0.001 and **** p ≤ 0.0001.   
Figure 8: 
A. i) – iii) Data is displayed as % however statistical analysis was performed on raw count 
data, three pair wise chi-squared tests were made comparing H99 to Δplb1, Δplb1 to 
Δplb1:PLB1 and Δplb1 to Δplb1:PLB1. Bonferroni correction was used to correct for 
multiple comparisons (3). The corrected  value was 0.017.  **** H99 vs. Δplb1 p = 
>0.0001. ** H99 vs. Δplb1:PLB1 p = 0.0014 **** Δplb1 vs. Δplb1:PLB1 p = >0.0001. 
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3. Results 
3.1 Plb1 deficiency leads to increased uptake of C. neoformans cells by J774 
macrophages 
I first assessed to what extent the PLB1 knockout strain, Δplb1, was phagocytosed by 
macrophages in comparison to the wild type parent H99 strain and a genetic reconstitution 
strain Δplb1:PLB1.  I found that following two hours of infection, the percentage of J774 
murine macrophages with at least one internalised C. neoformans cell was significantly 
greater for Δplb1 compared to H99 or Δplb1:PLB1 (Figure 3. A). Quantification of the 
fungal burden per macrophage also revealed a two-fold increase in the number of Δplb1 
cells phagocytosed per host cell (Figure 3. B). This suggests that Plb1 activity contributes 
significantly to the well-known antiphagocytic phenotype of C. neoformans.  
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Figure 3 A. Analysis of phagocytic uptake of C. neoformans strains by J774 
macrophages - Percentage of macrophages within a population that show C. neoformans 
infection following 2 hours incubation with opsonised cryptococci at a MOI of 1:10. N= 4, 
a minimum of 500 macrophages were counted for each condition. (Data displayed as % 
however statistical analysis was performed on infection rate data was analysed using the 
raw count (.e.g. total uninfected macrophages vs. total infected macrophages), three pair 
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wise chi-squared tests were made comparing H99 to Δplb1, Δplb1 to Δplb1:PLB1 and 
Δplb1 to Δplb1:PLB1. Bonferroni correction was used to correct for multiple comparisons 
(3). The corrected  value was 0.017. **** H99 vs. Δplb1 p = 0.00004, *** Δplb1 vs. 
Δplb1:PLB1 p = 0.005) B. Total burden of infection within a fixed population of J774 cells 
(1x105) following 2 hours incubation with opsonised cryptococci at a MOI of 1:10. N=9.  
*** H99 vs. Δplb1 p = 0.0003. ** Δplb1 vs. Δplb1:PLB1 p = 0.0038 (Unpaired two tailed 
T test performed comparing each strain, corrected for multiple comparisons (3) using 
Bonferroni correction. Corrected  = 0.017).  
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3.2 Plb1 is required for intracellular proliferation of C. neoformans within J774 
macrophages 
PLB1 knockout leads to reduced fungal lung burden during murine infection; in addition it 
abrogates dissemination to the brain (Chayakulkeeree et al., 2011; Maruvada et al., 2012) 
and reduces the budding of Cryptococcus cells within macrophages (Cox et al., 2001). To 
investigate this phenotype further I performed an intracellular proliferation rate (IPR) 
assay. I observed an intracellular proliferation defect for the Δplb1 strain vs. wild type H99 
(IPR=1.12, versus 2.42 for H99. p = 0.023), a defect that was fully restored in the 
Δplb1:PLB1 reconstitute strain (Figure 4. A). Interestingly, no intracellular proliferation 
defect was observed when I tested the Δsec14-1 strain (Figure 4. A). Since Sec14-1 is 
required for efficient secretion of Plb1 (Chayakulkeeree et al., 2011), it appears that 
intracellular, but not secreted, Plb1 is important for proliferation within host cells.  
Due to the increased efficiency of Δplb1 uptake observed, I wondered whether the reduced 
proliferation I saw for Δplb1 simply reflected initial overcrowding within the host 
macrophage as this phenotype has been described previously (Alanio et al., 2011). To test 
this, I reduced the uptake of Δplb1 by omitting the opsonisation step before infection. 
Infecting with unopsonised Cryptococcus reduced uptake for all three strains (Figure 4. E - 
i) – un-opsonised Cryptococcus can still be phagocytosed by macrophages but at a lower 
rate (Guerra et al., 2014; Ma , 2009). Omitting opsonisation did not alter the growth defect 
observed (Figure 4. E - ii). To test a different type of opsonisation I also tried opsonising 
with pooled serum instead of antibody. At the concentration used (5% pooled human 
serum) I did not see significant differences in uptake, as compared to antibody 
opsonisation (Figure 4. C - i), and the proliferation defect remained (Figure 4. C - ii). 
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Taken together, these data suggest that Plb1 plays a direct role in regulating intracellular 
proliferation in C. neoformans regardless of the fungal intracellular burden. 
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Figure 4 – Analysis of intracellular proliferation and viability of C. neoformans within 
J774 macrophages. A. Mean IPR for each C. neoformans strain within murine J774 
macrophages. N = 3. * H99 vs. Δplb1 p= 0.004, (Two tailed unpaired T tests used, each 
strain was compared to H99 wild type, knockouts strains were also compared to 
reconstitute strains corrected for multiple comparisons (6) using Bonferroni correction. 
Corrected  = 0.008). B. Viability of C. neoformans cells recovered from J774 
macrophages following IPR assay. Cells recovered following macrophage lysis were 
counted and diluted to give an expected plated inoculum of 200 cells. N = 4. * Δplb1 0hr 
vs. Δplb1 18hr p= 0.0422, Δplb1 0hr vs. Δplb1 24hr p= 0.0415 (Two-way ANOVA + 
Tukey post test comparing time points for each strain). Note –Figure 4 C - i is reproduced 
from Figure 3 B; it has been reproduced for ease of comparison. C. - i Total burden of 
infection within a fixed population of J774 cells (1x105) following 2 hours incubation with 
anti-capsule antibody (18B7) opsonised cryptococci at a MOI of 1:10. N=9. *** H99 vs. 
Δplb1 p = 0.0003 (Two tailed unpaired T test, each strain compared, corrected for 
multiple comparisons (3) using Bonferroni correction. Corrected  = 0.017). C. - ii Mean 
IPR for anti-capsule antibody (18B7) opsonised H99, Δplb1 and Δplb1:PLB1 within 
murine J774 macrophages. N= 8. **** H99 vs. Δplb1 p = <0.0001 (Two tailed unpaired T 
test, each strain compared, corrected for multiple comparisons (3) using Bonferroni 
correction. Corrected  = 0.017). D. - i Total burden of infection within a fixed population 
of J774 cells (1x105) following 2 hours incubation with pooled human serum opsonised 
cryptococci at a MOI of 1:10. N = 3. *** H99 vs. Δplb1 p = 0.0004,* H99 vs. Δplb1:PLB1 
p = 0.028 (Two tailed unpaired T test, each strain compared, corrected for multiple 
comparisons (3) using Bonferroni correction. Corrected  = 0.025) D. - ii Mean 
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intracellular proliferation rate for pooled human serum opsonised H99, Δplb1 and 
Δplb1:PLB1 within murine J774 macrophages. N= 3.  H99 vs. Δplb1 p = 0.016 (Two tailed 
unpaired T test, each strain compared, corrected for multiple comparisons (3) using 
Bonferroni correction. Corrected  = 0.017). E. - i Total burden of infection within a fixed 
population of J774 cells (1x105) following 2 hours incubation with unopsonised 
cryptococci at a MOI of 1:10. N=3. ** H99 vs. Δplb1 p = 0.0073 (Two tailed unpaired T 
test, each strain compared, corrected for multiple comparisons (3) using Bonferroni 
correction. Corrected  = 0.017). E. - ii Mean intracellular proliferation rate for 
unopsonised H99, Δplb1 and Δplb1:PLB1 within murine J774 macrophages. N=3. * H99 
vs. Δplb1 p= 0.010 (Two tailed unpaired T test, each strain compared, corrected for 
multiple comparisons (3) using Bonferroni correction. Corrected  = 0.017). 
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3.3 Plb1 contributes to C. neoformans cell survival during infection 
The low intracellular proliferation defect observed for Δplb1 could be due to slower 
Cryptococcus proliferation and/or increased intracellular killing by the macrophage. To 
address the second possibility, I plated C. neoformans cells recovered from macrophages at 
18 and 24 hours post infection on YPD agar to enumerate CFU. No significant difference 
in CFUs among any of the five strains was seen at time point 0 (2 hours post infection) 
however at time point 18 (20 hours post-infection) the viability of Δplb1, but not Δsec14-1, 
had dropped significantly (Figure 4. B) compared to H99.  Taken together these data 
suggest that both growth and survival of Δplb1 is impaired within the phagosome during 
macrophage infection.  
3.4 Plb1 deficiency does not significantly affect cryptococcal stress responses 
I hypothesised that low IPR in the macrophage may be a result of stressful conditions 
during macrophage infection – possibly because Δplb1 is unable to control or resist cellular 
stresses within the macrophage. I tested this hypothesis using three stress factors that may 
be found within the phagosome – SDS (membrane attack), NaCl (osmotic stress) and 
hydrogen peroxide (H2O2 – reactive oxygen species). I found a noticeable defect in the 
Δplb1 mutant ability to grow when challenged with SDS; this defect has been previously 
published (Chayakulkeeree et al., 2011). In addition to SDS susceptibility I also found that 
Δplb1 also appears to have a growth defect at high (1000 mM) concentrations of NaCl 
(Figure 5).  
  
103 
 
 
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
C o n c  S D S  (m M )
M
e
a
n
 O
D
0 0 .0 1 0 .0 5 0 .1 0 .2 5 0 .5
H 99
P L B 1
P L B 1 :P L B 1
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
C o n c  H 2 O 2  (m M )
M
e
a
n
 O
D
H 99
 p lb 1
 p lb 1 :P L B 1
0 0 .1 2 5 0 .2 5 0 .5 1 3 6 1 4
A
B
C
0 .0
0 .5
1 .0
1 .5
2 .0
M
e
a
n
 O
D
0               1 2 5          2 5 0          5 0 0             1 0 0 0
H 99
P L B 1
P L B 1 :P L B 1
C o n c  N a C l (m M )
 
Figure 5: Growth curve testing of C. neoformans strains to stresses similar to those 
found in the macrophage phagosome. Overlaid growth curves with increasing 
concentrations of stress factors which partly mimic stresses in the phagosome – A SDS 
(membrane attack), B NaCl (Osmotic stress) and C H2O2 (Reactive oxygen species). n = 3 
104 
 
 
3.5 PLB1 knockout leads to changes in cryptococcal cell body morphology 
During the course of this work I noticed that some Δplb1 cells showed a marked increase 
in cell body diameter within infected macrophages, a morphology that was not observed 
for H99 or Δplb1:PLB1 (Figure 6. E-F). Quantification of this phenomenon (Figure 6.) 
showed that the diameter of the cell body and capsule thickness of Δplb1 cells increased 
significantly during an 18 hour macrophage infection (Figure 6. A-E). Interestingly, I 
observed a significant decrease in cell diameter for H99 and Δplb1:PLB1 over the same 
incubation period (Appendix tables 13 and 14 pages 193 and 194 respectively), this is 
probably due to active cell budding occurring within the macrophage, leading to a drop in 
mean diameter for the overall population. Extending the period of live cell imaging to 48 
hrs I found that the enlarged Δplb1 cells did not noticeably increase in size after 18 hours 
post infection. 
Changes in Cryptococcus cell size during in vivo infection have been previously 
documented, ultimately resulting in the production of very large titan cells (Crabtree et al., 
2012; Feldmesser et al., 2001; Zaragoza et al., 2010). To my knowledge, though, this is the 
first published observation of a similar (albeit less dramatic) process occurring within a 
macrophage (rather than extracellulary) and the first time that Plb1 has been implicated in 
this pathway. Previous studies have reported that the size increase observed in titan cells is 
accompanied by increased nuclear content due to polyploidy (Okagaki et al., 2010; 
Zaragoza et al., 2010). In agreement with this, flow cytometry analysis of Δplb1 cells 
following macrophage infection revealed a population of cells (Figure 7A Q3) that are 
either polyploidy or likely on the verge of ploidy (Figure 7).  
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Figure 6. Analysis of the change in cell body size and capsule thickness of C. 
neoformans strains during the course of J774 macrophage infection. A-D Dimensions 
of C. neoformans cells were measured after either 18 hours inside J774 macrophages or 18 
hours in serum free DMEM media B. Capsule thickness was calculated by subtracting cell 
body diameter from total diameter including capsule. D The ratio of cell body to capsule 
was calculated by dividing cell body diameter by capsule thickness. A-D The top and 
bottom of the box mark the 75th and 25th percentiles respectively, the bisecting line in the 
box marks the median and the two whiskers mark the maximum and minimum range. 
Mann Whitney U tests were performed on each time point pair. Full statistical results are 
given in supplementary table 13 and 14 (see appendix, tables 13 and 14 pages 193 and 194 
respectively).  E Still bright field images from live cell microscopy following the same 
macrophage over 18 hours for H99, Δplb1 and Δplb1:PLB1. Black arrows indicate the 
location of single C. neoformans cells within the macrophage. F Still bright field images 
from live cell microscopy following viable Δplb1 infected macrophages – images taken at 
40 hours post infection, scale bar = 10 µm.  
F E 
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3.6 Δplb1 cells have a higher rate of titan cell formation than wild type during in vivo 
murine infection 
The Titan cell data (Figure 8) was the result of collaboration with Kirsten Nielsen and 
Zhongming Li, Department of Microbiology, University of Minnesota, MN 55455, USA. 
My in vitro observation of Δplb1 cell enlargement was reminiscent of the titan cell 
morphology observed during in vivo murine pulmonary infection (Feldmesser et al., 2001; 
Okagaki et al., 2010; Zaragoza et al., 2010). To test whether this phenotype was 
recapitulated in vivo, pulmonary infections were conducted in mice and then cryptococcal 
cell body diameter was quantified for following bronchoalveolar lavage (BAL) at 3 days 
post infection. As with my in vitro data, in vivo infection with Δplb1 produced about 2.5 
times more titan cells (cryptococci with a cell body diameter greater than 15 µm) than H99 
or Δplb1:PLB1 (Figure 8 Ai). Flow cytometry of lavaged, Hoechst stained Δplb1 titan cells 
indicate that there is a large population of cell which are either polyploidy, or on their way 
to becoming polyploidy. This in agreement with previously published characterisation of 
titan cells (Okagaki et al., 2010; Zaragoza et al., 2010) as well as my in vitro observation 
of Δplb1 cells (Figure 8 A). Taken together these findings suggest the morphological 
changes I observed during in vitro macrophage infection with Δplb1 are consistent with an 
increase in the production of titan cells by this strain in vivo. 
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Figure 7 – Flow cytometry analysis of C. neoformans samples pre and post incubation 
with J774 macrophages (18 hours). Samples were stained with Hoechst to quantify DNA 
content, FSC-A (forward scatter area) indicates relative cell size across the samples. Cells 
were gated based on size and nuclear content with cells in Q3 consistent with small cells in 
G1, Q4 indicative of small cells in G2, and Q2 indicative of polyploidy titan cells with 
both large size and increased DNA content. 
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3.7 In vivo Δplb1 Titan cell formation is not associated with phagocytosed cells. 
In addition to quantifying overall Titan cell formation in BAL samples, the number of 
Cryptococcus cells within host phagocytes following BAL was also counted, as well as the 
cell body diameter of each Cryptococcus within each lavaged host cell. 
Counting revealed there were significantly fewer lavaged host cells containing 
Cryptococcus for Δplb1 infected mice compared to H99 or Δplb1:PLB1 (Figure 8 A. - ii). 
Very few of these internalised Cryptococcus cells were above 10 µm in diameter and those 
that were above 10 µm could be found in similar numbers for H99, Δplb1 and Δplb1:PLB1 
(Figure 8 A. - iii). No cells greater than 15 µm were found inside phagocytes in either the 
control or Δplb1 infections (data not shown). This leads me to conclude that in vivo Δplb1 
Titan cell formation potentially occurs initially within host cells (as observed in vitro) but 
these large Cryptococcus are released from host cells either by host cell lysis in vivo or due 
to the physical process of lavage prior to the time point examined. 
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Figure 8 – In vivo titan cell assay on Cryptococcus cells lavaged from mouse lungs 3 
days post infection. A. - i A minimum of 500 cells per animal were analysed to quantify 
cell body diameter, Cryptococcus cells >15 µm in diameter were considered titan cells. 
Data displayed as % however statistical analysis was performed using raw count data (.e.g. 
total titan cells vs. total non titan cells), three pair wise chi-squared tests were made 
comparing H99 to Δplb1, Δplb1 to Δplb1:PLB1 and Δplb1 to Δplb1:PLB1. Bonferroni 
correction was used to correct for multiple comparisons (3). The corrected  value was 
0.017.  **** H99 vs. Δplb1 p = >0.0001. ** H99 vs. Δplb1:PLB1 p = 0.0014 **** Δplb1 
vs. Δplb1:PLB1 p = >0.0001. A. - ii Host cells lavaged from the lungs were examined for 
phagocytosed Cryptococcus cells. Data displayed as % however statistical analysis was 
performed on raw count data (.e.g. total Cryptococcus inside mammalian cells vs. total 
Cryptococcus outside mammalian cells), three pair wise chi-squared tests were made 
comparing H99 to Δplb1, Δplb1 to Δplb1:PLB1 and Δplb1 to Δplb1:PLB1. Bonferroni 
correction was used to correct for multiple comparisons (3). The corrected  value was 
0.017 **** H99 vs. Δplb1 p = <0.0001. **** Δplb1 vs. Δplb1:PLB1 p = <0.0001 A. - iii 
The cell body diameter of phagocytosed Cryptococcus cells within lavaged host 
macrophages was quantified, data for phagocytosed cells > 10 µm are given. Data 
displayed as % however statistical analysis was performed raw count data (.e.g. total 
Cryptococcus cells > 10 µm inside mammalian cells vs. total Cryptococcus 10 µm outside 
mammalian cells), three pair wise chi-squared tests were made comparing H99 to Δplb1, 
Δplb1 to Δplb1:PLB1 and Δplb1 to Δplb1:PLB1. Bonferroni correction was used to correct 
for multiple comparisons (3). The corrected  value was 0.017. No significance found. B. 
Cryptococcus from H99 and Δplb1 bronchoalveolar lavage samples were stained with 
Hoechst and analysed for size and nuclear content. Cells were gated based on size and 
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nuclear content with cells in Q3 consistent with small cells in G1, Q4 indicative of small 
cells in G2, and Q2 indicative of polyploidy titan cells with both large size and increased 
DNA content.  C Bright field images of lavaged cells from H99, Δplb1 or Δplb1:PLB1 
infected lungs. Scale bar = 15 µm. 
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4. Discussion 
During cryptococcal pathogenesis, C. neoformans interacts with professional phagocytes in 
the alveolar space (Feldmesser et al., 2000) and in the blood stream and other tissues 
following dissemination. The outcome of this interaction appears to be vital for disease 
progression, as the macrophage provides a protective niche for replication (Ma et al., 2009) 
and a potential ‘Trojan horse’ for dissemination to the CNS (Charlier et al., 2009; Chrétien 
et al., 2002).  Together with previous studies, my findings strongly suggest that expression 
of Plb1 is critical in regulating cryptococcal/macrophage interactions.   
Firstly, I show that PLB1 deletion leads to enhanced uptake by phagocytes in vitro (Figure 
3. B).  Since Plb1 is a GPI-linked, cell wall associated protein (Djordjevic et al., 2005b), it 
is likely that loss of this enzyme affects the cryptococcal cell surface and, presumably, this 
change facilitates more efficient binding of phagocyte receptors. Examination of different 
opsonisation methods (Figure 4.  C – i, D – i, E - i) suggests that increased uptake is due to 
a combination of antibody, complement and non-opsonic ligands. Cryptococcal cell wall 
instability following PLB1 deletion has been published previously (Siafakas et al., 2007) 
and thus this instability could lead to increased ligand exposure on the Cryptococcus cell 
surface. In light of these observations, a detailed chemical analysis of the cell surface 
composition in this strain would be of considerable future interest.  
Following phagocytosis, I found that C. neoformans requires the expression of Plb1 to 
proliferate and survive normally within the macrophage (Figure 4). This finding provides a 
mechanism to explain previous reports of reduced fungal burdens following infection with 
Δplb1 (Chayakulkeeree et al., 2011). Interestingly, however, the Δsec14-1 strain shows no 
such defect in intracellular proliferation (Figure 4A).  Since this strain shows strongly 
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reduced Plb1 secretion (Chayakulkeeree et al., 2011), the most likely explanation is that 
the primary role of Plb1 in driving intracellular proliferation is in the metabolism of fungal 
phospholipids within the cryptococcal cell, rather than in acting directly upon host 
phospholipids.  However, secreted Plb1 appears to have additional roles in virulence, since 
the Δsec14-1 strain is attenuated in animal models (Chayakulkeeree et al., 2011). It is 
tempting to speculate that the documented involvement of SEC14 in regulating 
vomocytosis (Chayakulkeeree et al., 2011) may be one such role. It is also possible that the 
expression of Plb1 by Cryptococcus within infected macrophages changes how the 
macrophage responds to infection – to explore this possibility further it will be essential in 
the future to determine whether the expression of Plb1 can alter the maturation state of 
macrophages and their subsequent cytokine production profile. 
A striking morphological observation arising from my macrophage infection experiments 
was that Δplb1 showed a marked increase in both cell body diameter and capsule thickness 
during infection, with a maximum measured diameter (including capsule) of almost 25 µm 
(Figure 6. C). That this size change was not seen in the wild type or Δplb1:PLB1 
reconstituted strains suggests that this morphology results from the loss of Plb1. Previously 
reported titan cells grown in vivo range in diameter from 15 - 100 µm, excluding capsule 
(Okagaki et al., 2010; Zaragoza et al., 2010). Therefore, the size increase observed is 
smaller than that of previously reported titan cells, but significantly larger than the normal 
cryptococcal size range.  Interestingly, previous reports of titan cells induced in vitro also 
noted the cells tended to be smaller than those generated in vivo (Okagaki et al., 2010). 
Flow cytometry analysis of Δplb1 cells following macrophage infection (Figure 7) 
indicates a mixed population of large cells with high DNA content but also a group of 
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normal sized cells with high DNA content which may be on the verge of becoming giant 
cells  (Okagaki et al., 2010).Thus it is likely these cells may represent individual yeast that 
are “en route” to becoming titan cells, or have somehow been constrained by the 
macrophage, or that the in vitro conditions do not provide the necessary stimulus to 
produce the largest titan cells.  
From my in vitro data I conclude that Δplb1 forms large cells within macrophages; similar 
to the Titan cell morphology seen in vivo. Titan cell formation has previously been induced 
in vitro using macrophage conditioned media (Okagaki et al., 2010), however titan cell 
formation induced inside an infected macrophage has, to my knowledge, not previously 
been reported. Although I have not identified the trigger for this morphology it is evidently 
linked to Plb1 deficiency. The development of this morphology within the macrophage 
may be a response to increased stress experienced by Δplb1 as indicated by the decreased 
viability of this strain within the phagosome. As well as confirming a previously published 
susceptibility to SDS (Chayakulkeeree et al., 2011) (Figure 5) I also noticed that the Δplb1 
strain was susceptible to high concentrations of NaCl indicating that this strain may be 
vulnerable to osmotic stress and membrane attack. The phagosome exposes Cryptococci to 
a diverse repertoire of additional stresses and it is likely that these complex conditions limit 
growth of this mutant. One possible source of stress within the phagosome that links my 
observed phenotypes is the observation that in wild type cryptococci, Plb1 concentrates at 
the neck of newly forming buds (Lev et al., 2014). This suggests that Plb1 may have a role 
in bud development and thus it is conceivable that modification of membrane 
phospholipids by Plb1 during budding could be required for membrane curvature at the 
newly formed bud site or release of the daughter cell. The inability of the Δplb1 strain to 
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properly bud would explain the proliferation defect observed and could generate sufficient 
cellular stress to reduce cryptococcal viability and trigger the development of titan like 
cells. 
A strong link between my in vitro observations and previously published in vivo 
development of titan cells is supported by the finding that the Δplb1 strain forms greater 
numbers of ‘classical’ titan cells (i.e. cell body diameter above 15 µm and high nuclear 
content indicative of polyploidy) in vivo compared to the wild type and reconstituted 
strains (Figure 8 A. i). These data suggest that Plb1 activity is involved in the repression of 
titan cell formation during infection. In addition, the fact that the Δsec14-1 strain does not 
manifest similar cell size increases during in vitro infection (unpublished data) indicates 
that intracellular rather than extracellular Plb1 activity regulates the titan cell morphology. 
Interestingly, titan cell development may be linked to phospholipid availability (Chrisman 
et al., 2011), suggesting a potential link to Plb1 activity. Titan cell formation in vivo has 
been reported to increase the pathogenicity of C. neoformans (Crabtree et al., 2012; 
Okagaki et al., 2010), my conclusion that Δplb1 has increased Titan cell formation 
therefore seems at odds with in vitro data presented in figure 3 and 4 showing that the 
Δplb1 is attenuated in macrophages. It is therefore possible that the large Δplb1 cells may 
not exhibit all the features of titan cells (for instance, in conferring “cross-protection” on 
non-titan cells in the same host).  Alternatively, it may be that full pathogenicity requires 
only a minor titan cell population and hence the enhanced titan cell frequency seen in 
Δplb1 actually reduces overall virulence. 
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In summary, my data indicate that Plb1 plays a key role both in intracellular survival 
within host phagocytes and in driving cryptococcal cell size changes both in vitro and in 
vivo.   
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CHAPTER 3 – THE ROLE OF EICOSANOIDS 
DURING CRYPTOCOCCAL INFECTION OF 
MACROPHAGES 
 
1. Introduction 
My own work, and that of others, has show that the C. neoformans virulence factor 
Phospholipase B1 (Plb1) helps the fungus survive within macrophages during infection 
(Cox et al., 2001; Evans et al., 2015; Noverr et al., 2003a). I have found that the C. 
neoformans Plb1 deficient strain Δplb1 is phagocytosed more efficiently by macrophages 
(Chapter 2. Figure 3), proliferates less within the phagosome (Chapter 2. Figure 4 - A) and 
is more susceptible to macrophage killing (Chapter 2. Figure 4 – B). Additionally, I have 
described a cryptococcal morphology that Plb1 deficient cells develop during macrophage 
infection (Chapter 2. Figure 6) which is closely related to Titan cell morphology seen 
during in vivo infection (Chapter 2. Figure 8) (Evans et al., 2015).  
Although a number of studies – including my own (Evans et al., 2015) - report phenotypes 
observed during macrophage infection with the Plb1 deficient mutant Δplb1, the 
mechanisms behind these observations has yet to be fully elucidated. Theories for how 
Plb1 causes virulence include the enzyme’s ability to attack host membranes and also to 
scavenge, metabolise and detoxify host derived lipids during infection (Djordjevic, 2010). 
This chapter describes work I have done to explore another theory. The theory is that Plb1 
allows C. neoformans to produce eicosanoid species during infection that closely resemble 
those produced by the host. The link between Plb1 and eicosanoid synthesis by C. 
neoformans is well known (Noverr et al., 2001; Noverr et al., 2003a). The effects these 
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eicosanoids have on the outcome of host infection though have not been well explored and, 
it is possible that Cryptococcus derived eicosanoids could mimic and interfere with host 
eicosanoid signalling in such a way as to influence the outcome of the host pathogen 
interaction between organisms.   
Eicosanoids are a class of lipid molecules; the prefix eicosa- (the number 20 in Greek) 
signifies their common origin as oxidised derivatives of 20 carbon fatty acids. The three 20 
carbon fatty acids that give rise to eicosanoids are eicosapentaenoic acid (EPA), 
arachidonic acid (AA) and di-homo-γ-linolenic acid (Harizi et al., 2008). It has been found 
that C. neoformans produces a number of eicosanoid species that are similar to those 
produced by mammalian cells, as can other fungi such Candida albicans (Noverr et al., 
2001). The eicosanoid synthesis pathway has been well characterised in mammalian cells 
but in fungi there is still much that is not known – one thing that is clear, however, is that 
the pathway is not analogous to that of mammalian cells.  
1.1 Mammalian eicosanoid production  
The main pool of stored AA in mammalian cells is located in cell membranes where this 
fatty acid (among other fatty acids) is found incorporated into the lipid bi-layer of cell 
membranes. Phospholipids are composed of three main subunit, a central glycerol 
backbone that is attached at one end to a phosphate head group and at the other end to two 
fatty acids via the Sn1 and Sn2 ester linkages (van Meer et al., 2008). In mammalian cells, 
AA is liberated from membrane phospholipids by the enzyme phospholipase A2 (PLA2). 
PLA2 activity specifically hydrolyses phospholipid Sn2 ester linkages; hydrolysis of this 
ester linkage cleaves the Sn2 fatty acid tail from the phospholipid producing a free fatty 
acid and a lysophospholipid (see chapter 3, figure 1). The enzymatic action of PLA2 on 
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phospholipids that contain AA at their Sn2 position results in the accumulation of free AA 
within the cell. PLA2 activity is often triggered as a result of cellular damage or 
inflammatory signalling (Harizi et al., 2008). 
In mammalian cells, AA is oxidised by three different enzymes that each produce different 
classes of eicosanoids. The three enzymes are cyclooxygenase (COX) of which there are 
two isotypes – COX-1 and COX-2, lipoxygenases (LOX) of which there are three isotypes 
– LO-1, LO-2 and LO-3 and finally P450 epoxygenase. Oxidation of AA by the COX 
enzymes produces prostaglandins, prostacyclins and thromboxanes (TXs) – eicosanoid 
species that are known collectively as prostanoids. Oxidation of AA by the LOX enzymes 
produces leukotrienes (LT), cysteninyl-leukotrienes (CysLTs) and lipoxins (LXs). Finally 
P450 epoxygenase produces hydroxyeicosatetraenoic acids (HETEs) and epoxides (EXs) 
as end products (Harizi et al., 2008).  
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Figure 1 – Diagram showing the different eicosanoids products of arachidonic acid (AA) 
metabolism by the COX, LOX and P450 enzymes.   
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1.2 Mammalian prostaglandins 
In mammalian cells, AA that has been liberated from cell membrane phospholipids is 
converted into the prostanoid species by the enzymes COX-1 and COX-2. Generally, 
COX-1 is constitutively expressed within mammalian cells at low levels and is involved 
with the production of prostanoids for homeostatic functions. COX-2 expression in 
contrast is induced as a result of cell signalling events such as those seen during 
inflammation and tissue injury (Simmons et al., 2004). COX mediated oxidation of AA 
produces PGG2. PGG2 is a volatile lipid species that is quickly converted to the more stable 
species PGH2. PGH2 is the universal precursor to all prostanoid species. The conversion of 
PGH2 to each prostanoid is catalysed by specific enzymes. In the case of prostaglandins the 
conversion of PGH2 to the end product is catalysed by prostaglandin synthase enzymes – 
each prostaglandin species has a specific synthase enzyme (Harizi et al., 2008). 
Mammalian cells produce a number of prostaglandins - PGE2, PGD2, PGI2, PGF2 and 15-
d-PGJ2. The prostaglandins PGE2, PGD2, PGI2 and PGF2 are all produced from PGH2 by 
end product specific prostaglandin synthase enzymes e.g. prostaglandin E synthase, 
prostaglandin D synthase etc. 15-d-PGJ2 is the exception as it formed via the spontaneous 
dehydration of PGD2 (Harizi et al., 2008).  
Following synthesis, prostaglandins are exported from mammalian cells into the 
extracellular space. In multi cellular organisms, prostaglandins act as potent signalling 
molecules; they are known to regulate a number of physiological processes including 
inflammatory cell activation, smooth muscle contraction / relaxation, and blood clotting 
via the activation of platelets. The effective distance of prostaglandin signalling is small; 
prostaglandin signalling is mostly autocrine e.g. they act on the cells that produces them, 
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however they may also signal to very closely neighbouring cells via paracrine signalling 
(Harizi et al., 2008; Ricciotti and FitzGerald, 2011). 
Prostaglandin signalling is facilitated by G-protein coupled prostaglandin receptors that are 
found expressed on the surface of cells. Each prostaglandin e.g. PGE2, PGD2 etc. signals 
via a separate group of receptors. PGE2 for example signals via EP receptors of which four 
are found in humans (EP1, EP2, EP3 and EP4). The cellular response that prostaglandin 
signalling triggers depends on the pattern of prostaglandin receptors expressed on the cell 
surface and the cell type and tissue where the signalling occurs.  In terms of inflammation 
the signalling of a prostaglandin such as PGE2 can result in anti-inflammatory or pro-
inflammatory effects depending on which of the EP receptors are expressed on the surface 
of a cell. Thus it is hard to ascribe specific effects to each prostaglandin as their action 
varies so greatly throughout the body (Harizi et al., 2008; Ricciotti and FitzGerald, 2011). 
1.3 Eicosanoid production by C. neoformans  
Although fungi are known to produce eicosanoids, the pathways that lead to their synthesis 
are still largely uncharacterised. Much of the research done in this area to date has focussed 
on trying to identify fungal enzymes that are analogous to enzymes in higher organisms 
such as cyclooxygenase and prostaglandin synthase homologs. The conclusions from these 
investigations so far, are that direct homologs do not exist, or at least not enough of them 
to constitute a completely analogous fungal pathway of synthesis. In this respect the only 
analogous enzymatic activity that can be identified across many fungal species is 
phospholipase A2 activity – possessed by enzymes such as Plb1 from C. neoformans – that 
presumably liberates AA from membrane phospholipids (Chen et al., 2000). Concurrently 
in C. neoformans Plb1 is one of only two enzymes that is conclusively linked to eicosanoid 
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synthesis by the fungus (Erb-Downward et al., 2008; Noverr et al., 2003a). Noverr et al 
found that the Plb1 deficient C. neoformans strain plb1 produced lower levels of 
eicosanoids when grown in standard media; however, when exogenous AA was substituted 
into the media eicosanoid production returned to wild type levels. This suggests that Plb1 
fulfils the role of mammalian PLA2 for C. neoformans (Noverr et al., 2003a). 
Further down the eicosanoid pathway a couple of studies in C. neoformans have attempted 
to determine whether eicosanoid synthesis relies on the expression of an enzyme similar to 
COX. Attempts to disrupt Cryptococcus eicosanoids synthesis using pharmacological COX 
inhibition have proved inconclusive. In this respect, in a 2001 study Noverr et al. observed 
that COX inhibitors such as indomethacin significantly decreased prostaglandin production 
by C. neoformans (Noverr et al., 2001) but a later 2007 study by Erb-Downward et al.  
found that C. neoformans prostaglandin production was not affected by indomethacin (Erb-
Downward and Huffnagle, 2007). Additionally, homology searches using BLAST do not 
reveal any proteins with a direct homology to mammalian COX (personal observation, 
unpublished). Similarly poor results occur when BLAST searches are used to identify 
homologous prostaglandin synthase enzymes and prostaglandin receptors in C. neoformans 
(personal observation, unpublished) however in a 2003 review Noverr et al. do mention 
finding a Cryptococcus gene homologous to a PGF synthase found in Trypanosoma bruceii 
(Noverr et al., 2003b) .   
Although fungi and other lower eukaryotes such as protozoa do not seem to possess COX 
enzymes analogous to those found in higher eukaryotes these organisms still produce 
eicosanoids. Therefore, alternative COX independent pathways of production must exist. 
To explain this, two potential routes of synthesis have been proposed. The first involves 
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the action of lipoxygenases; these enzymes can form lipid species that have similar 
structural properties to eicosanoids via the addition of dioxygen molecules to carbon 
chains, but,  prefer linoleic acid to AA (Noverr et al., 2003b); to date, however homologs 
have not been identified in C. neoformans (Erb-Downward et al., 2008). The second 
possibility is that arachidonic acid may be oxidised in a non enzymatic reaction by oxygen 
free radicals (Noverr et al., 2003b). 
In C. neoformans the only other protein known to be linked to prostaglandin production 
other than Plb1 is Laccase (Erb-Downward et al., 2008). This enzyme is a known virulence 
factor in C. neoformans however until recently this was solely thought to be due to its 
involvement in the production of melanin (Casadevall et al., 2000). Cryptococcus 
neoformans has two genes that code for laccase enzymes LAC1 and LAC2. DNA 
microarray analysis has found that cryptococcal expression of LAC1 and LAC2 is induced 
when C. neoformans cells are phagocytosed by macrophages - LAC1 and LAC2 were found 
to be induced 3.8 fold and 3.0 fold respectively 2 hours after phagocytosis by J774 murine 
like macrophages in vitro (Fan et al., 2005).     
Laccase’s role in the production of eicosanoids highlights a previously unknown aspect of 
this virulence factor. Analysis shows that laccase cannot convert AA to prostaglandins 
species although it can convert PGG2 to PGE2, suggesting that in C. neoformans laccase 
may fulfil the role of prostaglandin E2 synthase (Erb-Downward et al., 2008). Interestingly 
in a recent study Sabiiti et al. found that high Cryptococcus laccase activity of clinical 
isolates in vitro correlated to poor clinical outcome when compared against patient medical 
records. Although laccase activity correlated to poor patient outcome the relative amount 
of melanin produced by a representative selection of these strains did not (Sabiiti et al., 
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2014). This suggests that laccase has virulence attributes independent of melanin 
production and perhaps laccase’s involvement in prostaglandin synthesis could be this 
attribute. 
1.4 Potential functions of C. neoformans derived eicosanoids during infection 
C. neoformans is known to produce a number of eicosanoids during infection (Noverr et 
al., 2003a) – PGE2, PGD2, PGF2TXB2 and 5-HETE are among those detected (Noverr et 
al., 2001).  Some of the eicosanoid species produced by C. neoformans such as PGE2 and 
PGD2 have been found to have a remarkable similarity to their respective mammalian 
prostaglandin standards (Erb-Downward et al., 2008). Due to this similarity, is it likely that 
fungal derived prostaglandins can mimic and interfere with host signalling during 
infection. Due to the fact that prostaglandins are involved in the control of the 
inflammatory response (Harizi et al., 2008) it is therefore likely that fungal eicosanoids 
could influence the host immune response against C. neoformans. 
In this respect a very recent study has found compelling evidence suggesting that PGE2 
produced during C. neoformans pulmonary infection is beneficial to the fungus and 
detrimental to the host. During murine infection, blockage of the PGE2 receptors EP2 and 
EP4 led to increased survival of treated mice. Additionally, PGE2 signalling in the lung via 
EP2 and EP4 was shown to be correlated to increased alternative macrophage activation 
and decreased classical activation (Shen and Liu, 2015). It has already been discussed in 
previous chapters that in order to effectively control C. neoformans infection, host 
macrophages must be classically activated (Kawakami et al., 1995; Voelz et al., 2009). 
This suggests that eicosanoid production in the lung may influence the macrophage 
response to infection; in agreement with this are findings that eicosanoids derived from C. 
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neoformans can reduce TNF- and increase IL-10 cytokine production by murine 
splenocytes (Noverr et al., 2001). 
In addition to influencing macrophage biology, fungal eicosanoids may be able to 
manipulate the immune response at a wider level. PGE2, which is one of the most 
ubiquitous prostaglandins during inflammation, can produce a Th2 CD4+ biased immune 
response by down regulating IL-12 release from macrophages (van der Pouw Kraan et al., 
1995). With this in mind it has been observed that the development of Th1 adaptive 
immune responses is protective against C. neoformans infection whereas the Th2 adaptive 
immune response is not (Hoag et al., 1997; Voelz et al., 2009; Wormley et al., 2007). 
In chapter 2 of this thesis, and the associated published work (Evans et al., 2015), I report a 
number of phenotypes that develop during J774 macrophage infection if C. neoformans is 
deficient in Plb1. Using a Plb1 deficient C. neoformans strain, Δplb1, I have shown that 
Plb1 deficiency increases phagocytosis of C. neoformans by macrophages (Chapter 2. 
Figure 3), reduces intracellular proliferation and viability within the phagosome (Chapter 
2. Figure 4) and also triggers a novel intracellular cell morphology switch (Chapter 2. 
Figure 6) that is linked to extracellular Titan Cell formation (Chapter 2. Figure 8) (Evans et 
al., 2015). 
The Δplb1 strain has been found to have almost completely abrogated eicosanoid 
production unless exogenous AA is present (Noverr et al., 2003a). With this in mind the 
data I present in this chapter was aimed at determining whether C. neoformans derived 
eicosanoids – or the lack thereof – can account for the observed phenotypes during 
macrophage infection.  
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I show that the addition of exogenous AA and PGE2 – but not PGD2 – increases the 
intracellular proliferation of Δplb1 within J774 macrophages; but does not reach statistical 
significance. In the discussion, I discuss how this hypothesis can be better addressed with 
future work. 
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2. Materials and methods 
2.1 Strains, media and cell lines 
Strains used in this work are listed in the Appendix (Appendix Table 1, page 188). All C. 
neoformans strains used were stored long-term in MicroBank vials at -80oC.  Strains were 
recovered onto YPD agar (YPD 50 g/L Sigma Aldrich, 2 % Agar – Melford) for 48 hours 
at 25oC and then stored until needed at 4oC. Before experimentation, liquid cultures were 
grown from these stock plates in 2 ml YPD growth medium (50 g/L) for 24 hours at 25oC 
under constant rotation. 
The J774 murine macrophage cell line was used for all in vitro infection assays. Cells were 
passaged in DMEM culture media with serum (Dulbecco’s Modified Eagle medium, low 
glucose, Sigma Aldrich, 10 % FBS - Invitrogen, 1% 10,000 units Penicillin / 10 mg 
streptomycin – Sigma Aldrich, 1 % 200 mM L – glutamine – Sigma Aldrich). Assays were 
performed with J774 cells between passages 4 and 15. Assays were performed in serum-
free DMEM (DMEM high glucose, 1% P/S, 1% L-glutamine) unless otherwise stated. 
2.2 Cryptococcus preparation for assays 
Overnight C. neoformans cultures grown at 25 oC in YPD were washed three times in 
sterile 1x PBS, counted and adjusted to 1 x107 cells per ml in PBS before opsonisation for 
1 hour with 10 μg/ml anti capsular 18B7 antibody (a kind gift from Arturo Casadevall, 
Albert Einstein College of Medicine, New York USA). The opsonisation step was timed so 
that the incubation time finished at the same time as the macrophage activation step 
described below. 
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2.3 Macrophage activation for assays 
24 hours before infection, 1x105 J774 macrophages were seeded into 24 well plastic plates 
(Greiner Bio One Cell Star) in 1 ml culture media with serum and incubated for 24 hours at 
37 oC 5% CO2. Before infection, J774 cells were activated with 150 ng/ml phorbol 12-
myristate 13-acetate (PMA) dissolved in DMSO (Sigma) in 1 ml serum free culture 
medium for 45 minutes. This media was then replaced with serum-free media alone. The 
activation step was timed so that the incubation ended at the same time as the 
Cryptococcus opsonisation step described above. 
2.4 Eicosanoid treatment  
Treatment with the exogenous eicosanoids PGE2 and PGD2 or the eicosanoid precursor AA 
was performed after the macrophage activation step of the macrophage infection protocol 
described above. The SF DMEM macrophage activation media was removed and replaced 
with 1 ml SF DMEM supplemented with PGE2, PGD2, or AA at the desired concentration, 
untreated and vehicle infection controls were also performed for each experiment.  
Activated and treated J774 cells were then infected with 100 μl opsonised C. neoformans 
to give an MOI of 10 (e.g. 1x105 J774 / 1x106 C. neoformans) and incubated for 2 hours at 
37oC 5% CO2. After two hours, infected wells were washed at least 3 times with warm 1x 
PBS until all non-phagocytosed C. neoformans cells were removed from the wells. 
Following washing the PBS was removed and replaced with 1 ml SF DMEM containing 
PGE2, PGD2, or AA at the same concentration as used initially. Infected macrophages 
were then incubated at 37oC until the appropriate time point for the assay. 
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2.5 Intracellular proliferation assay 
For calculation of the intracellular proliferation rate the number of internal cryptococci was 
counted at time points 0 (time point 0 = 0 hr after non phagocytosed cells washed away) 
and 18 hours (Time point 18 = 18 hr after time point 0).  At each time point each well to be 
counted was washed three times with 1x PBS to remove any extracellular yeast. The 
macrophages in the well were then lysed in 200 μl deionised water (dH2O) for 30 minutes. 
To remove lysed macrophages and cryptococci a pipette tip was used to scrape the surface 
of the well, the 200 μl of lysate was then removed to a clean Eppendorf and a further 200 
μl dH2O added to the well to wash any remaining cells, this 200 μl was also added to the 
Eppendorf to give a final sample volume of 400 μl.  
 C. neoformans cells in the lysate were quantified at each time point with a cell counting 
chamber and the intracellular proliferation rate (IPR) calculated by dividing the count at 
which intracellular burden peaked by the count at time point 0.  
Viability testing of the recovered cells was achieved by diluting the lysate to give a 
concentration of 200 yeast cells per 100 μl, and then plating onto YPD agar at 25oC for 48 
hours prior to counting colony forming units. 
2.6 Co-infection assay 
Subsequent to the washing away of non-phagocytosed Cryptococcus cells and replacement 
of the eicosanoid treatment media, the 24-well plate was placed into an environmentally 
controlled stage (Okolabs) set to 37oC, 5 % CO2.  The cells were imaged using a Nikon 
TE2000 microscope fitted with a Digital Sight DS-Qi1MC camera and a Plan APO Ph1 20 
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x dry objective. Images were recorded every 4 minutes for 20 hours. Image acquisition and 
analysis was performed using the Nikon NIS Elements software package (Nikon). 
Movies were scored manually, First co-infected macrophages (i.e. those that contained at 
least one fluorescent H99-GFP Cryptococcus cell and at least one non-fluorescent Δplb1 
Cryptococcus cells were identified at the start of the movie (0 hr) and fungal burden (total 
number of each strain) scored. Each co-infected macrophage was followed over 18 hr. At 
the 18 hr time point the fungal burden within each macrophage was re-scored. The IPR 
was calculated by totalling the fungal burdens of co-infected macrophages and dividing the 
0 hr burden by the 18 hr burden. Singly infected H99-GFP and Δplb1 controls were scored 
in the same way. Around 120 co-infected macrophages were scored per experimental 
replicate. 
2.7 PGE2 EIA ELISA 
Culture supernatant from eicosanoid infected macrophages infected with C. neoformans as 
described above were collected at 0 hour and 18 hour time points. Supernatants were 
analysed as per the PGE2 EIA ELISA kit instructions (Cayman Chemical, Item Number 
514010).  
2.8 Statistics 
Figure 2: Two independent, two tailed, unpaired T tests performed for H99-GFP vs. Δplb1 
and H99-GFP (co-infection) vs. Δplb1 (Co-infection). 
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Figure 3: 
Figure 3A: Intracellular proliferation rate (IPR) data was determined to be normally 
distributed using the Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that 
data is not normally distributed) (see appendix table 15, page 195). Bonferroni correction 
was used to correct for multiple comparisons. The Bonferroni correction was used to 
correct for multiple comparisons (3) the corrected  value was 0.016.  
Figure 3B: CFU viability data was determined to be normally distributed using the 
Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not normally 
distributed) (See appendix table 16, page 195). A two-way ANOVA with Tukey post test 
was used to compare 0hr, 18hr and 24hr time points for each strain. P values under 0.05 
were taken to be statistically significant * p ≤ 0.05, ** p ≤ 0.01, *** p ≤ 0.001 and **** p 
≤ 0.0001. 
Figure 4: PGE2 EIA ELISA data was determined to be normally distributed using the 
Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that data is not normally 
distributed) (See appendix table 16).  (See appendix table 17, page 196). Two-way 
ANOVA with Tukey post test performed to compare concentrations within treatment 
groups – no significance found within respective treatment group. 
Figure 5:  
Figure 5 A: Intracellular proliferation rate (IPR) data was determined to be normally 
distributed using the Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that 
data is not normally distributed) (See appendix table 15, page 195). Unpaired two tailed T 
tests were performed, comparing each strain to the H99 wild type. The Bonferroni 
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correction was used to correct for multiple comparisons (3) the corrected  value was 
0.016. 
Figure 5 B: Intracellular proliferation rate (IPR) data was determined to be normally 
distributed using the Shaprio-Wilk normality test (p-value < 0.05 reject null hypothesis that 
data is not normally distributed) (see appendix table 15, page 195). Unpaired two tailed T 
tests were performed, comparing each strain to the H99 wild type. The Bonferroni 
correction was used to correct for multiple comparisons (3) the corrected  value was 
0.016. 
Figure 5 C: Two-way ANOVA with Tukey post test performed to compare time points and 
treatment for each strain. 
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3. Results 
I have previously described how the Δplb1 mutant (a mutant C. neoformans strain with 
abrogated Plb1 expression) has decreased proliferation (Chapter 2, Figure 4A) and viability 
(Chapter 2, Figure 4B) within macrophages as well as a novel intracellular morphology 
(Chapter 2, Figure 7). The aim of my work in this chapter was to begin to determine why 
these phenotypes occur. One reason for these phenotypes may be because the Δplb1 mutant 
is deficient in eicosanoid production unless exogenous AA is provided (Noverr et al., 
2003a). It is possible that eicosanoids such as PGE2 and PGD2 produced by C. neoformans 
during macrophage infection may interfere with normal macrophage eicosanoid signalling 
and as a result influence the outcome of macrophage infection. 
3.1 The IPR defect of Δplb1 may be dependent on a secretory factor (but additional 
replicates needed). 
A number of published studies conclude that secreted Plb1 enzyme activity (as opposed to 
intrinsic Plb1 activity) contributes to cryptococcal virulence during infection 
(Chayakulkeeree et al., 2011; Santangelo et al., 2004). In the previous chapter however I 
found that for Δplb1’s intracellular proliferation and viability phenotypes this is not the 
case (Chapter 2. Figure 4). In this respect I found that the Δsec14-1 strain, which still 
expresses Plb1 but has almost completely abrogated Plb1 secretion (Chayakulkeeree et al., 
2011), did not have a significantly different growth or viability phenotype to the H99 wild 
type strain. 
To further investigate whether a secretory factor produced by C. neoformans during 
macrophage infection influences cryptococcal growth within macrophages I co-infected 
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macrophages with both H99 and Δplb1 strains then calculated an IPR value for each strain. 
If Plb1, or a Plb1 related secretory factor such as an eicosanoid, did influence cryptococcal 
growth within macrophages then it was hoped that the Δplb1 mutant cells would grow at 
wild type levels if wild type H99 cells were present inside the same macrophage. 
To test this co-infection hypothesis, I co-infected J774 macrophages with two strains of C. 
neoformans simultaneously – I used the Δplb1 mutant strain and a GFP-tagged H99 strain 
(H99-GFP). The H99-GFP strain was chosen because it is a fluorescently tagged 
Cryptococcus strain made in the same genetic background as Δplb1. It was hoped that the 
fluorescence of H99-GFP would differentiate it from Δplb1 during macrophage infection 
and thus allow me calculate an IPR for each co-infecting strain.  
To produce co-infected macrophages I inoculated a 1x105 J774 murine macrophage 
monolayer seeded into a 24 well plate with a 50:50 mix of antibody opsonised H99-GFP 
and Δplb1 at an MOI of 1:10 (i.e. 5x105 H99-GFP and 5x105 Δplb1). I found that this 
inoculum mixture gave me a co-infection rate of about 5 % (i.e. macrophages that 
contained at least one H99-GFP cell and at least one Δplb1 cell when viewed with 
microscopy). To calculate the co-infection IPR, an 18 hour live cell microscopy movie was 
made. Co-infected macrophages at 0 hr (the movie start time) were scored manually for 
their initial fungal burden, followed for 18 hours and re-scored for final fungal burden. The 
IPR of each co-infected strain was calculated by totalling the total fungal burden for each 
strain at 0 hr and 18 hr and dividing the final net burden at 18 hr by the initial net burden at 
0 hr. For control and comparison singly infected H99-GFP and Δplb1 J774 monolayers 
were also scored in the same way. 
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The data appears to show that the intracellular proliferation defect of Δplb1 is slightly but 
significantly rescued within co-infected macrophages that have H99-GFP cells within them 
(Figure 2 (p = 0.017). Unfortunately, with an experimental replicate number of only two 
there is insufficient power to support this conclusion with statistical testing. Taken together 
this suggests that further work will need to be performed in order elucidate the effects of 
co-infection. 
 
 
  
138 
 
 
.          
  
H
9
9
-G
F
P
 

p
lb
1
 
H
9
9
-G
F
P
 (
C
o
- i
n
fe
c
t i
o
n
)

p
lb
1
 (
C
o
-i
n
fe
c
t i
o
n
)
0 .0
0 .5
1 .0
1 .5
2 .0
2 .5
M
e
a
n
 I
P
R
*
 
Figure 2 – A Co-infection experiment between Δplb1 and H99-GFP to determine if 
secreted Plb1 affects cryptococcal growth within the macrophage. Co-infected 
macrophages (i.e. those that contained both H99-GFP and Δplb1) at 0 hr were scored for 
fungal burden and then followed and scored again at 18 hr.  The IPR was calculated by 
totalling the number of cryptococci at both time points and dividing the fungal burden at 
18 hr by the fungal burden at 0 hr. The ‘H99-GFP’ and ‘Δplb1’ conditions represent singly 
infected controls. n = 2, error bars = Standard deviation. Independent two tailed, unpaired 
T tests performed for H99-GFP vs. Δplb1 and H99-GFP (co-infection) vs. Δplb1 (Co-
infection). * H99-GFP vs. Δplb1 p = 0.019. 
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3.2 Treatment of Δplb1 infected macrophages with exogenous AA appears to reverse 
its defective IPR phenotype 
Although my co-infection experiment was not conclusive, it has been published that 
eicosanoids such as PGE2 and PGF2 are secreted by C. neoformans and furthermore their 
production is dependent on Plb1 expression. In this respect it has been observed that the 
Δplb1 mutant strain cannot produce eicosanoids unless exogenous arachidonic acid (AA) is 
added its growth medium (Noverr et al., 2003a). This finding suggests that Plb1 is required 
to produce a pool of AA that is then metabolised into eicosanoid species such as PGE2.. 
This finding could fit with data from another study which implicates that Plb1 facilitates 
the metabolism of host macrophage derived AA (Wright et al., 2007). With this in mind C. 
neoformans may use AA derived from host cells during infection to produce eicosanoids 
that can influence the outcome of infection. 
To examine this possibility I infected J774 macrophages with H99, Δplb1 and Δplb1:PLB1 
and treated infected cells with 30 μg/ ml AA. If eicosanoids do help Cryptococcus grow 
within macrophages, then it was hoped that by adding exogenous AA to infected cells the 
IPR and viability of the Δplb1 strain would be raised. Interestingly I did find that the IPR 
of Δplb1 could be increased via the addition of exogenous AA (Figure 3. A). In untreated 
macrophages the IPR of Δplb1 is significantly reduced compared to the wild type strain 
H99 (p = <0.001) however when exogenous AA is added the mean IPR of Δplb1 increases 
to a point where it is no longer significantly different from H99 – this data suggests that 
exogenous AA can in fact boost the IPR of Δplb1 during macrophage infection – this 
indicates that eicosanoids such as PGE2 may drive C. neoformans intracellular proliferation 
and that additionally this process may be Plb1 dependant. Although I observed an increase 
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in IPR for Δplb1 upon addition of exogenous AA I did not see an increase in intracellular 
viability (Figure 3. B). This suggests that although AA can boost Δplb1 intracellular 
proliferation it does not affect Δplb1’s underlying susceptibility to macrophage killing. 
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Figure 3 - A. Intracellular proliferation of C. neoformans strains H99, Δplb1 and 
Δplb1:PLB1 following treatment with 30 μg/ml Arachidonic Acid (AA). Untreated and 
vehicle controls (AA solvent – 100% ethanol) were also performed. IPR is given relative to 
the H99 wild type strain for each condition. n = 6, error bars = standard deviation.  
Multiple unpaired T tests performed for each treatment group vs. H99. H99 untreated vs. 
Δplb1 * p = < 0.001, H99 vehicle vs. Δplb1 * p = <0.001, Δplb1 untreated vs. Δplb1 + 30 
μg/ml AA ns p = 0.122. The Bonferroni correction was used to correct for multiple 
comparisons (3) the corrected  value was 0.016. B. Viability of C. neoformans cells 
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recovered from J774 macrophages following IPR assay. Cells recovered following 
macrophage lysis were counted and diluted give an expected plated inoculum of 200 cells. 
n = 4, error bars = standard deviation. Two-way ANOVA with Tukey post test performed 
to compare time points and treatment for each strain. Untreated 0 hr vs. Untreated 18 hr ** 
p = 0.001.  
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3.3 Treatment of infected macrophages with exogenous AA leads to increased PGE2 
production 
The fact that adding exogenous AA to infected macrophages increases the IPR of the 
Δplb1 strain suggests that C. neoformans IPR may be boosted by increased eicosanoid 
levels within the macrophage. It has been shown in another study that PGE2 signalling 
during pulmonary cryptococcosis in mice can produce favourable conditions for 
cryptococcal growth in the lung. In the same study it was observed that alveolar 
macrophages from infected lung tissue were alternatively rather than classically activated. 
This suggests that PGE2 signalling during infection may alter macrophage activation and 
help C. neoformans to survive (Shen and Liu, 2015). The next step after observing that 
exogenous AA could significantly increase the IPR of Δplb1 therefore was to determine 
which eicosanoid was responsible. 
Noverr et al. described how the Δplb1 mutant could only produce eicosanoids if exogenous 
AA was present. Noverr et al. tested this phenomenon in liquid growth media (Sabourand 
dextrose broth), but they did not examine whether eicosanoids were produced during 
macrophage infection (Noverr et al., 2003a). In this study Noverr et al. showed that the 
widely studied prostaglandin PGE2 is produced in a Plb1 dependant manner. The next step 
of this research therefore was to determine whether the addition of exogenous AA 
increased the amount of PGE2 produced by C. neoformans infected macrophages. 
Additionally, I also wanted to determine whether C. neoformans infected macrophages 
produce PGE2 in a Plb1 dependant manner. If this were the case then one might expect 
Δplb1 infected macrophages to produce less PGE2 compared to H99 and Δplb1:PLB1 
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infected macrophages, furthermore one might observe that when exogenous AA is 
available this deficiency would be restored. 
In order to test this idea I infected J774 macrophages with either H99, Δplb1 or the genetic 
reconstituted strain Δplb1:PLB1 and after 18 hours of infection measured the levels of 
PGE2 in the cell culture supernatant using a PGE2 specific ELISA. In addition to measuring 
the base level of PGE2 production during infection I also measured PGE2 levels when 
infected macrophages were treated with exogenous AA at a concentration of 30 μg/ml – 
the same concentration used in my IPR experiment (Figure 3). 
ELISA analysis revealed that C. neoformans infected macrophages do produce detectable 
levels of PGE2 (Figure 4) - for non arachidonic acid treated, H99 infected macrophages the 
mean PGE2 concentration in the supernatant was determined to be 482 pg/ml. Importantly 
however Δplb1 infected macrophages (also untreated) did not produce significantly 
different levels of PGE2 (Mean = 445 pg/ml), additionally uninfected macrophages also 
produced similar levels of PGE2 (Mean = 491 pg/ml). Interestingly however I did find that 
treatment of infected macrophages with exogenous AA did increase the amount of 
detectable PGE2 in the supernatant about 4 fold – for AA treated, H99 infected 
macrophages the mean PGE2 concentration in the supernatant was determined to be 1908 
pg/ml – however as before there was no significant difference in PGE2 produced by H99 
infected macrophages, Δplb1 infected macrophages or even uninfected macrophages. 
Taken together these findings suggest that C. neoformans infection does not significantly 
increase PGE2 levels within macrophage supernatants and that the PGE2 that is produced is 
macrophage derived. However because PGE2 levels still increased when exogenous AA is 
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added to macrophages, this suggests the boost in IPR observed for Δplb1 when AA is 
added may be due to increased PGE2 levels within infected macrophages. 
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Figure 4 – PGE2 monoclonal EIA ELISA performed on supernatants from C. neoformans 
infected macrophages collected at 18 hr time point of infection (i.e. 18 hours after non-
phagocytosed cryptococci were washed away).  Mean concentration (pg/ml) of PGE2 
plotted with SD. n = 4.  Two-way ANOVA with Tukey post test performed to compare 
concentrations within treatment groups – no significance found. 
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3.4 Efforts to determine whether increased PGE2 levels due to exogenous AA 
treatment increase the IPR of Δplb1 remain inconclusive 
In order to determine whether the increased IPR for Δplb1 observed when exogenous AA 
was added to infected macrophages (Figure 3. A) was due to increased PGE2 as indicated 
by the subsequent ELISA experiment (Figure 4), the next step in the project was to 
perform an IPR experiment with exogenous PGE2. It is likely however that addition of AA 
to macrophages increases a number of prostaglandins as well as PGE2, therefore to see if 
the IPR increase seen for Δplb1 was PGE2 specific or a result of other prostaglandins I also 
chose to test an addition prostaglandin – PGD2.  
Unfortunately, IPR analysis of Δplb1 infected macrophages after the addition of either 
PGE2 or PGD2 did not provide conclusive evidence that either prostaglandin can promote 
C. neoformans IPR. The reason for this was because the IPRs for either treatment condition 
were too variable to accurately determine if any effect was occurring (Figure 5. A and 
Figure 5. B). Similarly variable results were also seen for viability testing (Figure 5. C). In 
order to determine if either prostaglandin does influence C. neoformans growth within the 
macrophage optimisation of the experiment or alternatively a new experimental approach 
is needed.     
In conclusion I have found that although co-infection of Δplb1 with H99 may rescue 
Δplb1’s IPR (Figure 2), the addition of exogenous AA can significantly increase the IPR of 
Δplb1, but not intracellular viability (Figure 3). Additionally, I show that C. neoformans 
infected macrophages treated with exogenous AA produce significantly higher levels of 
PGE2 (Figure 4) indicating that prostaglandin levels may mediate this IPR increase. Taken 
together this data suggests that eicosanoid levels within infected macrophages do affect C. 
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neoformans IPR in a Δplb1 dependant manner, however the main source of these 
eicosanoids is likely to be the macrophage. Although exogenous AA increases the IPR of 
Δplb1, experiments to determine whether this increase is a specific effect of PGE2 remain 
inconclusive. 
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Figure 5 – A Intracellular proliferation of C. neoformans strains H99, Δplb1 and 
Δplb1:PLB1 following treatment with 0.6 ng/ml Prostaglandin E2 (PGE2). Untreated and 
vehicle controls (PGE2 solvent – 100% ethanol) were also performed. IPR is given relative 
to the H99 wild type strain for each condition. n = 3, error bars = standard deviation.  
Multiple unpaired T tests performed for each treatment group vs. H99. H99 vehicle control 
vs. Δplb1 vehicle control * p= 0.003 B Intracellular proliferation of C. neoformans strains 
150 
 
 
H99, Δplb1 and Δplb1:PLB1 following treatment with 0.6 ng/ml Prostaglandin D2 (PGD2). 
Untreated and vehicle controls (PGD2 solvent – 100% ethanol) were also performed. IPR is 
given relative to the H99 wild type strain for each condition. n = 3, error bars = standard 
deviation.  Multiple unpaired T tests performed for each treatment group vs. H99 vehicle 
control vs. Δplb1 vehicle control * p= 0.003. C. Viability of C. neoformans cells recovered 
from J774 macrophages following IPR assay. Cells recovered following macrophage lysis 
were counted and diluted give an expected plated inoculum of 200 cells. n = 2, error bars = 
standard deviation. Two-way ANOVA with Tukey post test performed to compare time 
points and treatment for each strain. No significance found. 
  
151 
 
 
4. Discussion 
I have previously found that Plb1 is required by C. neoformans for intracellular 
proliferation and viability within macrophages (Chapter 2. Figure 4). The purpose of the 
work described in this chapter was to begin to determine how Plb1 mediates these effects. 
Within this in mind the theory that I wanted to test was that Plb1 allows C. neoformans to 
produce eicosanoids (Noverr et al., 2003a) which may mimic and interfere with 
macrophage function during infection. 
In Chapter 2, I show that the proliferative and viability defects of the Δplb1 mutant within 
macrophages are due to a deficiency in intrinsic Cryptococcus Plb1 activity as opposed to 
secreted Plb1 activity (Chapter 2. Figure 4). To confirm this observation, I designed a co-
infection experiment to determine whether the intracellular proliferation defect of the 
Δplb1 mutant could be reversed by the presence of H99-GFP within the same macrophage.  
I found that co-infection does appear to slightly but significantly rescue the IPR defect of 
the Δplb1 mutant (Figure 2), however this experiment had a low number of experimental 
repeats (n=2) so statistical testing of this effect was not powerful enough to offer firm 
conclusions. There are also a few caveats to this experiment. Firstly, macrophages were 
determined to be ‘co-infected’ if they contained both H99-GFP and Δplb1 however there 
was no way to determine if the Cryptococcus strains shared the same phagosome. This 
experimental limitation meant that secreted factors may have gone undetected if they were 
unable to move between phagosomes. The best way to address this problem in future 
experiments would be to visualise the phagosome membrane using fluorescent antibodies 
against a phagosomal marker such as LAMP-1 (Levitz et al., 1999b)  and con-focal 
microscopy. Demarcating the phagosome membrane will allow co-infected Cryptococcus 
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strains within the same phagosome to be identified and scored appropriately. The second 
caveat to the co-infection experiment is that the wild type H99-GFP strain I used was not 
technically wild type as it has been modified to express a fluorescent tag. Although it is 
assumed that the H99-GFP strain expresses and secretes normal levels of Plb1 this has not 
been experimentally determined. It is worth noting that this strain’s stress responses and 
also some key virulence characteristics within macrophages such as intracellular 
proliferation and phagocytosis have been found to-be very similar to wild type H99, 
however this said the expression of Plb1 was not a parameter that was tested. It is therefore 
possible that the genetic manipulation performed on this strain could have affected the 
expression of Plb1. For proper verification of the data therefore, radiometric analysis of the 
H99-GFP strain is needed to confirm that it possesses wild type Plb1 activity. If the H99-
GFP does have reduced Plb1 activity, then the wild type H99 strain could be used instead 
with a suitable differentiating stain such as calcofluor white instead of the GFP tag. 
Due to the limitations of the co-infection experiment I decided to directly test whether 
eicosanoids produced during macrophage infection may influence IPR. It has been 
previously shown that C. neoformans produces immune modulatory eicosanoids (Noverr et 
al., 2001) and that their production is Plb1 dependant unless exogenous AA is provided 
(Noverr et al., 2003a). This suggests that the role of Plb1 in eicosanoid production is the 
liberation of AA from cell membranes prior to eicosanoid synthesis. 
Interestingly I found that treating Δplb1 infected macrophages with exogenous AA (30 
μg/ml) increased Δplb1’s IPR (Figure 3. A). This indicates that Δplb1’s intracellular 
proliferation deficiency may be due to eicosanoid deficiency (Noverr et al., 2003a). 
Although exogenous AA increases the IPR of Δplb1, it does not appear to improve the 
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reduced viability of the Δplb1 strain (Chapter 2. Figure 4- B). This is intriguing as it 
suggests that although the IPR and viability phenotypes observed in the Δplb1 mutant are 
both linked to Plb1 they may occur due to divergent aspects of Plb1 deficiency. 
C. neoformans produces a number of eicosanoid species (Noverr et al., 2001) however 
some of the most abundant species produced by the fungus are prostaglandins such as 
PGE2, PGD2 and PGF2. Although C. neoformans produces its own eicosanoids, the 
macrophages they infect are also key producers during inflammation – especially when 
exogenous AA is provided (Stenson et al., 1981). For this reason, it was important for me 
to determine firstly whether the IPR boosting effect of adding AA to infected macrophages 
was due to increased eicosanoid levels, and secondly to determine whether these 
eicosanoids were macrophage or Cryptococcus derived. 
To do this I took the supernatant from Δplb1 infected macrophages and measured the 
amount of PGE2 produced after 18 hours of infection with and without exogenous AA 
treatment (30 μg/ml). Through ELISA analysis of macrophage supernatants, I found that 
there was no significant difference in the amount of PGE2 produced by H99 or Δplb1 
infected macrophages, and additionally, that uninfected macrophages produced similar 
amounts of PGE2. Taken together the data suggest that neither Plb1 nor C. neoformans 
infection itself significantly affects the amount of PGE2 produced by infected 
macrophages.  I did find however that treating C. neoformans infected macrophages with 
AA does significantly increase the amount of PGE2 they produce, these findings indicate 
that the increased IPR of Δplb1 I observed following AA treatment (Figure 3. A) may have 
been due to increased amounts of PGE2 within treated macrophages. 
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The ELISA I used could only determine the amount of PGE2 produced by macrophages; 
however, it is likely that macrophages produce a range of eicosanoids following exogenous 
AA treatment. For this reason, addition work must be done to determine which eicosanoids 
are produced. To do this I could use an ELISA with a much broader specificity – for 
instance I could use an ELISA which is reactive against all prostaglandin species. This 
broader approach could then be supplemented by performing additional ELISAs, each 
specific to a different eicosanoid species in order to pinpoint important species. An 
alternative method to multiple ELISAs would be to analyse culture supernatants with 
HPLC – by using [3H]-AA and appropriate standards, multiple radiolabelled eicosanoid 
species and their relative abundance can be identified in a single experiment (Noverr et al., 
2001). Additionally, using HPLC, the type and amount of eicosanoids produced by either 
Cryptococcus or the macrophage during infection could be determined by pre-incubating 
C. neoformans cultures and/ or macrophage monolayers with [3H]-AA before infection. 
Finally, to determine whether the increase in IPR seen for Δplb1 following exogenous AA 
treatment (Figure 3) was a result of increased PGE2 levels detected by the ELISA (Figure 
4). I performed a series of IPR and viability assays as before but instead of treating with 
exogenous AA, I used exogenous PGE2 (0.6 ng/ml) or PGD2 (0.6 ng/ml). Unfortunately, I 
found that the IPR and viability data generated was too variable to determine whether these 
exogenous prostaglandins modulated the IPR of Δplb1 in the same way that I saw with 
AA. The reason for this variability is likely to be because prostaglandins are highly volatile 
molecules and as such it is likely that following addition to tissue culture media they were 
quickly degraded. This degradation could result in a highly variable amount of 
prostaglandin actually reaching infected macrophages during each experimental replicate.  
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The simplest way to decrease the variability of this assay would be to perform a greater 
number of experimental repeats. If this approach does not work, then the assay may need 
to be adapted to reduce the variability. One solution to this problem might be to use 
alternative prostaglandin derivatives that are more stable than their natural counterparts. In 
this respect a more stable PGE2 derivative called 16, 16-dimethyl prostaglandin E2 exists. If 
the breakdown of PGE2 could be reduced then the concentration of the prostaglandin 
reaching infected macrophages, and the duration of its effect, could be increased; 
potentially increasing the efficacy of this treatment. Another alternative could be to 
selectively target specific prostaglandin receptors with pharmacological receptor agonists. 
In the case of PGE2 the EP2 and EP4 have recently been shown to promote C. neoformans 
infection (Shen and Liu, 2015), selective agonists to both of these receptors have been 
identified and could be used instead of PGE2 itself (Billot et al., 2003; Paralkar et al., 
2003). 
In conclusion, thus far experiments with Δsec14-1 (Chapter 2. Figure 4. A) as well as 
tentative co-infection data (Figure 2) indicate that a secreted IPR inducing factor is not 
produced by C. neoformans (and specifically it is not likely to be Plb1). I have shown that 
the IPR deficiency of the Δplb1 strain can be reversed by treating infected macrophages 
with exogenous AA (Figure 3 A) which is known to be linked to C. neoformans eicosanoid 
production (Noverr et al., 2003a). ELISA analysis of C. neoformans macrophages revealed 
that exogenous AA treatment increases the levels of PGE2; however, this PGE22 is likely 
to be largely macrophage derived as opposed to being produced by C. neoformans. 
Nonetheless these results indicate that PGE2 or a related eicosanoid induced by exogenous 
AA treatment is able to increase the proliferation of C. neoformans within macrophages. 
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Future work must focus on determining which eicosanoids are involved in these effects 
and additionally how C. neoformans and Plb1 fit into this puzzle.   
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CHAPTER 4 – DEVELOPMENT OF A HIGH 
THROUGHPUT FLOW CYTOMETRY 
METHOD FOR THE DETERMINATION OF 
CRYPTOCOCCUS INTRACELLULAR 
PROLIFERATION 
 
1 - Introduction 
During pulmonary cryptococcosis, Cryptococcus neoformans is phagocytosed by alveolar 
macrophages. The function of phagocytosis is to destroy pathogenic organisms, however 
Cryptococcus is able to survive within the macrophage phagosome and proliferate 
(Feldmesser et al., 2000). Survival and proliferation of C. neoformans within macrophages 
is important to disease pathogenesis, in this respect it has been shown that C. neoformans 
strains which proliferate well inside macrophages have a higher overall virulence 
compared to strains that proliferate poorly within macrophages (Alanio et al., 2011; 
Mansour et al., 2011).  
1.1 Why a new method for measuring intracellular proliferation is needed. 
The study of cryptococcal virulence is currently being revolutionised by the creation of 
systematic gene knockout libraries (Liu et al., 2008). The library produced by Liu et al. 
(which consists ~1200 gene knockout mutants) represents the first part of a much larger 
project by the Madhani and Noble groups that aims to create a signature tagged knockout 
mutant for every expressed gene within the C. neoformans genome (with the C. 
neoformans var. grubii serotype A H99 strain as the wild type genetic background). The 
completion of this library and its subsequent release to the wider scientific community will 
158 
 
 
provide a powerful resource for researchers as it will allow systematic analysis of all 
virulence associated genes within the Cryptococcus genome. The first 1,201 gene knockout 
mutants (Liu et al., 2008) are available for purchase as 13 separate 96 well plates; C. 
neoformans is estimated to have ~6500 genes (Loftus et al., 2005) meaning that once 
finished the completed genome knockout library will be spread over at least 67 plates 
(assuming the 96 well plate format is maintained). 
In order to fully utilise genomic knockout libraries, high throughput protocols must be 
developed to quickly and accurately interrogate the huge number of mutants involved. 
Established assays designed to quantify the proliferative capacity of C. neoformans strains 
within macrophages are generally slow and laborious as they require manual quantification 
of macrophage burden using microscopy analysis. Therefore, there is a need to develop 
faster protocols for sample preparation and analysis before high throughput analyses can be 
performed.  
1.2 A discussion of existing methodologies 
In their 2008 study Liu et al. assessed the proliferative capacity for each of their 1,201 
mutants by placing them into groups of 48 (where each mutant had a distinct signature tag) 
and inoculating each group into mice. After the end point of infection, the relative 
abundance of each mutant within the lungs was determined using quantitative PCR. Using 
this method Liu et al. were able to correlate the virulence of a mutant with its ability to 
grow within the lung; however with this assay it is difficult to determine whether a 
mutant’s proliferation was intracellular or extracellular during infection (Liu et al., 2008). 
Additionally, to assay all 1,201 mutants Liu et al. used around 75 mice (25 groups of 48, 3 
mice per group). To do a similar assay with the full genomic library at least 407 mice 
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would be needed (136 groups of 48, 3 mice per group). With this in mind it is quite 
reasonable in terms of ethics, expense and logistics to suggest an alternative in vitro screen 
using a macrophage cell line before in vivo work is attempted.  
The aim of this project was to optimise the existing intracellular proliferation rate (IPR) 
assay used by our group (Evans et al., 2015; Ma et al., 2009; Voelz et al., 2009) so that 
sample analysis could be completed faster. To accomplish this, I adapted the assay so that 
a flow cytometer could be used to quantify Cryptococcus as an alternative to manual 
counting by haemocytometer.   
The IPR assay I adapted is described fully in the materials and methods section of Chapter 
2. Briefly J774 murine macrophages are seeded into 24 well plates and infected with 
antibody opsonised C. neoformans cells at an MOI of 1:10 (1x105 J774 cells, 1x106) C. 
neoformans cells. After two hours of phagocytosis the macrophage monolayer is washed 
with PBS to remove non phagocytosed cryptococci. Macrophages are then lysed with 
deionised water (dH2O) at several time points and the number of Cryptococcus cells within 
each lysate sample quantified. A baseline count is always taken 2 hours after infection (i.e. 
as soon as non-phagocytosed cryptococci are removed); subsequent time points are usually 
taken at 18 hours and 24 hours after the baseline time point. The IPR of a strain is 
calculated by dividing the maximal fungal burden (usually the 18 hour time point) by the 
baseline - e.g. a baseline count of 2x106 cryptococci per ml and an 18 hours count of 4x106 
cryptococci per ml would give an IPR of 2 (4x106 / 2x106 = 2). The counting of IPR assay 
samples is normally performed manually using a light microscope and a haemocytometer 
counting chamber. Depending on the concentration of cryptococci in the cell lysate this 
counting process can take up to 2 minutes per sample and as such is a rate limiting step in 
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the assay. By developing a faster method to count each sample, the IPR assay should be 
more amenable to high throughput analyses of genomic knockout libraries as well as large 
clinical isolate collections.  
The flow cytometer used for this project was a two laser Attune© bench top flow cytometer 
(Life Technologies – Thermo Fisher Scientific, USA). The advantage of this instrument for 
the project was that it had been designed for day to day use by a single lab (as opposed to a 
much more complex central facility flow cytometer). Due to the relative simplicity of the 
instrument it is possible for lab members to use it with very little experience. An additional 
advantage of this instrument is the availability of a plate ‘autoloader’; this add-on allows 
an entire 96 or 384 well plate to be analysed automatically using software commands. 
Our lab has shown that an IPR assay can be performed using flow cytometry (Voelz et al., 
2010). To visualise and count cryptococci within macrophages this assay used a GFP-
tagged C. neoformans strain. The drawback to this protocol was that the creation of GFP-
tagged C. neoformans strains was laborious and unfeasible for high throughput screening 
unless a library is constructed in a fluorescent background. As well as our own group, 
other groups have also used flow cytometry to measure Cryptococcus intracellular 
proliferation (Alanio et al., 2011). In this study Alanio et al. negated the need for GFP -
tagged strains by employing calcofluor white (CFW - a chitin specific stain) to stain C. 
neoformans cells and fluorescently conjugated antibodies to differentiate between 
phagocytosed and non-phagocytosed cryptococci. In their study Alanio et al. assayed 54 C. 
neoformans clinical isolates, the need for antibody staining adds additional labour and 
expense to sample preparation which might make a larger high throughput screen (e.g. 
6,500 strains, or even 1,201 strains) difficult to perform in the same way. Another aim of 
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this project therefore was to ensure that minimal sample preparation was required in order 
to make the protocol quick, cost effective and compatible with a high throughput 96 well 
plate format.       
Herein I report that that a mixture of two cell dyes - propidium iodide (PI) and CFW – can 
be used to stain and count C. neoformans cells within assay samples using flow cytometry. 
This staining protocol is quick and easy to perform; additionally I present evidence that the 
data produced is comparable to manual haemocytometer counting of IPR samples. 
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2. Materials and methods 
2.1 Strains, media and cell lines 
Strains used in this work are listed in the Appendix (Appendix Table 1 page 186). C. 
neoformans strains were stored long-term in MicroBank vials at -80oC.  Strains were 
rescued onto YPD agar (YPD 50 g/L Sigma Aldrich, 2 % Agar – Melford) for 48 hours at 
25oC and then stored until needed at 4oC. Before experimentation, liquid cultures were 
grown from these stock plates in 2 ml YPD growth medium (50 g/L) for 24 hours at 25oC 
under constant rotation. 
The J774 murine macrophage cell line used was passaged in DMEM culture media with 
serum (Dulbecco’s Modified Eagle medium, low glucose, Sigma Aldrich, 10 % FBS - 
Invitrogen, 1% 10,000 units Penicillin / 10 mg streptomycin – Sigma Aldrich, 1 % 200 
mM L– glutamine – Sigma Aldrich). Assays were performed with J774 cells between 
passages 4 and 15. Assays were performed in serum-free DMEM (DMEM high glucose, 
1% P/S, 1% L-glutamine) unless otherwise stated. 
2.2 Macrophage infection 
Briefly, 24 hours before infection, 1x105 J774 macrophages were seeded into 24 well 
plastic plates (Greiner Bio One Cell Star) in 1 ml culture media with serum and incubated 
for 24 hours at 37oC 5% CO2. Before infection, J774 cells were activated with 150 ng/ml 
phorbol 12-myristate 13-acetate in DMSO (Sigma), in 1 ml serum free culture medium for 
45 minutes. This media was then replaced with serum-free media alone. Simultaneously, 
overnight C. neoformans cultures grown at 25oC in YPD were washed three times in sterile 
1x PBS, counted and adjusted to 1 x107 cells per ml in PBS before opsonisation for 1 hour 
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with 10 μg/ml anti capsular 18B7 antibody (a kind gift from Arturo Casadevall, Albert 
Einstein College of Medicine, New York USA). The activated J774 cells were then 
infected with 100 μl opsonised C. neoformans to give an MOI of 10 (e.g. 1x105 J774 / 
1x106 C. neoformans) in un-supplemented serum-free DMEM and incubated for 2 hours at 
37oC 5% CO2. After two hours (time point 0) infected wells were washed at least 3 times 
with warm 1x PBS until all non-phagocytosed C. neoformans cells were removed from the 
wells. 
For calculation of the intracellular proliferation rate the number of internal cryptococci 
were counted at time point 0 hr and time point 18 (18 hours after time point 0).  At each 
time point each well to be counted was washed three times with 1x PBS to remove any 
extracellular yeast. The macrophages in the well were then lysed in 200 μl deionised water 
(dH2O) for 30 minutes. To remove lysed macrophages and cryptococci a pipette tip was 
used to scrape the surface of the well, the 200 μl of lysate was then removed to a clean 
Eppendorf and a further 200 μl dH2O added to the well to wash any remaining cells, this 
200 μl was also added to the Eppendorf to give a final sample volume of 400 μl.  
2.3 Manual counting 
C. neoformans cells in the lysate were quantified at time points 0 and 18 with a 
haemocytometer counting chamber and the intracellular proliferation rate (IPR) calculated 
by dividing the number of cryptococci per 0.1 μl at time point 18 by the same count made 
at time point 0. 
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2.4 Flow cytometry counting 
IPR lysate samples (macrophage debris and cryptococci washed from infected wells, 400 
μl in dH2) were stained with Calcofluor White (CFW - 2 µg/ml final concentration) and 
Propidium Iodide (PI - 5 µg/ml final concentration), mixed well and incubated for 10 
minutes at room temperature before analysis.  
Flow cytometry analysis was performed using the Attune blue / violet bench top flow 
cytometer (Life Technologies, Thermo Fisher Scientific USA). Samples were first 
visualised using FSC-H (Forward scatter) and SSC-H (side scatter) channels to ensure that 
events of the correct size and complexity were analysed. The VL1-H channel (430 nm – 
470 nm emission wavelength) was used to detect CFW fluorescence, the BL3-H channel 
(640 nm ‘long pass’ emission wavelength) was used to detect PI fluorescence and the BL1-
H channel (515 nm – 545 nm emission wavelength) was used to detect GFP fluorescence. 
Baseline PMT sensitivities were set using an unstained sample control before experiments 
with the unstained signal set to 102 relative fluorescence (the recommended baseline for 
the Attune). Data was acquired at a flow rate of 100 µl/ min; 10,000 events were collected 
for each sample. 
To count each sample, the Attune flow cytometer software was used. Dot plots of BL3-H 
vs. VL1-H were produced for each sample. First using a macrophage alone sample 
(macrophage debris, no Cryptococcus) a gate was drawn to the bottom right of the 
macrophage debris population (Figure 5 A), next a sample infected with GFP-tagged 
Cryptococcus neoformans H99 strain was used to confirm the position of the gate in 
relation to the Cryptococcus population (Figure 5 B) (as defined by a GFP positive signal). 
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Once the position of the gate was verified PI/CFW stain IPR samples could be analysed 
and counted (Figure 5 C).  
To quantify the number of cryptococci within each sample the Attune software was able to 
output a statistic of ‘events per µl’ in a defined gate; this output was used for all counts. To 
calculate the IPR the ‘number of events per µl’ at 18 hr was divided by the ‘number of 
events per µl’ at 0 hr count. 
2.5 Statistics 
Figure 5: 
Figure 5A: Two tailed, unpaired T test performed, comparing methodologies for each 
strain (e.g. flow cytometry vs. haemocytometer). 
Figure 5B: Data was tested for normality using the Shapiro Wilk test (see appendix table 
18 page 196). Two tailed, unpaired T test performed, comparing methodologies for each 
clinical isolate (e.g. flow cytometry vs. haemocytometer). 
Figure 6: Two-way ANOVA performed for each sample (‘Tube’ versus ‘Plate’ versus 
‘Haemocytometer’ for each sample, no significant differences). 
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3. Results 
It has been already been demonstrated that Cryptococcus intracellular proliferation can be 
quantified using flow cytometry (Alanio et al., 2011; Voelz et al., 2010), however new 
methodologies must be developed if flow cytometry is to be used as a high throughput 
screen. 
3.1 Flow cytometry analysis of unstained lysate samples revealed that staining was 
needed to differentiate macrophage debris for Cryptococcus cells. 
Flow cytometry analysis of unstained IPR samples via forward scatter (FSC - used to 
express a cell’s physical size) and side scatter (SSC – used to express a cell’s internal 
complexity) revealed that all events within the sample clustered into a single homogenous 
population (Figure 1- A) – this population contained Cryptococcus cells as well as partially 
lysed macrophages and macrophage debris. Thus to accurately quantify the number of 
Cryptococcus cells within the lysate, fluorescent staining was required so that the 
Cryptococcus population could be gated and the macrophage debris discarded. 
3.2 The use of a GFP tagged Cryptococcus strain confirmed the existence of the 
Cryptococcus population within the lysate. 
To confirm where on this dot plot the Cryptococcus population resided I used a GFP 
tagged C. neoformans strain (H99-GFP) that could easily be gated using its GFP 
positive signal (Voelz et al., 2010). By back-gating this GFP positive signal (Figure 1- 
Bi) to the original FSC/SSC scatter plot, the Cryptococcus population could easily be 
identified within the sample (Figure 1- Bi and Figure 1- Bii).   
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In order to quantify the Cryptococcus population identified using the H99-GFP control 
for non GFP strains, I needed to design a protocol that would allow me to specifically 
stain either the macrophage or the Cryptococcus populations. By doing so I would be 
able to produce a fluorescent signal that could be detected by the flow cytometer and 
gated around to separate each population.  
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Figure 1: Flow cytometry method for detecting C. neoformans using the H99-GFP 
strain. A. Dot plot (FSC-H vs. SSC-H) unstained IPR sample (X axis minimum = 104, Y 
axis minimum 102). B i. Histogram BL1-H channel (515-545 nm emission wavelength), 
gated for GFP positive macrophage around 106 intensity. B ii. GFP positive gate from Bi 
back gated onto FSC-H vs. SSC-H scatter plot for the same sample. B iii. Scatter plot FSC-
H vs. SSC-H displaying GFP positive population only. 
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3.3 Attempts to differentiate the Cryptococcus population from macrophage debris 
using anti-capsular antibody staining indicated that an alternative might be more 
efficient  
My first approach to specifically stain Cryptococcus cells within the IPR samples, was to 
use the 18B7 anti-capsular antibody (a kind gift from Arturo Casadevall) because in theory 
this antibody should bind only to C. neoformans cells, I then used a FITC conjugated anti 
mouse IgG secondary antibody to allow visualisation using the flow cytometer’s BL-1 
channel (515nm -545 nm emission wavelength).  
Antibody staining of the lysate (primary stain - 1 hour with 10 μg/ml anti capsular 18B7) 
did reveal a similar population (in terms of position and shape on the dot plot) to the 
Cryptococcus population I had previously identified with GFP H99 (Figure 1- Biii and 
Figure 2- C). Although the GFP positive Cryptococcus population was identifiable, it could 
not be well resolved from the non-fluorescent signal (Figure 2- B) suggesting that the 
antibody was staining macrophage debris as well as Cryptococcus cells (Figure 2- D). I felt 
that the overlap between the two populations would make gating too subjective to give an 
accurate count; additionally, the staining protocol itself was too complicated for high 
throughput screening of large numbers of samples. For these reasons I decided to try 
another approach that did not require antibody staining.   
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Figure 2: Flow cytometry method for detecting C. neoformans using anti capsular 
antibody staining. A. Histogram BL1-H (FITC channel – 515nm – 545 nm emission 
wavelength), gate “FITC” shows FITC positive peak. B. FSC-H vs. SSC-H scatter plot IPR 
sample stained with primary anti-capsular antibody and secondary FITC. C. FITC positive 
population back-gated onto FSC-H vs. SSC-H dot plot. D. FSC-H vs. SSC-H scatter plot, 
FITC positive population isolated. Cells stained for 1 hour with 10 μg/ml anti capsular 
18B7 antibody (a kind gift from Arturo Casadevall, Albert Einstein College of Medicine, 
New York USA) and a further 30 minutes with an a rabbit anti mouse IgG FITC 
conjugated secondary (1:500 dilution, Life Technologies).  
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3.4 A staining protocol using propidium iodide and calcofluor white proved to be 
effective at separating Cryptococcus and macrophage debris populations during 
analysis 
The poor resolution of populations I observed when I used the anti-capsular antibody led 
me to me to develop a protocol that used two cell dyes, with different fluorescent signals, 
to specifically stain both the macrophage and the Cryptococcus populations within the 
sample. The two dyes I selected to do this were Calcofluor white (CFW) and propidium 
iodide (PI). The reason these two dyes were selected is because CFW stains chitin, which 
is found in the fungal cell wall but not in mammalian cells, and PI can stain dead cells due 
its ability to bind to nucleic acids released during cell lysis. I hypothesised therefore that 
Cryptococcus cells would stain PI low and CFW high while the macrophage debris would 
stain PI high and CFW low.  
Flow cytometry analysis of samples stained with PI and CFW revealed two distinct 
populations (Figure 3- B) – PI was detected using the BL3 channel (640 nm plus emission 
wavelength) and CFW was detected using the VL-1 channel (430 nm – 470 nm emission 
wavelength). By running a mock infection control (Figure 3- Cii) (e.g. only macrophage 
debris) and a H99- GFP control sample (Figure 3- Ciii) the smaller population to the right 
of the plot was confirmed to be the C. neoformans cell population – the GFP signal was 
detected using the BL-1 channel (515 nm – 545 nm emission wavelength). These data 
show that using PI and CFW in combination allows Cryptococcus cells to be reliably 
separated from macrophage debris.  
The H99-GFP tagged control did reveal that there were detectable GFP signals within the 
macrophage debris population (Figure 3- Ciii) suggesting that the populations may not be 
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completely resolved – some of these signals are likely due to auto-fluorescence however it 
is possible that macrophages that have not completely lysed may still contain some 
Cryptococcus cells. 
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Figure 3: Flow cytometry method for detecting C. neoformans using calcofluor white 
(CFW) and propidium iodide (PI) A. FSC-H vs. SSC-H scatter plot IPR sample stained 
with CFW and PI B. Dot plot (PI vs. CFW) IPR sample stained with Propidium Iodide (PI) 
and Calcofluor White (CFW), (PI – BL3-H 640 nm plus emission wavelength, CFW – 
VL1-H 530nm – 570 nm emission wavelength). C i. Dot plot (PI vs. CFW) unstained IPR 
sample (PI – BL3-H 640 nm plus emission wavelength, CFW – VL1-H 530 nm – 570 nm 
emission wavelength). ii. Dot plot (PI vs. CFW) ‘macrophage alone’ control sample (PI – 
BL3-H 640 plus emission wavelength, CFW – VL1-H 530 nm – 570 nm emission 
wavelength). iii. Dot plot (PI vs. CFW) H99-GFP infection control sample (PI – BL3-H 
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640 nm plus emission wavelength, CFW – VL1-H 530 nm – 570 nm emission 
wavelength), GFP positive cells are shown in green.  
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To count each sample, the Attune flow cytometer software was used. A Dot plot of BL3-H 
vs. VL1-H was produced to analyse each sample. First using a ‘macrophage alone’ control 
(macrophage debris, no Cryptococcus) a gate was drawn to the bottom right of the 
macrophage debris population (Figure 4 - A), next a sample infected with GFP-tagged 
Cryptococcus neoformans H99 strain was used to confirm the position of the gate in 
relation to the Cryptococcus population (Figure 4 - B) (as defined by a GFP positive 
signal). Once the position of the gate was verified PI/CFW stain IPR samples could be 
analysed and counted (Figure 4 - C). To quantify the number of cryptococci within each 
sample the Attune software was able to output a statistic of ‘events per µl’ in a defined 
gate; this output was used for all counts. To calculate the IPR the ‘number of events per µl’ 
at 18 hr was divided by the ‘number of events per µl’ at 0 hr count. 
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Figure 4 – An example of how an IPR sample is gated and analysed using my new 
assay. A. First a ‘Macrophage alone’ control sample is used to determine the boundaries of 
the macrophage debris; a gate (red box) is drawn where the Cryptococcus population is 
anticipated to be B. Next a H99-GFP infected control sample is used to confirm the 
position of the Cryptococcus population and the gate (red box), the GFP positive signal is 
detected using the BL-1 channel (515 nm – 545 nm wavelength emission) and back-gated 
onto the dot pot. C. Finally, the PI/CFW stained sample(s) are analysed using the drawn 
gate (red box). The ‘number of events per µl’ in the drawn gate (red box) is used to 
quantify the number of cryptococci in the sample. 
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3.5 Comparing the new flow cytometry based counting protocol against existing 
haemocytometer counting methods indicates that the new method gives comparable 
results   
To confirm that flow cytometry analysis of IPR samples gave similar results to 
haemocytometer counting I first analysed three strains that I have used extensively during 
this research – H99, Δplb1 and Δplb1:PLB1. This set of strains is a useful test for the assay 
because the Δplb1 strain (a knockout strain deficient in a C. neoformans virulence factor 
Phospholipase B1) is a Cryptococcus mutant that has been previously shown to have a 
proliferation defect in macrophages. Comparison of analysis methods for these three 
strains show that flow cytometry counting gives very similar results to the established 
haemocytometer counting method (Figure 5- A), furthermore a two tailed T test revealed 
no significant difference between the two methods. To further verify my assay, I tested 6 
C. neoformans clinical isolates (coded CL1 – CL6) in the same way comparing the 
haemocytometer count and flow cytometry count of identical samples (Figure 5- B). Once 
again I found no significant difference between the quantification methods. The fact that 
the flow cytometry counts are consistent with the haemocytometer counts and that the flow 
cytometer can detect an intracellular proliferation defect resulting from gene knockout 
suggesting that my flow cytometry based assay should work with the analysis of gene 
knockout libraries. 
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Figure 5 Comparison of identical IPR samples counted with a haemocytometer and 
the now flow cytometry assay. A. The Δplb1 strain has been previously shown by myself 
to have a growth defect compared to its wild type background H99 and a genetic 
reconstitute ΔPlb1:PLB1 (Haemocytometer count n = 2, Flow cytometry count n = 3, error 
bars = standard deviation) Two tailed, unpaired T test performed for each sample 
(Haemocytometer versus Flow cytometry, no significant differences). B. Comparison of 
identical IPR samples counted with a haemocytometer and the new flow cytometry assay. 
Six clinical isolates (coded CL1 – CL6) were chosen to represent the real world application 
of the assay. (n = 3, error bars = Standard deviation). Two tailed, unpaired T test 
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performed for each sample (Haemocytometer versus Flow cytometry, no significant 
differences). 
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In addition to validating the assay versus established counting methods I also began the 
process of optimising the protocol for high throughput analysis of 96 well plates. In this 
respect I wanted to test how the assay would work if samples were stained and analysed in 
a 96 well plates. Up to this point in the project I had stained and analysed IPR samples in 
0.5 ml Eppendorf tubes – a potentially huge time and labour saver for high throughput 
analysis would be if the ‘autoloader’ add on that is available for the Attune flow cytometer 
could be used instead. 
Comparison of the counts given by the flow cytometer when the same IPR samples were 
loaded manually in Eppendorf tubes for analysis and also automatically by using a 96 well 
plate shows that samples can be analysed with the flow cytometer’s ‘auto loader’ add-on 
with comparable counts to both manual tube loading and also haemocytometer counting 
(Figure 6). 
In conclusion I present a flow cytometry based IPR assay that can significantly increase the 
speed of determining the intracellular proliferation rate of C. neoformans (Figure 3 and 
Figure 4). This technique uses readily available cell dyes (PI); additionally, once stained, 
the samples should be able to be analysed on almost all models of flow cytometer that have 
blue and red lasers. This protocol offers a significant improvement over existing protocols 
and importantly gives comparable results to existing methods (Figure 5). The ability to 
analyse strains in a 96 well plate format with this protocol should allow the screening of 
significantly more strains within a single experiment (Figure 6). This development will 
allow high throughput analyses of C. neoformans gene knockout libraries (Liu et al., 2008) 
as well as large clinical isolate collections. 
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Figure 6 – A comparison between different sample loading methods.  The IPR given 
when IPR samples were stained and analysed in 0.5 ml Eppendorf tubes (n=2) or a 96 well 
plate (n=2, analysed using the Attune ‘Auto sampler’ add on) were compared to 
haemocytometer counts (n=3).  Error bars = standard deviation. Two-way ANOVA 
performed for each sample (‘Tube’ versus ‘Plate’ versus ‘Haemocytometer’ for each 
sample, no significant differences). 
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4. Discussion 
In this project I sought to optimise flow cytometry as a method for determining the 
intracellular proliferation rate of a Cryptococcus strain growing in vitro within a 
macrophage cell line. The assay that I optimised has been widely used by our lab, the rate 
limiting step of the assay is quantifying the fungal burden of Cryptococcus infection 
macrophages at each time point – currently this is performed manually using a light 
microscope and a haemocytometer cell counter. The ability to perform this count using a 
flow cytometer would significantly speed up the assay and mean that many more strains 
and/or conditions could be analysed within a single experiment. The ability to analyse 
more samples in a single experiment would make our IPR assay more high throughput and 
allow analyses of genomic knockout libraries as well as large clinical isolate collections in 
order to determine genes and factors that help C. neoformans replicate within macrophages 
during host infection. 
Our lab has previously used flow cytometry to similar effect however this protocol relied 
on the creation of GFP tagged C .neoformans strains (Voelz et al., 2010). Alanio et al. 
have published an assay that uses flow cytometry to measure the intracellular proliferation 
of C. neoformans however the protocol uses a number of different antibodies to stain 
cryptococci meaning that the protocol may be too complex for high throughput of whole 
genome knockout libraries which will likely consist of 6,500 plus mutants (Loftus et al., 
2005).   
The samples produced by the IPR assay that had to be counted consisted of a mixture of 
partially lysed macrophages, macrophage debris and Cryptococcus cells. The lysis step is 
required in the assay to release cryptococci from the macrophage so that they can be 
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counted however this step also introduces additional complexity to the count and I found 
that the physical size (FSC) and complexity (SSC) of the macrophage debris was similar to 
that of Cryptococcus cells (Figure 1- A), this meant that additional staining steps were 
required in order to resolve the two populations before accurate counts could be made.  
The first approach I took to separate the two populations was to stain the C. neoformans 
cells in the lysate with a primary antibody generated against Cryptococcus capsule 
polysaccharide (18B7) and a second FITC conjugated anti mouse IgG antibody. This 
staining approach did a reasonable job of staining the Cryptococcus cells within the lysate; 
however, there was a high level of unwanted staining within the macrophage population 
(Figure 2- i). The reason for this was twofold – firstly when using immunohistochemistry 
there is always the risk of non specific binding of either the primary or secondary antibody. 
Secondly it has been found that during infection C. neoformans sheds capsule 
polysaccharide into its environment and that this exopolysaccharide can accumulate within 
macrophages (Eng et al., 1986; Tucker and Casadevall, 2002)  – this means that 
macrophages might have specifically bound 18B7 due to the presence of 
exopolysaccharide in partially lysed cells. If this were the case it would mean that 
antibodies against capsule polysaccharide are not a good way to specifically stain C. 
neoformans cells as the polysaccharide is not found exclusively in the Cryptococcus 
capsule during infection.       
A second, more successful approach was found to resolve the Cryptococcus and 
macrophage populations in the lysate using two different cell stains – calcofluor white 
(CFW) and propidium iodide (PI). These two cell stains work in combination to resolve the 
macrophage and Cryptococcus populations within the lysate – CFW specifically stains 
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Cryptococcus cells by binding to chitin and PI stains lysed macrophages by binding to 
nucleic acids released during cell lysis. It was anticipated that each stain alone would have 
background staining and auto-fluorescence issues similar to antibody staining, however in 
combination it was hoped that resolution would be improved. This proved to be the case as 
analysis of lysate samples stained with PI and CFW using a dot plot with CFW (VL-1) 
verses PI (BL-3) revealed two much more distinct populations (Figure 3 – B).  
The larger population had variable staining with PI and generally less CFW staining 
(Figure 3 – B) – this population was identified as the macrophage debris using a control 
‘macrophage alone’ sample that contained lysed macrophages but no cryptococci (Figure 
3- Cii). The variability in PI staining is likely due to the heterogeneity of this population as 
it contains macrophages in varying states of lysis and fragmentation. The second, smaller 
population stained poorly with PI but stained well with CFW (Figure 3 – B) – by using the 
H99-GFP tagged C. neoformans strain (Voelz et al., 2010) as a control I was able to verify 
that this population was composed of Cryptococcus cells (Figure 3- Ciii).  
The H99-GFP tagged control did reveal that there were detectable GFP signals within the 
macrophage debris population (Figure 3- Ciii) suggesting that the populations may not be 
completely resolved – some of these signals are likely due to auto-fluorescence however it 
is possible that macrophages that have not completely lysed may still contain some 
Cryptococcus cells. Optimisation of the lysis step should be able to reduce this from 
occurring – to optimise I would suggest increasing the lysis time when using dH2O from 
what is currently used (30 minutes at 37oC). Additional lysis efficiency might be achieved 
by lysing macrophages with a detergent such as Triton X-100 or SDS instead of dH20. A 
possibly related observation is that the macrophage debris has at least two different 
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components – a large proportion of the macrophage debris stains poorly with PI while a 
smaller part stains well with both PI and CFW (Figure 3 – B). The larger PIlow CFWlow 
proportion of the macrophage debris is likely to be well lysed macrophages as well as 
cellular debris from cell culture and background interference from the PMT detectors, the 
smaller PIhigh CFWhigh proportion is likely to be partially lysed macrophages that may still 
contain C. neoformans cells. While the current analysis is accurate enough to give 
comparable IPR data to haemocytometer counting, it would be beneficial in the future to 
examine each of the populations defined by the BL-3/VL-1 dot plot (Figure 3 – B) in order 
to determine their composition. One way to do this would be to separate each population 
using FACS and then manually examine each population via microscopy scoring for the 
occurrence of important observations e.g. extracellular cryptococci/ partially lysed 
macrophages / partially lysed macrophages containing cryptococci. If the smaller PIhigh 
CFWhigh population did contain partially lysed macrophages with cryptococci inside, then 
as discussed optimisation of lysis step will be required. 
To validate my flow cytometer based assay I have shown that IPR data generated with it is 
comparable to IPRs calculated using haemocytometer counting (Figure 5). In addition to 
demonstrating that my flow cytometry assay can detect a known intracellular proliferation 
defect (Figure 5 –A), I also demonstrate that the assay can be used with a small array of 
clinical isolates (Figure 5- B). Although the mean IPR result using the flow cytometry 
method is similar to the haemocytometer result the standard deviation is generally larger, 
this suggesting that a larger number of replicates may need to be performed when using the 
flow cytometer assay the get an accurate result – the improved speed of the assay and 
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subsequently the increased number of conditions that can be tested in a single assay 
however should hopefully mitigate this requirement. 
Finally, I show that the assay can be performed on the Attune© flow cytometer (Life 
Technologies, Thermo Fisher Scientific) using the ‘auto sampler’ add on (Figure 6). This 
add-on allows the user to analyse an entire 96 or 384 well plate automatically. The 
advantage of analysing samples in this way is two-fold, firstly hands off sample analysis 
means is a time saver for users as they do not have to load each sample manually. Secondly 
the ability to analyse a 96 well plate means that the C. neoformans genomic knockout 
library currently under construction (Liu et al., 2008) could be analysed in its supplied 96 
well format. By maintaining the same format through macrophage infection, staining and 
analysis, sample manipulation would be kept to a minimum reducing labour and pipetting 
error. Keeping to a 96 well format also offers the possibility of using liquid handling robots 
for sample preparation. With this in mind the next step to optimise the assay for high 
throughput analysis would be to perform macrophage infection in 96 well plates instead of 
24 well plates. Switching plate format is likely to cause increased assay variability as from 
experience cell seeding densities do not always scale appropriately, additionally the 
washing steps will become harder as washing efficiency is generally reduced when a 
smaller well size is used. 
In conclusion this chapter reports a successful adaption of an existing IPR assay in order to 
vastly speed up sample analysis. To do this I have made use of flow cytometry to count C. 
neoformans cells. Experimentation with staining methods revealed that a mix of PI and 
CFW could consistently separate macrophage debris and Cryptococcus components of the 
sample for counting. Flow cytometry analysis of IPR samples is significantly faster than 
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the alternative haemocytometer – whereas haemocytometer counting can take up to 3 
minutes per sample my flow cytometer method takes about 20 seconds per sample. 
Importantly this new method of counting gives comparable results to haemocytometer 
counting (Figure 5); additionally, future optimisation of the protocol should allow the 
entire assay to be performed in a 96 well plate format (Figure 6). These findings are a 
significant step towards developing a truly high throughput IPR assay. The development of 
such as assay will allow researchers to screen large genomic knockout libraries currently 
being made (Liu et al., 2008) in order to identify every Cryptococcus gene associated with 
intracellular growth within macrophages.     
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Appendix 
 
1. Supplementary Data 
Strain Description Reference 
H99 C. neoformans serotype A 
mating type α. Wild type parent 
strain. 
 
Δplb1 PLB1 gene knockout (Cox et al., 2001) 
Δplb1:PLB1 Δplb1 with PLB1 gene 
reconstituted 
(Cox et al., 2001) 
Δsec14 SEC14-1 gene knockout (Chayakulkeeree et al., 2011) 
Δsec14:SEC14 Δsec14 with SEC14-1 gene 
reconstituted 
(Chayakulkeeree et al., 2011) 
H99-GFP H99 strain with GFP under 
constitutive expression (actin 
promoter) 
(Voelz et al., 2010) 
 
Table 1:  
Cryptococcus neoformans strains used in this study 
Figure (Chapter 2) H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
3B and 4C i) 0.849 0.684 0.409 
4D i) 0.694 0.169 0.883 
4E i) 0.089 0.764 0.087 
 
Table 2: Shapiro Wilk normality test for phagocytic uptake data (Chapter 2 Figures 3B, 
4C i), 4D i) and 4E i). p-value < 0.05 reject null hypothesis that data is not normally 
distributed 
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Figure 
(Chapter 2) 
H99 
(p value) 
Δplb1 
(p value) 
Δplb1:PLB1 
(p value) 
Δsec14 
(p value) 
Δsec14:SEC14 
(p value) 
4A and 4 Cii 0.214 0.441 0.689 0.731 0.05 
4D ii) 0.437 0.871 0.738   
4E ii) 0.323 0.591 0.061   
 
Table 3: Shapiro Wilk normality test for intracellular proliferation rate data (Chapter 2 
Figures 4A, 4C ii), 4D ii) and 4E ii). p-value < 0.05 reject null hypothesis that data is not 
normally distributed. 
Figure 
(Chapter 2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 24 hr 0 hr 18 hr 24 hr 0 hr 18 hr 24 hr 
4B 0.163 0.38 0.813 0.896 0.188 0.209 0.611 0.282 0.072 
 Δsec14 (p value) Δsec14:SEC14 (p value)  
 0 hr 18 hr 24 hr 0 hr 18 hr 24 hr 
4B 0.686 0170 0.072 0.153 0.084 0.659 
 
Table 4: Shapiro Wilk normality test for CFU viability data (Chapter 2 Figure 4B). p-
value < 0.05 reject null hypothesis that data is not normally distributed. 
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Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 A 
‘J774 
infection’ 
0.007 < 0.0001 < 0.0001 < 0.0001 0.021 < 0.0001 
 
Table 5: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6A ‘J774 
infection’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 A 
‘DMEM 
control’ 
0.109 < 0.0001 0.071 < 0.0001 0.146 < 0.0001 
 
Table 6: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6A ‘DMEM 
control’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
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Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 B 
‘J774 
infection’ 
0.109 < 0.0001 0.072 < 0.0001 0.146 < 0.0001 
 
Table 7: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6B ‘J774 
infection’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 B 
‘DMEM 
control’ 
< 0.0001 0.0001 0.0012 0.0001 < 0.0001 < 0.0001 
 
Table 8: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6B ‘DMEM 
control’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 C 
‘J774 
infection’ 
0.21 0.0010 0.14 0.92 < 0.0001 < 0.0001 
 
Table 9: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6C ‘J774 
infection’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
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Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 C 
‘DMEM 
control’ 
< 0.0001 0.0001 0.0012 0.0001 < 0.0001 < 0.0001 
 
Table 10: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6C ‘DMEM 
control’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 D 
‘J774 
infection’ 
< 0.0001 < 0.0001 < 0.0001 0.0001 < 0.0001 0.0001 
 
Table 11: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6D ‘J774 
infection’). p-value < 0.05 reject null hypothesis that data is not normally distributed. 
Figure 
(Chapter 
2) 
H99 (p value) Δplb1 (p value) Δplb1:PLB1 (p value) 
 0 hr 18 hr 0 hr 18 hr 0 hr 18 hr 
Figure 6 D 
‘DMEM 
control’ 
< 0.0001 < 0.0001 < 0.0001 0.001 < 0.0001 0.0001 
 
Table 12: Shapiro Wilk normality test for cell size data (Chapter 2 Figure 6D ‘DMEM 
control’). p-value < 0.05 reject null hypothesis that data is not normally distributed.    
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Table 13 – Mann Whitney U test statistical analysis for cell size experiments ‘J774 
infection’ condition – Chapter 2. Figure 6 – A,B,C,D. 
  
Measurement Comparison P value Mann-Whitney 
U 
Difference 
between 
medians (actual) 
Cell body 
diameter  
(Chapter 2. 
Figure 7- A) 
H99 0hr vs. H99 
18hr 0.0001 1.014e+006 -0.2028 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 546491 1.208 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
1.956e+006 
 
-0.5025 
 
Capsule thickness 
(Chapter 2. 
Figure 7 - B) 
H99 0hr vs. H99 
18hr 
< 0.0001 
11394 
 
1.280 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
3745 
 
3.959 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
10367 
 
1.371 
 
Total diameter 
(Chapter 2. 
Figure 7 - C) 
H99 0hr vs. H99 
18hr 
< 0.0001 
 
10680 
 
0.8187 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
1216 
 
7.275 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
11269 
 
2.156 
 
Ratio cell body to 
capsule 
(Chapter 2. 
Figure 7- D) 
H99 0hr vs. H99 
18hr 
< 0.0001 
 
10608 
 
0.1257 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
2504 
 
0.5094 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
0.6907 
 
19736 
 
 
0.008603 
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Measurement Comparison P value Mann-Whitney 
U 
Difference 
between 
medians (actual) 
Cell body 
diameter 
(Chapter 2. 
Figure 7- A) 
H99 0hr vs. H99 
18hr 
< 0.0001 
 
132678 
 
-0.8300 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
165572 
 
-0.6700 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
159019 
 
-0.4900 
 
Capsule thickness 
(Chapter 2. 
Figure 7- B) 
H99 0hr vs. H99 
18hr 
< 0.0001 
 
7343 
 
2.340 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
9941 
 
2.330 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
8137 
 
1.500 
 
Total diameter 
(Chapter 2. 
Figure 7- C) 
H99 0hr vs. H99 
18hr 
< 0.0001 
 
12835 
 
3.410 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
11712 
 
2.975 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
14594 
 
2.200 
 
Ratio cell body to 
capsule. 
(Chapter 2. 
Figure 7- D) 
H99 0hr vs. H99 
18hr 
0.0675 
 
41824 
 
-0.01000 
 
plb1 0hr vs. 
plb1 18hr 
< 0.0001 
 
13214 
 
0.3750 
 
plb1:PLB1 0hr vs.  
plb1:PLB1 18hr 
< 0.0001 
 
24158 
 
0.0600 
 
 
Table 14 – Mann Whitney U test statistical analysis for cell size experiments ‘DMEM 
control’ condition – Chapter 2. Figure 6 – A,B,C,D. 
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Table 15: Shapiro Wilk normality test for intracellular proliferation data (Chapter 3 
Figures 3A, 5A and 5B). 
Figure 
(Chapter 
3) 
H99 0hr (p value) H99 18 hr (p value) Δplb1 0hr (p value) 
 Un- 
treated 
Vehicle AA Un- 
treated 
Vehicle AA Un- 
treated 
Vehicle AA 
3B 0.114 0.638 0.252 0.654 0.149 0.659 0.905 0.972 0.413 
 Δplb1 18hr (p value) Δplb1:PLB1 0hr 
 (p value) 
Δplb1:PLB1 18hr 
 (p value) 
 Un- 
treated 
Vehicle AA Un- 
treated 
Vehicle AA Un- 
treated 
Vehicle AA 
3B 0.179 0.799 0.333 0.748 0.301 0.474 0.550 0.465 0.119 
 
Table 16: Shapiro Wilk normality test for CFU viability data (Chapter 3 Figure 3B). 
 
 
 
Figure 
(Chapter 3) 
H99 
 
Δplb1 
(p value) 
Δplb1:PLB1 (p value) 
Untreated Vehicle Eicosanoid Untreated Vehicle Eicosanoid 
3A 
(AA) 
N/A 0.1114 0.2606 0.7123 0.7168 0.1885 0.8798 
5A (PGE2) N/A 0.72 0.053 0.004 0.618 0.943 0.562 
5B (PGD2) N/A 0.717 0.053 0.937 0.618 0.943 0.479 
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Untreated 
Vehicle 
control 
Arachidonic 
Acid 
H99 0.934 0.1966 0.239 
plb1 0.704 0.951 0.274 
plb1:PLB1 0.278 0.512 0.939 
Uninfected 
control 0.153 0.368 0.36 
 
Table 17: Shapiro Wilk normality test for PGE2 EIA ELISA data (Chapter 3 Figure 4). 
 
Haemocytometer 
Flow 
cytometer 
CL1 0.185 0.599 
CL2 0.078 0.549 
CL3 0.757 0.417 
CL4 0.523 0.688 
CL5 0.926 0.766 
CL6 0.346 0.346 
 
Table 18: Shapiro Wilk normality test for Flow cytometry IPR method comparison data 
(Chapter 4 Figure 5B). 
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2. Purification and crystallisation of the C. neoformans protein CnLyso1 
2.1 Introduction 
To date crystallographic study of cryptococcal proteins has been limited. A species 
search of the RCSB protein databank (http://www.rcsb.org/pdb) for Cryptococcus 
neoformans returns 24 crystal structures representing 15 unique proteins. Only 3 
structures have been reported at a resolution smaller than 2 Å. 
C. neoformans expresses an independent enzyme to CnPlb1 which only exhibits 
lysophospholipase and lysophospholipase transacetylase activities.  LYSO1 encodes the 
426 amino acid protein CnLyso1 which has a predicted molecular weight of 48.3 kDa, 
although analysis of secreted fractions suggest the protein may exist as a dimer or trimer 
with a size of 97 – 140 kDa. Interestingly enzyme activity experiments using a LYSO1 
knockout C. neoformans mutant suggests that expression of LYSO1 is required for wild 
type levels of CnPlb1 activity. This suggests that CnPlb1 and CnLyso1 may interact post 
translationally. 
I attempted to clone and purify two cryptococcal proteins associated with phospholipid 
modification – Phospholipase B1 and Lysophospholipase. Lysophospholipase was the first 
protein I attempted to purify and crystallise; this was because this protein had fewer 
glycosylation that CnPlb1 and as a result biologically active protein should have been 
expressible in E. coli. In contrast CnPlb1 has glycosylation sites which are needed for full 
activity. Thus for CnPlb1 a different approach would be needed, it is likely that I would 
have had to express the protein in a eukaryote such as Pichia pastoris in order to obtain 
active protein. 
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I attempted to express two versions of CnLyso1; the full length protein and a truncated 
protein which has had the first 85 amino acids cleaved from the N terminus, the reasoning 
behind this being that these amino acids are not predicted to contribute to the protein 
structure and may in fact hinder successful purification. The vector system I used to 
express CnLyso1 was the pMALx vector – either the pMALc (cytoplasmic) or pMALp 
(periplasmic variant. Expression of eukaryotic proteins in a prokaryote like E. coli can lead 
to problems in post translational modification and folding. Expression of the protein with a 
periplasmic transport tag may improve folding efficiency. 
Although I managed to construct the clones, preliminary expression experiments indicated 
that optimisation of expression; purification and crystallisation would take more time than 
was availible. The results presented below are given as record for future researchers. 
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2.2 Materials and methods 
Primers 
All of the Primers used in this project were ordered from MWG-biotech. For cloning the 
following primers were used: pMALxLongFwd 5’-CAA CAA CCT CGG GAT CGA 
GGG AAG GAT GCC ACT TCA CAA TCC CAT CTG G-3’, pMALxShortFwd 5’-CAA 
CAA CCT CGG GAT CGA GGG AAG GGA AGA ACT TGA TTC TGG CGC CAA 
ACG-3’ , pMALxRev 5’-GGT TTT CCC AGT CAC GAC GTT GTA AAA CCT AGC 
ATC GCT GCA CCA GCC ACG AGC G-3’. For sequencing the following primers were 
used: pMALxSeqFwd 5’-ACT GTC GAT GAA GCC CTG AA-3’, pMALxSeqRev 5’-
GCG GGC CTC TTC GCT ATT AC-3’. Unless otherwise stated primers were used in the 
following pairs – PP1 (pMALx:CnLYSO1 full length) – pMALxLongFwd and 
pMALxRev. PP2 (pMALx:CnLYSO1 truncated) – pMALxShortFwd and pMALxRev. 
Cloning 
Amplification of the LYSO1 from our source plasmid and subsequent transfer into the 
target plasmids was performed using an adapted restriction free protocol from van den Ent 
et al. (Van den Ent at al. 2006 J. Biochem. Biophys. Methods 67 (2006) 67 - 74). 
Restriction free cloning is a method for cloning a gene of interest into a target plasmid 
without the use of restriction enzymes. The protocol requires two PCR reactions. In the 
first reaction the gene of interest is amplified from a source plasmid using a pair of ~48 bp 
primers (ending in a 3’ G or C) designed to complement ~24 bp from the gene of interest 
as well as a ~24 bp flanking region at either the 5’ (forward primer) or 3’ (reverse primer) 
of the insertion site. In the second PCR the product from the first reaction is mixed with the 
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empty target plasmid. Linear (rolling circle) replication of the plasmid occurs however the 
newly replicated plasmid contains the gene insert. Following the reaction un used template 
plasmid is degraded with Dpn1 enzyme. The plasmid can then be transformed into suitable 
E. coli strains, firstly DH5a is used for plasmid propagation and confirmation of gene 
insert using sequencing and the BL-1 for expression.  
The source plasmid containing full length cryptococcal LYSO1 was a kind gift from a 
collaborator (Julie Djordjevic, Centre for Infectious Diseases and Microbiology, Westmead 
Millennium Institute, Sydney, Australia). For the first PCR reaction 1 µl source plasmid 
(1:10 diluted from stock) was mixed with 2.5 µl of each forward and reverse primer (PP1 
or PP2 100 pmol/ µl), 4 µl dNTP mix (Bioline, 5 mM stock concentration for each dNTP), 
1 µl Phusion polymerase (New England Biolabs), 20 µl 5X Phusion HF buffer, 3 µl 
DMSO, 2 µl 2.5nM MgCl2. The reaction volume was then made up to 100 µl with sterile 
deionised water. The PCR program followed the conditions recommended for the Phusion 
polymerase – an initial denaturation step of 98 oC for 30 seconds then 35 cycles of 
denaturation at 98 oC for 10 seconds, annealing at 57 oC for 30 seconds and extension at 72 
oC for 40 seconds (15-30 seconds per kb), followed by a final extension step at 72 oC for 
10 minutes.  
Following the first PCR reaction, the PCR products were checked for purity on a 2 % 
agarose gel (100 V ~ 30 minutes). Reactions giving a single clean band at the right size 
were purified using the QIAquick PCR purification kit (Qiagen) following the instructions 
provided.  
For the second PCR reaction the following mix was used: 4 µl PCR product from the first 
reaction, 2 µl dNTP mix, 20 µl Phusion 5X HF buffer, 1 µl Phusion polymerase and 1 µl 
201 
 
 
target plasmid (used at stock concentration or diluted 1:5 or 1:40 in sterile deionised 
water). The reaction volume was then made up to 100 µl with sterile deionised water.  
Each 100 µl reaction was then split into three separate tubes (e.g. 33 µl each) marked A, B 
or C. 
The PCR program used had an initial denaturation step at 98 oC for 30 seconds followed by 
35 cycles of the following: denaturation at 98 oC for 30 seconds for tubes A, B and C. Then 
an annealing step where a temperature gradient was used, tubes marked A were annealed at 
62 oC, tubes marked B at 55.5 oC and tubes marked C at 50 oC all for 30 seconds, then an 
extension step at 72 oC for 12 minutes was applied to tubes A, B and C. Finally a extension 
step at 72 oC for 10 minutes was used. 
Dpn1 digestion 
After the second PCR program all unreplicated target plasmid was removed using a Dpn1 
digest – newly synthesised copies of the plasmid with LYSO1 inserted are not methylated 
whereas any leftover target plasmid is. For each 33 µl PCR reaction the following was 
added – 1 µl Dpn1 (New England Biolab 20,000 units/ml), 1.1 µl B4 buffer and 14.9 µl 
sterile deionised water    to give a digestion reaction volume of 50 µl. Tubes were digested 
at 37 oC for 5 hours. Tubes A, B and C for each condition were then combined and purified 
using the QIAquick PCR purification kit.  
Transformation 
Following purification, the pMALx plasmid with either full length or truncated LYSO1 
inserted was transformed into E. coli strain DH5a – 80 µl chemically competent E. coli 
were added to 12 µl of the purified PCR product, mixed and left on ice for 20 minutes. The 
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cells were then heat shocked at 42 oC for 90 seconds and then rested on ice for 5 minutes, 
700 µl SOC (Super Optimal broth with Catabolite repression) was added then to each tube 
before incubating at 37 oC / 200 rpm shaking for one and a half hours. The tubes were then 
centrifuged at 13g for 1 minute to pellet the cells which were then concentrated by 
resuspending in 100 µl of the original supernatant. This 100 µl was then streaked onto an 
LB agar plate with Carbenicillin selection (100 µg/ml) and incubated at 37 oC overnight to 
allow transformed colonies to grow. 
Colonies which had grown overnight were tested for the presence of the LYSO1 gene with 
colony PCR using the primer pairs used in the first round of PCR. Colonies showing 
positive bands for the colony PCR were grown up in overnight culture with selection and 
mini-prepped. The purified plasmid was sequenced in the School of Biosciences Central 
Genomic facility using pMALxShortFwd and pMALxRev – primers to confirm proper 
insertion of LYSO1. For expression the completed plasmid was cloned into E. coli BL-1. 
IPTG induction small scale 
A single colony of each transformant was picked and grown in a 10 ml overnight LB 
culture with 100 µg/ml carbenicillin. This overnight culture was diluted 1:100 into fresh 
LB and incubated for 3 hours at 37 oC with 200 rpm shaking. After 3 hours 1 µl/ml 
10mg/ml IPTG was added to induce expression and the culture was incubated for a further 
3 hours. 
Samples from each culture were taken and checked for OD to equalise protein levels for 
gel loading. Samples were lysed in SDS loading buffer at 100 oC for 10 minutes then 
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centrifuged to clear particular debris. Samples were analysed on a 10 % acrylamide SDS-
PAGE gel run at 150 v for hour before coomassie staining. 
Auto induction 
The autoinduction media had the following composition: 10 g/L tryptone, 5 g/L yeast 
extract, 25 mM g/L Na2HPO4, 25 mM KH2PO4, 50 mM NH4CL, 2 mM MgCl2, 0.5% 
glycerol, 0.05 % glucose, 0.2 % lactose and 5 ml/L trace metal solution, 100 µg/L 
carbenicillin [80]. 
A 10 ml overnight culture grown from a single colony of transformed BL-1 E. coli was 
grown at 37 oC with 200 rpm shaking under selection with 100 µg/ml carbenicillin in half 
strength LB broth. This culture was diluted 1:100 into 400 ml autoinduction media in a 2L 
conical flask. The flask was incubated at 37 oC for 4.5 hours with 200 rpm shaking and 
then incubated at 18 oC overnight with 200 rpm shaking. After overnight incubation 
cultures were pelleted at 6000 rpm for 8 minutes 4 oC, the supernatant was then discarded, 
the pellets weighed and frozen at -80 oC. 
Protein purification 
The frozen pellet was removed from -80 oC and allowed to thaw before being resuspended 
in 40 ml ‘MBP binding buffer’ or buffer ‘A’ (20 mM Tris Hcl pH 7.4, 200 mM NaCl, 1 
mM EDTA) and left to mix for 45 minutes before being chilled on ice. Cells were then 
lysed via sonication at 40 % power for eight 20 second bursts interspaced with chilling on 
ice.  
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Cell lysate was clarified in two centrifugation steps. The first centrifugation at 15,000 g for 
25 minutes, the second at 50,000 g for one hour, both at 4 oC. For both steps the 
supernatant was retained and the pellet discarded. 
The clarified lysate (also known as ‘onto’) was loaded onto a 5 ml MBP column (GE 
healthcare), the column was then washed with several column volumes of buffer A before 
protein elution with MBP ‘elution buffer’ or ‘buffer B’ (20 mM Tris HCL pH 7.4, 200 mM 
NaCl, 1 mM EDTA and 10 mM Maltose), eluted fractions were retained and tested for 
protein concentration with Bradford’s reagent and analysed with SDS-PAGE and western 
blotting. 
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2.3 Results 
The cloning and purification of CnLyso1 in E. coli was to be attempted before CnPlb1. To 
maximise our chances of producing functional, soluble protein we chose to express 
CnLyso1 using in two different cellular locations – within the cytosol or transported to the 
periplasmic space. For this we chose to express CnLyso1 using the pMALx vector system 
as cytoplasmic (pMALc) and periplasmic (pMALp) variants of the vector exist. In addition 
to varying protein localisation we also attempted to optimise future crystallisation by 
creating a truncated version of CnLyso1 with the first 85 amino acids cleaved from the N 
terminal – these amino acids were not predicted to contribute to the overall structure of 
CnLyso1 and thus might affect successful crystallisation of the protein. Thus we planned to 
produce four different clones – pMALc: LYSO1 ‘full length’, pMALc: LYSO1 ‘truncated’, 
pMALp: LYSO1 ‘full length’ and pMAL:LYSO1 ‘truncated’. 
To clone LYSO1 into the pMALx vectors we used restriction free cloning. Full length or 
truncated copies of the LYSO1 gene were first amplified from a plasmid containing 
cryptococcal LYSO1 (kindly provided by our collaborator Julie Djordjevic). The purify of 
this amplification was checked on a 4 % agarose gel (Figure 1), for each reaction this 
revealed clean single bands at the approximate size for each product. 
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Figure 1 – 4 % agarose gel to check the purity of each primary PCR reaction. Lane 1 – 
LYSO1 full length, Lane 2 – LYSO1 truncated. 
The resulting purified fragment from each amplification product were mixed with empty 
pMALc or pMALp vector in a second PCR reaction where the empty plasmid replicates 
via rolling circle replication, however when the plasmid replicates there is a chance that the 
DNA fragment containing the LYSO1 gene will be incorporated into the plasmid at the 
appropriate integration site. Following PCR left over empty plasmid (methylated DNA) 
was removed from the reaction using Dpn1 leaving only newly synthesised plasmid copies 
(unmethylated). The plasmids were then transformed into DH5a E. coli. Resulting colonies 
were tested for the presence of the insert using colony PCR. Positive colonies were 
sequenced to confirm LYSO1 was present and correctly inserted into the plasmid. 
Interestingly doing the colony PCR I encountered a high occurrence of false positives – 
e.g. colonies which appeared positive during colony PCR but when sequenced did not 
contain LYSO1 but instead empty vectors. The reason for these false positives was unclear 
however it may be due to E. coli cells becoming coated with empty vector and the LYSO1 
gene fragment during transformation but not internalising the molecules. Modification of 
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the sequencing step improved the detection rate. Initially I was using the same primers for 
both sequencing and the initial PCR step; these primers complement sequence in both the 
gene of interest and the target plasmid. Switching to new sequencing primers one of which 
only complemented the plasmid and one which only complemented LYSO1 decreased the 
number of false positives occurring, hugely improving the efficiency of the protocol.  
An initial small scale expression was performed with the first clone to be completed – 
pMALc: LYSO1 truncated. Expression of CnLyso1 was tested in three successful E. coli 
BL-1 transformants – A, B and C. A clear band at ~40 kDa is visible for each induced 
culture (+ve) but not for unindicted cultures (-ve). This band would match the size of 
truncated CnLyso1, however it does not match the total size of the CnLyso1: MBP fusion 
protein – therefore if this band does show IPTG dependant expression it is not the 
complete, tagged protein (Figure 2). 
 
Figure 2 - Small scale expression study with IPTG induction using the pMALc: LYSO1 
construct transformed into E. coli BL-1. 10 % acrylamide gel run for 1 hour at 150 V.  
Once all four clones were completed it was decided to try auto induction instead of IPTG 
induction to see if this would improve the yield and stability of the expressed protein. From 
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experience auto induction generally produces high yields of protein, if this is the case with 
SDS-PAGE the band containing the tagged protein should be much larger than the 
background lysate. Following autoinduction a small sample of each culture was taken and 
lysed in SDS running buffer before running on SDS-PAGE. Examining the gel there are no 
bands at the expected size for either the full length CnLyso1: MBP (~100 kDa) or 
fragmented length that stands out from the background of the lysate. This suggests that if 
the protein is being expressed it is being expressed at low levels (Figure 4) 
 
Figure 3 – SDS-PAGE analysis of lysed culture samples following autoinduction. 10 % 
acrylamide gel, 150 V 1 hour. 
Although the yield during autoinduction did not appear to be high I chose to purify the 
protein from the clarified lysate by passing over a MBP column and performed a Western 
blot with against MBP just to see if the protein was present at low levels. The Western blot 
shows that for each clone there are three main bands with MBP present – one at 110 kDa, 
one at 50 kDa and one at 40 kDa. The band at 110 kDa could represent the full sized 
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CnLyso1: MBP tagged protein whereas the two smaller bands could be the result of 
fragmentation for some of the expressed protein. 
 
 
Figure 4 – Western blot analysis following protein purification with MBP columns for 
each clone. The antibody used is against the MBP tag. 
  
210 
 
 
  
Cryptococcal Phospholipase B1 Is Required for Intracellular
Proliferation and Control of Titan Cell Morphology during
Macrophage Infection
Robert J. Evans,a Zhongming Li,b William S. Hughes,a,c Julianne T. Djordjevic,d Kirsten Nielsen,b Robin C. Maya,e
Institute of Microbiology and Infection and School of Biosciences, University of Birmingham, Birmingham, United Kingdoma; Department of Microbiology, University of
Minnesota, Minneapolis, Minnesota, USAb; University of Warwick, Coventry, United Kingdomc; Centre for Infectious Diseases and Microbiology, Westmead Millennium
Institute, Westmead, New South Wales, Australiad; NIHR Surgical Reconstruction and Microbiology Research Centre, University Hospitals of Birmingham NHS Foundation
Trust, Queen Elizabeth Hospital Birmingham, Birmingham, United Kingdome
Cryptococcus neoformans is an opportunistic fungal pathogen and a leading cause of fungal-infection-related fatalities, espe-
cially in immunocompromised hosts. Several virulence factors are known to play a major role in the pathogenesis of cryptococ-
cal infections, including the enzyme phospholipase B1 (Plb1). Compared to other well-studied Cryptococcus neoformans viru-
lence factors such as the polysaccharide capsule andmelanin production, very little is known about the contribution of Plb1 to
cryptococcal virulence. Phospholipase B1 is a phospholipid-modifying enzyme that has been implicated in multiple stages of
cryptococcal pathogenesis, including initiation and persistence of pulmonary infection and dissemination to the central nervous
system, but the underlying reason for these phenotypes remains unknown. Here we demonstrate that aplb1 knockout strain of
C. neoformans has a profound defect in intracellular growth within host macrophages. This defect is due to a combination of a
50% decrease in proliferation and a 2-fold increase in cryptococcal killing within the phagosome. In addition, we show for the
first time that theplb1 strain undergoes a morphological change during in vitro and in vivo intracellular infection, resulting in
a subpopulation of very large titan cells, which may arise as a result of the attenuated mutant’s inability to cope within the
macrophage.
Cryptococcus neoformans is a pathogenic fungus that can causesevere and often fatal meningoencephalitis, especially in im-
munocompromised hosts. In recent years, C. neoformans has be-
come a major emerging pathogen, due largely to the global HIV
pandemic. In sub-Saharan Africa, for example, C. neoformans
likely accounts for up to 44% of fatal HIV-related secondary in-
fections (1). During infection, C. neoformans is known to interact
closely with host macrophages (2) following inhalation of infec-
tious spores from the environment into the lungs (3). Many viru-
lence factors expressed byC. neoformans allow the fungus to evade
phagocytosis by macrophages or to improve survival once phago-
cytosed (4).
One such virulence factor is phospholipase B1 (Plb1), a phos-
pholipid-modifying enzyme with multiple enzymatic activities
(5). In cryptococcal cells, a significant proportion of Plb1 enzy-
matic activity is cell wall associated, although secretion of Plb1
from Cryptococcus is known to occur in vitro (6). Plb1 is secreted
following cleavage of a glycosylphosphatidylinositol (GPI) anchor
motif, which anchors the enzyme to the cell wall (7, 8), and export
of Plb1 to the cell wall is facilitated by Sec14-1, which is part of C.
neoformans’s protein export system (9). Plb1 has optimal activity
under acidic conditions, at around pH 4.0 to 5.0 (conditions sim-
ilar to that of the phagosome), and is active at 37°C (10).
In line with this putative role in pathogenesis, deletion of PLB1
strongly attenuates virulence in C. neoformans (9, 11–13). Mice
infected with a PLB1 deletion C. neoformans strain (plb1) show
reduced fungal burden in the lungs (9). In addition, during mu-
rine infection Plb1 appears to be required for cryptococcal dis-
semination from the lungs into the bloodstream (12) and addi-
tionally may be involved in the translocation of cryptococcal cells
across the blood-brain barrier into the brain (14).
The reason why theplb1 strain is attenuated during infection
has not yet been fully elucidated. In this study, we sought to ex-
plore the role of Plb1 during macrophage infection. We report
that Plb1 is critical for both proliferation and survival within the
macrophage. In addition, we show that the plb1 strain responds
to macrophage infection by significantly increasing both capsular
diameter and overall cell size within the phagosome and in the
murine lung. This morphology is reminiscent of previously re-
ported titan cells (15–17) and suggests that control of cryptococcal
cell size by Plb1 may play a vital role in the outcome of host mac-
rophage infection.
MATERIALS AND METHODS
Ethics statement. A total of 14 mice were handled in strict accordance
with good animal practice, as defined by the relevant national and/or local
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animal welfare bodies. All animal work was approved by the University of
Minnesota Institutional Animal Care and Use Committee (IACUC) un-
der protocol no. 1308A30852.
Strains, media, and cell lines. The strains used in this work are listed
in Table 1. Strains were stored long-term in MicroBank vials at 80°C.
Strains were rescued onto yeast extract-peptone-dextrose (YPD) agar
(YPD, 50 g/liter [Sigma-Aldrich]; 2% agar [Melford]) for 48 h at 25°C and
then stored until needed at 4°C. Before experimentation, liquid cultures
were grown from these stock plates in 2 ml YPD growth medium (50
g/liter) for 24 h at 25°C under constant rotation.
The J774murinemacrophage cell linewas used for all in vitro infection
assays. Cells were passaged in Dulbecco’s modified Eagle medium
(DMEM) culture media with serum (DMEM, low glucose, from Sigma-
Aldrich; 10% fetal bovine serum [FBS] from Invitrogen; 1% 10,000 units
penicillin–10 mg streptomycin from Sigma-Aldrich; 1% 200 mM L-glu-
tamine from Sigma-Aldrich). Assays were performed with J774 cells be-
tween passages 4 and 15. Assays were performed in serum-free DMEM
(DMEM [high glucose], 1% penicillin-streptomycin, 1% L-glutamine)
unless otherwise stated.
Intracellular proliferation assay.The intracellular proliferation assay
was performed as previously described (18). Briefly, 24 h before infection,
1  105 J774 macrophages were seeded onto 24-well plastic plates
(Greiner Bio One Cell Star) in 1 ml culture medium with serum and
incubated for 24 h at 37°C and 5% CO2. Before infection, J774 cells were
activated with 150 ng/ml phorbol 12-myristate 13-acetate in dimethyl
sulfoxide (DMSO; Sigma) in 1ml serum-free culturemedium for 45min.
This medium was then replaced with serum-free medium alone. Simul-
taneously, overnight C. neoformans cultures grown at 25°C in YPD were
washed three times in sterile 1 phosphate-buffered saline (PBS), quan-
tified, and adjusted to 1 107 cells per ml in PBS before opsonization for
1 h with 10 g/ml anticapsular 18B7 antibody (a kind gift from Arturo
Casadevall, Albert Einstein College of Medicine, New York, NY, USA).
The activated J774 cells were then infected with 100 l opsonized C. neo-
formans to give a multiplicity of infection (MOI) of 10 (e.g., 1 105 J774
cells for 1  106 C. neoformans cells) in unsupplemented serum-free
DMEM and incubated for 2 h at 37°C, 5% CO2. After 2 h (time point 0),
infected wells were washed at least 3 times with warm 1 PBS until all
nonphagocytosed C. neoformans cells were removed from the wells.
For calculation of the intracellular proliferation rate, the number of
internal cryptococci was determined at time points 0, 18, and 24 (time
points 0, 0  18 h, and 0  24 h, respectively). At each time point, each
well to be counted was washed three times with 1 PBS to remove any
extracellular yeast. The macrophages in the well were then lysed in dis-
tilled water for 30 min. C. neoformans cells in the lysate were quantified at
each time point with a cell-counting chamber, and the intracellular pro-
liferation rate (IPR) was calculated by dividing the count at which the
intracellular burden peaked by the count at time point 0. Viability testing
of the recovered cells was achieved by diluting the lysate to give a concen-
tration of 200 yeast cells per 100l and then plating ontoYPDagar at 25°C
for 48 h prior to counting CFU.
Phagocytosis assay. Twenty-four hours before assaying, J774 macro-
phages were seeded onto 13-mm glass coverslips (nitric acid treated) in-
side 2-cm2 24-well plates at a concentration of 1 105 cells per ml in 1ml
DMEM culture medium with serum and incubated at 37°C and 5% CO2.
Activation and infection of the macrophages with opsonized C. neofor-
mans cells followed the same protocol as described above for the intracel-
lular proliferation assay. After 2 h of incubation, the cells were washed 3
times with 1 PBS to remove unphagocytosed cells and then fixed for 10
minwith 250l 4%paraformaldehyde in PBS at 37°C. Following fixation,
coverslips were washed with 1 PBS and sterile deionized water and
mounted on glass slides using Mowiol mountant (100 mMTris-HCl [pH
8.5], 9% Mowiol, 25% glycerol). Mounted coverslips were analyzed on a
Nikon Ti-S inverted microscope fitted with a Plan apochromatic
(APO) 60  1.40 differential interference contrast (DIC) oil immer-
sion objective.
Cell size assay. J774 cells were plated into 24-well plates, activated, and
infected with opsonized C. neoformans strains as described above for the
IPR assay. Two hours postinfection, each well was washed at least 3 times
with warm 1 PBS until all nonphagocytosed C. neoformans cells were
removed from the wells, and 1 ml serum-free DMEM was then added to
each well.
The 24-well plate was placed into an environmentally controlled stage
(Okolabs) set to 30°C, 5% CO2. The cells were imaged using a Nikon
TE2000 microscope fitted with a Digital Sight DS-Qi1MC camera and a
PlanAPOPh1 20dry objective. Imageswere recorded every 4min for 20
h. Image acquisition and analysis was performed using the Nikon NIS
Elements software package (Nikon).
Cell size was measured using the ellipse area tool, measuring from the
center of eachCryptococcus cell to the edge, to obtain the diameter of each
cell.
In vivo titan cell and phagocytosis assay. Cryptococcus neoformans
cells were grown in YPD broth overnight. Cells were pelleted and resus-
pended in sterile phosphate-buffered saline at a concentration of 1 107
cells/ml based on hemocytometer count. Groups of 6- to 8-week-old fe-
male A/J mice (Jackson Laboratory, Bar Harbor, ME) were anesthetized
by intraperitoneal pentobarbital injection. Four to fivemice per treatment
were infected intranasally with 5  105 cells in 50 l PBS. At 3 days
postinfection,micewere sacrificed byCO2 inhalation. Lungswere lavaged
with 1.5 ml sterile PBS three times using a 18.5-gauge needle placed in the
trachea. Cells in the lavage fluid were pelleted and fixed in 3.7% formal-
dehyde at room temperature for 30min.Cells werewashed oncewith PBS,
and500 cells per animal were analyzed for size bymicroscopy (AxioIm-
ager, Carl Zeiss, Inc.). Cell body sizes were measured, and cells were clas-
sified as small cells (15m in cell body diameter) or titan cells (15m
in cell body diameter).
Titan cell flow cytometry.H99 was cultured in YPD broth overnight.
Cells were pelleted, washed three times in PBS, and fixed in 3% parafor-
maldehyde at room temperature for 10 min. Bronchoalveolar lavage
(BAL) samples were washed once in 0.05% sodium dodecyl sulfate (SDS)
to lysemammalian cells and thenwashed three times in sterile water. Cells
were pelleted and fixed in 3% paraformaldehyde at room temperature for
10 min. Following fixation, samples were washed with PBS, stained with
0.5 g/ml Hoechst (Sigma, St. Louis, MO) at room temperature for 10
min, washed again with PBS, and then resuspended in PBS. Approxi-
mately 10,000 cells were examined for cell size by forward scatter (FSC)
and for DNA content by Hoechst staining using an LSRII flow cytometer
with FACSDiva software (BD Biosciences, San Jose, CA). Graphs were
generated using Flowjo software (Tree Star, Inc., Ashland, OR). The t test
was used to analyze the differences in titan cell formation and phagocyto-
sis, and P values of0.05 were considered significant.
Cell stress.OvernightC. neoformans cultures in 2ml YPDwere grown
at 25°C. Cultures were diluted 1:1,000 into 500 l buffered YPD (pH 7.0,
15mMHEPES) in plastic-bottomed 48-well plates (Greiner) with various
concentrations of SDS (0, 0.01, 0.05, 0.1, 0.25, and 0.5 mM), of H2O2 (0,
0.125, 0.25, 0.5, 1, 3, 6, and 14 mM), or of NaCl (0, 125, 250, 500, 1,000
mM). The plate was then sealed with a breathable membrane, and growth
curve assays were performed for 24 h at 30°C in a Fluostar Omega plate
reader using a custom script that took 600-nm absorbance readings from
TABLE 1 Strains used in this study
Strain or
genotype Description Reference
H99 C. neoformans serotype A mating type 	; wild-
type parent strain
plb1 PLB1 gene knockout 10
plb1::PLB1 plb1 strain with PLB1 gene reconstituted 10
sec14 SEC14-1 gene knockout 13
sec14::SEC14 sec14 strain with SEC14-1 gene reconstituted 13
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the bottom of the plate every 30 min. Between reads, the plate was shaken
at 200 rpm with a linear shaking pattern.
Statistics. Unless otherwise stated, all statistics were performed using
Prism Graphpad software. For cell size measurement comparison be-
tween time points, aMann-Whitney U test was performed (e.g., StrainX 0
h versus StrainX 18 h). Unless stated otherwise, a P value below 0.05 was
taken as significant. Unless otherwise stated, all figures have error bars
representing standard errors. Significance is shown on figures by asterisks
as follows: *, P 0.05; **, P 0.01; ***, P 0.001; and ****, P 0.0001.
RESULTS
Plb1 deficiency leads to increased uptake ofC. neoformans cells
by J774 macrophages. We first assessed to what extent the PLB1
knockout strain, plb1 strain, was phagocytosed by macrophages
in comparison to thewild-type parent strainH99 and a genetically
reconstituted strain,plb1::PLB1 strain.We found that, following
2 h of infection, the percentage of J774 murine macrophages with
at least one internalized C. neoformans cell did not differ signifi-
cantly between wild-type strain H99, plb1 strain, and plb1::
PLB1 reconstituted strain (Fig. 1A). Quantification of the fungal
burdenpermacrophage, however, revealed a 2-fold increase in the
number of plb1 cells phagocytosed per host cell (Fig. 1B, P 

0.0003). This suggests that Plb1 activity contributes significantly
to the well-known antiphagocytic phenotype of cryptococci.
Plb1 is required for intracellular proliferation of C. neofor-
mans within J774 macrophages. PLB1 knockout leads to a re-
duced fungal lung burden duringmurine infection; in addition, it
abrogates dissemination to the brain (9, 14) and has previously
been shown to reduce budding of C. neoformans within macro-
phages (11). To investigate this phenotype further, we performed
an intracellular proliferation rate assay. We observed an intracel-
lular proliferation defect for the plb1 strain versus the wild-type
strain (IPR 
 1.12 versus 2.42 for H99; P 
 0.023), a defect that
was fully restored in the plb1::PLB1 reconstituted strain (Fig.
2A). Interestingly, no intracellular proliferation defect was ob-
served when we tested thesec14 strain (Fig. 2A). Since Sec14-1 is
required for efficient secretion of Plb1 (9), it appears that intracel-
lular, but not secreted, Plb1 is important for proliferation within
host cells.
Due to the increased efficiency of plb1 cell uptake observed,
we wondered whether the reduced proliferation we see for plb1
H9
9
Δp
lb1
Δp
lb1
::P
LB
1
Δp
lb1
::P
LB
1
0
20
40
60
80
100
M
ea
n
%
in
fe
ct
ed
ce
lls
H9
9
Δp
lb1
0
5.0×104
1.0×105
1.5×105
2.0×105
2.5×105
3.0×105
M
ea
n
up
ta
ke
pe
r1
x1
05
J7
74
ce
lls
***
**
A B
FIG 1 (A) Percentages of macrophages within a population that show C. neoformans infection following 2-h incubation with opsonized cryptococci at an MOI
of 1:10 (n
 4). Aminimumof 500macrophageswere counted for each condition. (Unpaired t test was performed, no significance.) (B) Total burden of infection
within a fixed population of J774 cells (1 105) following 2-h incubation with opsonized cryptococci at an MOI of 1:10 (n
 9). ***, H99 versus plb1 strain,
P
 0.0003; **, plb1 versus plb1::PLB1 strains, P
 0.0038 (unpaired t test).
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FIG 2 (A) Mean intracellular proliferation rate for each C. neoformans strain within murine J774 macrophages (n
 3). *, H99 versus plb1 strain, P
 0.023;
*, plb1 versus plb1::PLB1 strains, P
 0.033; *, plb1 versus sec14::SEC14 strains, P
 0.0263 (one-way analysis of variance [ANOVA] plus Tukey posttest).
(B) Viability of C. neoformans cells recovered from J774 macrophages following the IPR assay. Cells recovered following macrophage lysis were counted and
diluted, giving an expected plated inoculum of 200 cells (n
 4). *, plb1 strain 0 h versus plb1 strain 18 h, P
 0.0422; *, plb1 strain 0 h versus plb1 strain
24 h, P
 0.0415 (two-way ANOVA plus Tukey posttest comparing time points for each strain).
Evans et al.
1298 iai.asm.org April 2015 Volume 83 Number 4Infection and Immunity
cells simply reflects initial overcrowding within the host macro-
phage. To test this, we reduced the uptake of plb1 cells by omit-
ting the opsonization step before infection. Infecting with unop-
sonized Cryptococcus reduced uptake for all three strains (see Fig.
S1Ci in the supplemental material: unopsonized Cryptococcus can
still be phagocytosed by macrophage but at a lower rate [19, 20])
but did not alter the growth defect observed (see Fig. S1Cii in the
supplemental material). To test a different method of opsoniza-
tion, we also tried opsonizing with pooled serum instead of anti-
body. At the concentration used (5% pooled human serum), we
did not see significant differences in uptake, compared to anti-
body opsonization (see Fig. S1Bi in the supplemental material),
and the proliferation defect remained (see Fig. S1Bii in the sup-
plemental material). Taken together, these data suggest that Plb1
plays a direct role in regulating intracellular proliferation in cryp-
tococci regardless of the fungal intracellular burden.
Plb1 contributes toC. neoformans cell survival during infec-
tion. The low intracellular proliferation defect observed forplb1
could be due to slowerCryptococcusproliferation and/or increased
intracellular killing by the macrophage. To address the second
possibility, we plated C. neoformans cells recovered from macro-
phages at 18 and 24 h postinfection on YPD agar to enumerate
CFU. No significant difference in CFU among any of the five
strains was seen at time point 0 (2 h postinfection); however, at
time point 18 (20 h postinfection), the viability ofplb1 strain but
not that of the sec14-1 strain had dropped significantly (P 

0.04) (Fig. 2B) compared to that of H99. Taken together, these
data suggest that both growth and survival of the plb1 strain are
impaired within the phagosome during macrophage infection.
Plb1 deficiency does not significantly affect cryptococcal
stress responses. We hypothesized that low IPR in the macro-
phage may be a result of stressful conditions during macrophage
infection—possibly because the plb1 strain is unable to control
or resist cellular stresses within the macrophage. However, expos-
ing the plb1 strain to a variety of stresses showed no significant
difference from the wild type other than the previously reported
susceptibility to SDS (9) (Fig. 3A and B).
PLB1 knockout leads to changes in cryptococcal cell body
morphology. During the course of this work, we noticed that
some plb1 cells showed a marked increase in cell body diameter
within infected macrophages, a morphology that was not ob-
served for H99 or the plb1::PLB1 strain (Fig. 4E and F). Quanti-
fication of this phenomenon (Fig. 4) showed that the diameter of
both the cell body and the capsule of plb1 cells increased signif-
icantly during an 18-hmacrophage infection (Fig. 4A to E). Inter-
estingly, we observed a significant decrease in cell diameter for
H99 and plb1::PLB1 cells over the same incubation period (see
Table S1 in the supplemental material), which is probably due to
active cell budding occurring within the macrophage, leading to a
drop in mean diameter for the overall population. Extending the
period of live cell imaging to 48 h, we found that the enlarged
plb1 cells did not noticeably increase in size after 18 h postinfec-
tion.
Changes in Cryptococcus cell size during in vivo infection have
been previously documented, ultimately resulting in the produc-
tion of very large titan cells (15–17, 21). To our knowledge,
though, this is the first published observation of a similar (albeit
less dramatic) process occurring within a macrophage (rather
than extracellularly) and the first time that PLB1 has been impli-
cated in this pathway. Previous studies have reported that the size
increase observed in titan cells is accompanied by increased nu-
clear content due to polyploidy (15, 16). In agreement with this,
flow cytometric analysis of plb1 cells following macrophage in-
fection demonstrated a positive correlation between cell size and
DNA quantity (Fig. 5A), indicating increased nuclear content
within these cells.
plb1 cells have a higher rate of titan cell formation than do
wild-type cells during in vivomurine infection.Our in vitro ob-
servation of plb1 cell enlargement was reminiscent of the titan
cell morphology observed during in vivo murine pulmonary in-
fection (15, 16, 21). To test whether this phenotype was recapitu-
lated in vivo, we conducted pulmonary infections inmice and then
quantified cryptococcal size following bronchoalveolar lavage
(BAL) at 3 days postinfection. As with our in vitro data, in vivo
infection with plb1 cells produced about 2.5 times more titan
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cells (cryptococci with a cell body diameter greater than 15 m)
than H99 or plb1::PLB1 cells (Fig. 6Ai). Flow cytometry of la-
vaged, Hoechst-stained plb1 titan cells indicated that these cells
are polyploid, in agreement with previously published character-
ization of titan cells (15, 16) as well as our own in vitro observation
ofplb1 cells (Fig. 5A). Taken together, these findings suggest that
themorphological changes that we observed in ourplb1 cells are
consistent with an increase in the production of titan cells by this
strain both in vitro and in vivo.
In vivo plb1 titan cell formation is not associated with
phagocytosed cells. In addition to quantifying overall titan cell
formation in BAL samples, we also counted the Cryptococcus cells
within host phagocytes following BAL andmeasured the cell body
diameter of each Cryptococcus cell within each lavaged host cell.
We found that there were significantly fewer lavaged host cells
containing Cryptococcus for plb1 strain-infected mice than for
mice infected with H99 or plb1::PLB1 strain (Fig. 6Aii, H99 ver-
sus plb1, P 
 0.0001; plb1 versus plb1::PLB1, P 
 0.0018).
FIG 4 (A toD)C. neoformans cells weremeasured after either 18 h inside J774macrophages or 18 h in serum-free DMEM. The top and bottom of each boxmark
the 75th and 25th percentiles, respectively, the bisecting line in the boxmarks the median, and the two whiskers mark themaximum andminimum of the range.
Mann-Whitney U tests were performed for each time point pair. Full statistical results are given in Tables S1 and S2 in the supplemental material. (B) Capsule
thickness was calculated by subtracting cell body diameter from total diameter including capsule. (D) The ratio of cell body to capsule was calculated by dividing
cell body diameter by capsule thickness. (E) Still bright-field images from live-cell microscopy following the same macrophage over 18 h for H99, plb1, and
plb1::PLB1 strains. Black arrows indicate the location of singleC. neoformans cells within themacrophage. (F) Still bright-field images from live-cellmicroscopy
following viable plb1 strain-infected macrophages. Images were taken at 40 h postinfection; bar, 10 m.
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inQ3 consistentwith small cells inG1, cells inQ4 indicative of small cells inG2, and cells inQ2 indicative of polyploidy titan cells with both large size and increased
DNA content. (B) Mean percentage of total events (10,000 collected) across 3 repeats occurring in the Q2 gate. A one-tailed t test was performed for H99 and
plb1 strains as well as plb1and plb1::PLB1 strains to determine if the increase in events within the Q2 gate observed was significant: *, H99-infected versus
plb1 strain-infected cells, P
 0.034; *,plb1 strain-infected versusplb1::PLB1 strain-infected cells, P
 0.015; **,plb1 strain-uninfected versusplb1::PLB1
strain-uninfected cells, P
 0.001.
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Very fewof these internalizedCryptococcus cells were above 10m
in diameter, and those that were above 10 m could be found in
similar numbers for H99, plb1, and plb1::PLB1 cells (Fig.
6Aiii). No cells greater than 15 mwere found inside phagocytes
in either the control or the plb1 strain infections (data not
shown). This leads us to conclude that in vivo plb1 titan cell
formation potentially occurs initially within host cells (as we ob-
serve in vitro) but these large cryptococci are released from host
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FIG 6 In vivo titan cell assay on Cryptococcus cells lavaged from mouse lungs 3 days postinfection. (Ai) A minimum of 500 cells per animal were analyzed to
quantify cell body diameter, Cryptococcus cells 15 m in diameter were considered titan cells (***, H99 versus plb1 strain, P 
 0.0001; ***, plb1 versus
plb1::PLB1 strains,P
 0.0018 [two-tailed unpaired t test]). (Aii)Host cells lavaged from the lungswere examined for phagocytosedCryptococcus cells (***,H99
versus plb1 strain, P
 0.0001; ***, plb1 versus plb1::PLB1 strains, P
 0.0001 [two-tailed unpaired t test]). (Aiii) The cell body diameter of phagocytosed
Cryptococcus cells within lavaged host macrophages was quantified, and data for phagocytosed cells10m are given. (B) Bronchoalveolar lavage samples with
Cryptococcus fromH99 andplb1 strains were stainedwithHoechst and analyzed for size and nuclear content. Cells were gated based on size and nuclear content
with cells in Q3 consistent with small cells in G1, Q4 indicative of small cells in G2, and Q2 indicative of polyploidy titan cells with both large size and increased
DNA content. (C) Bright-field images of lavaged cells from H99, plb1, or plb1::PLB1 strain-infected lungs. Bar, 15 m.
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cells either by host cell lysis in vivo or due to the physical process of
lavage prior to the time point examined.
DISCUSSION
During cryptococcal pathogenesis, C. neoformans interacts with
professional phagocytes in the alveolar space (2), in the blood-
stream, and in other tissues following dissemination. The out-
come of this interaction appears to be vital for disease progression,
as themacrophage provides a protective niche for replication (18)
and a potential “Trojan horse” for dissemination to the central
nervous system (22, 23). Together with previous studies, our find-
ings strongly suggest that expression of Plb1 is critical in regulat-
ing cryptococcus-macrophage interactions.
First, we show that PLB1 deletion leads to enhanced uptake by
phagocytes in vitro (Fig. 1B). Since Plb1 is a GPI-linked, cell wall-
associated protein (7), it is likely that loss of this enzyme affects the
cryptococcal cell surface and, presumably, this change facilitates
more-efficient binding of phagocyte receptors. Examination of
different opsonization methods (see Fig. S1 in the supplemental
material) suggests that increased uptake is due to a combination of
antibody, complement, and nonopsonic ligands. Cryptococcal
cell wall instability following PLB1 deletion has been published
previously (8), and thus this instability could lead to increased
ligand exposure on the Cryptococcus cell surface. In light of these
observations, a detailed chemical analysis of the cell surface com-
position in this strain would be of considerable future interest.
Following phagocytosis, we find that C. neoformans requires
the expression of Plb1 to proliferate and survive normally within
the macrophage (Fig. 2). This finding provides a mechanism to
explain previous reports of reduced fungal burdens following in-
fection with plb1 cells (9). Interestingly, however, the sec14-1
strain shows no such defect in intracellular proliferation. Since
this strain shows strongly reduced Plb1 secretion (9), the most
likely explanation is that the primary role of Plb1 in driving intra-
cellular proliferation is in themetabolism of fungal phospholipids
within the cryptococcal cell, rather than in acting directly upon
host phospholipids. However, secreted Plb1 appears to have addi-
tional roles in virulence, since the sec14-1 strain is attenuated in
animal models (9). It is tempting to speculate that the docu-
mented involvement of SEC14 in regulating vomocytosis (9) may
be one such role.
A strikingmorphological observation arising from ourmacro-
phage infection model was that plb1 cells showed a marked in-
crease in both cell body diameter and capsule thickness during
infection, with a maximum measured diameter (including cap-
sule) of almost 25m(Fig. 4C). That this size change was not seen
in the wild-type orplb1::PLB1 reconstituted strains suggests that
this morphology results from the loss of Plb1. Previously reported
titan cells grown in vivo range in diameter from 15 to 100 m,
excluding the capsule (15, 16). Therefore, the size increase that we
observed is smaller than that of previously reported titan cells but
significantly larger than the normal cryptococcal size range.
Interestingly, previous reports of titan cells induced in vitro
also noted that the cells tended to be smaller than those gener-
ated in vivo (16). Flow cytometry analysis of plb1 cells follow-
ing macrophage infection (Fig. 5) indicates that the large cells
show increased DNA content, consistent with the defining fea-
ture of titan cells (16). Thus, these cells may represent individ-
ual yeast cells that are “en route” to becoming Titan cells or
have somehow been constrained by the macrophage, or it may
be that the in vitro conditions do not provide the necessary
stimulus to produce the largest titan cells.
Fromour in vitro data, we conclude that theplb1 strain forms
large cells within macrophages, which are similar to the titan cell
morphology seen in vivo. Titan cell formation has previously been
induced in vitro usingmacrophage-conditionedmedia (16); how-
ever, titan cell formation induced inside an infected macrophage
has to our knowledge not previously been reported. Although we
have not identified the trigger for this morphology, it is evidently
linked to Plb1 deficiency. The development of this morphology
within the macrophage may be a response to increased stress ex-
perienced by the plb1 strain, as indicated by the decreased via-
bility of this strain within the phagosome. Although we did not
detect any significant difference stress tolerance for plb1 organ-
isms in vitro, other than the previously published susceptibility to
SDS (9), growth within the phagosome exposes cryptococci to a
diverse repertoire of additional stresses, and it is likely that these
complex conditions limit the growth of this mutant. One possible
source of stress within the phagosome, which links our observed
phenotypes, is the observation that in wild-type cryptococci, Plb1
concentrates at the neck of newly forming buds (24). This suggests
that Plb1 may have a role in bud development, and thus it is
conceivable that modification of membrane phospholipids by
Plb1 during budding could be required for membrane curvature
at the newly formed bud site or release of the daughter cell. The
inability of the plb1 strain to properly bud would explain the
proliferation defect observed and could generate sufficient cellular
stress to reduce cryptococcal viability and trigger the development
of titan-like cells.
A strong link between our in vitro observations and previously
published in vivo development of titan cells is supported by our
finding that the plb1 strain forms greater numbers of “classical”
titan cells (i.e., cell body diameter above 15 m and high nuclear
content indicative of polyploidy) in vivo than do thewild-type and
reconstituted strains (Fig. 6Ai). These data suggest that Plb1 ac-
tivity is involved in the repression of titan cell formation during
infection. In addition, the fact that the sec14-1 strain does not
manifest similar cell size increases during in vitro infection (our
unpublished data) indicates that intracellular rather than extracel-
lular Plb1 activity regulates the titan cell morphology. Interest-
ingly, titan cell development may be linked to phospholipid avail-
ability (25), suggesting a potential link to Plb1 activity. Titan cell
formation in vivo has been reported to increase the pathogenicity
ofC. neoformans (16, 17); our conclusion that theplb1 strain has
increased titan cell formation therefore seems at odds with the in
vitro data presented in Fig. 1 and 2 showing that theplb1 strain is
attenuated in macrophages. It is therefore possible that the large
plb1 cells may not exhibit all the features of titan cells (for in-
stance, in conferring “cross-protection” on nontitan cells in the
same host). Alternatively, it may be that full pathogenicity re-
quires only a minor titan cell population and hence, the enhanced
titan cell frequency seen in the plb1 strain actually reduces over-
all virulence.
In summary, our data indicate that Plb1 plays a key role both in
intracellular survival within host phagocytes and in driving cryp-
tococcal cell size changes both in vitro and in vivo.
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